<!DOCTYPE html>
<html>
<head>

      <meta http-equiv="Content-Type" content="text/html; charset=utf-8">

        <script> var url = encodeURIComponent('https://www.mdpi.com/journal/vaccines');</script>

        <script> var body_html = '<body> <div > <div > <div > <a > <h2>25th Anniversary</h2> </a> <a > <h2>Journals</h2> </a> <div > <div > <h2>Information</h2> </div> <div > <div > <div > <a >For Authors</a> <a >For Reviewers</a> <a >For Editors</a> <a >For Librarians</a> <a >For Publishers</a> <a >For Societies</a> </div> <div > <a >Article Processing Charges</a> <a >Open Access Policy</a> <a >Institutional Open Access Program</a> <a >Editorial Process</a> <a >Awards</a> <a >Research and Publication Ethics</a> </div> </div> </div> </div> <a > <h2>Author Services</h2> </a> <div > <div > <h2>Initiatives</h2> </div> <div > <div > <div > <a >Sciforum</a> <a >MDPI Books</a> <a >Preprints</a> <a >Scilit</a> <a >SciProfiles</a> <a >Encyclopedia</a> <a >JAMS</a> <a >Proceedings Series</a> </div> </div> </div> </div> <a > <h2>About</h2> </a> </div> <div > <a >Sign In / Sign Up</a> </div> </div> </div> <div > <h2 >Notice</h2> <a > <i >clear</i> </a> </div> <div > <div > <div > <h2 >Notice</h2> <p> You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader. </p> </div> </div> <div > <div > <a >Continue</a> <a >Cancel</a> </div> </div> <a > <i >clear</i> </a> </div> <div > <p> All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. </p> </div> <div > <p> Feature Papers represent the most advanced research with significant potential for high impact in the field. Feature Papers are submitted upon individual invitation or recommendation by the scientific editors and undergo peer review prior to publication. </p> <p> The Feature Paper can be either an original research article, a substantial novel research study that often involves several techniques or approaches, or a comprehensive review paper with concise and precise updates on the latest progress in the field that systematically reviews the most exciting advances in scientific literature. This type of paper provides an outlook on future directions of research or possible applications. </p> </div> <div > <p> Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to authors, or important in this field. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal. </p> </div> <div > <div >  </div> <section > <header> <div > <div > <div > <ul> <li > <a >25th Anniversary</a> </li> <li > <a >Journals</a> </li> <li > <a >Information</a> <ul > <li> <div > <div > <ul> <li> <a >For Authors</a> </li> <li> <a >For Reviewers</a> </li> <li> <a >For Editors</a> </li> <li> <a >For Librarians</a> </li> <li> <a >For Publishers</a> </li> <li> <a >For Societies</a> </li> </ul> </div> <div > <ul> <li> <a >Article Processing Charges</a> </li> <li> <a >Open Access Policy</a> </li> <li> <a >Institutional Open Access Program</a> </li> <li> <a >Editorial Process</a> </li> <li> <a >Awards</a> </li> <li> <a >Research and Publication Ethics</a> </li> </ul> </div> </div> </li> </ul> </li> <li > <a >Author Services</a> </li> <li > <a >Initiatives</a> <ul > <li> <div > <div > <ul> <li> <a > Sciforum </a> </li> <li> <a > MDPI Books </a> </li> <li> <a > Preprints </a> </li> <li> <a > Scilit </a> </li> <li> <a > SciProfiles </a> </li> <li> <a > Encyclopedia </a> </li> <li> <a > JAMS </a> </li> <li> <a > Proceedings Series </a> </li> </ul> </div> </div> </li> </ul> </li> <li > <a >About</a> </li> </ul> </div> <div > <div> <a >Sign In / Sign Up</a> <a >Submit</a> </div> </div> </div> </div> <div > <div > <div > <div > <a > Covered in: PubMed </a> </div></div> <div > <div > <a > IMPACTFACTOR 4.422 </a> </div> </div> </div> <div > Journals </div> <div > Vaccines </div> </div> </header> <div > <div > <div > <div > <div > <ul > <li> <a > <div > Less Isn't Always More: Antibody Dynamics Following Cocktail Vaccination </div> </a> </li> <li > <a > <div > COVID-19 Vaccination Willingness—Illness and Treatment Perceptions as Predictors </div> </a> </li> <li > <a > <div > TB and SIV Coinfection; a Model for Evaluating Vaccine Strategies against TB Reactivation: A Pilot Study Using BCG Vaccination </div> </a> </li> <li > <a > <div > Structurally Sound—Focused Subunit Vaccine Designed to Maximize Fc-Effector Activities Against HIV </div> </a> </li> <li > <a > <div > Interests of the Non-Human Primate Models for HIV Cure Research </div> </a> </li> </ul> </div> </div> <div > <div > <h2 >Journal Description</h2> </div> <div > <div > <h1> Vaccines </h1> <div > Vaccines is an international, <a >peer-reviewed</a>, open access journal published monthly online by MDPI. <a >The American Society for Virology (ASV)</a> is affiliated with Vaccines and their members receive a discount on the article processing charges. <ul> <li>Open Access— free for readers, with <a >article processing charges (APC)</a> paid by authors or their institutions.</li> <li>High Visibility: indexed within <a >Scopus</a>, <a >SCIE (Web of Science)</a>, <a >PubMed</a>, <a >PMC</a>, <a >Embase</a>, <a >CAPlus / SciFinder</a>, and many <a >other databases</a>.</li> <li>Journal Rank: JCR - Q2 (Immunology)</li> <li>Rapid Publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the first half of 2021).</li> <li>Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.</li> </ul> </div> <div > Impact Factor: 4.422 (2020) ; 5-Year Impact Factor: 5.513 (2020) </div> <div> <a > <i >subject</i> Imprint Information </a> <a > <i >get_app</i> Journal Flyer </a> <a > Open Access </a> ISSN: 2076-393X </div> </div> </div> </div> <div > <div > <h2 >Latest Articles</h2> </div> <div > <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page <a >Full-Text HTML</a> </div> </div> <div >Open AccessArticle</div> Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis <div > by <span ><div >Lutz Achtnichts</div>, </span><span ><div >Barbara Jakopp</div>, </span><span ><div >Michael Oberle</div>, </span><span ><div >Krassen Nedeltchev</div>, </span><span ><div >Christoph Andreas Fux</div>, </span><span ><div >Johann Sellner</div> and </span><span ><div >Oliver Findling</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1470; https://doi.org/10.3390/vaccines9121470 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > CD20 depletion is a risk factor for unfavorable outcomes of COVID-19 in people with MS (pwMS). Evidence suggests that protective IgG response to mRNA-based vaccines in B cell-depleted individuals is limited. We studied the seroconversion after the third mRNA SARS-CoV-2 vaccine in B [...] Read more. </div> <div > CD20 depletion is a risk factor for unfavorable outcomes of COVID-19 in people with MS (pwMS). Evidence suggests that protective IgG response to mRNA-based vaccines in B cell-depleted individuals is limited. We studied the seroconversion after the third mRNA SARS-CoV-2 vaccine in B cell-depleted pwMS with limited or no IgG response after the standard immunization. Sixteen pwMS treated with ocrelizumab or rituximab received a third homologous SARS-CoV-2 mRNA vaccine, either the Moderna mRNA-1273 or Pfizer-BioNTech’s BNT162b2 vaccine. We quantified the response of IgG antibodies against the spike receptor-binding domain of SARS-CoV-2 four weeks later. An antibody titer of 100 AU/mL or more was considered clinically relevant. The median time between the last infusion of the anti-CD20 treatment and the third vaccination was 22.9 weeks (range 15.1–31.3). After the third vaccination, one out of 16 patients showed an IgG titer deemed clinically relevant. Only the seroconverted patient had measurable B-cell counts at the time of the third vaccination. The development of a humoral immune response remains rare in pwMS on anti-CD20 therapy, even after third dose of the homologous SARS-CoV-2 mRNA vaccine. It remains to be determined whether T-cell responses can compensate for the lack of seroconversion and provide sufficient protection against CoV-2 infections. Full article </div> </div> <div > (This article belongs to the Section COVID-19 Vaccines and Vaccination) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Intention of Parents to Immunize Children against SARS-CoV-2 in Italy <div > by <span ><div >Luisa Russo</div>, </span><span ><div >Ileana Croci</div>, </span><span ><div >Ilaria Campagna</div>, </span><span ><div >Elisabetta Pandolfi</div>, </span><span ><div >Alberto Villani</div>, </span><span ><div >Antonino Reale</div>, </span><span ><div >Maria Antonietta Barbieri</div>, </span><span ><div >Massimiliano Raponi</div>, </span><span ><div >Francesco Gesualdo</div> and </span><span ><div >Alberto Eugenio Tozzi</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1469; https://doi.org/10.3390/vaccines9121469 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > Several countries have targeted adolescents for immunization against SARS-CoV-2 to mitigate COVID-19 spread. In Italy, immunization for children ≥ 12 years has been available starting from June 2021. We conducted a cross-sectional study to investigate the knowledge, attitude and intention to vaccinate children [...] Read more. </div> <div > Several countries have targeted adolescents for immunization against SARS-CoV-2 to mitigate COVID-19 spread. In Italy, immunization for children ≥ 12 years has been available starting from June 2021. We conducted a cross-sectional study to investigate the knowledge, attitude and intention to vaccinate children &lt; 18 years in Italian families. We used a multinomial logistic regression model to investigate factors associated with intention to vaccinate. We collected a total of 1696 responses. Among the 491 families of children ≥ 12 years, 41.2% would not vaccinate their children and 21.2% were uncertain, while among the 1205 families of children &lt; 12 years, 36.1% would not vaccinate and 33.8% were uncertain. Determinants of intention to vaccinate both age groups were perceived safety and efficacy of vaccines and perceived risk of transmitting infection to adults. For children &lt; 12 years, additional determinants were perceived risk of being infected and being hospitalized because of COVID-19. In view of the expanding strategy to vaccinate adolescents and the availability of immunization for children &lt; 12 years, our results call for a communication strategy targeted at families of children focused on the safety and efficacy of COVID-19 vaccine in children and on the dynamics of infection spread across different age groups. As perceptions in families are volatile and may change rapidly over time, repeated surveys for measuring attitudes to vaccinate would be advisable. Full article </div> </div> <div > (This article belongs to the Special Issue Factors Associated with Vaccine Hesitancy) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults <div > by <span ><div >Eve Versage</div>, </span><span ><div >Esther van Twuijver</div>, </span><span ><div >Wim Jansen</div>, </span><span ><div >Ad Theeuwes</div>, </span><span ><div >Daphne Sawlwin</div> and </span><span ><div >Matthew Hohenboken</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1468; https://doi.org/10.3390/vaccines9121468 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > Modern cell culture-based technology eliminates vaccine manufactures reliance on embryonated chicken eggs, which may become compromised during an avian influenza pandemic. Four studies (total N = 6230) assessed the immunogenicity and safety of mammalian cell-based, MF59<sup>®</sup>-adjuvanted, A/H5N1 vaccine (aH5N1c; AUDENZ™) as [...] Read more. </div> <div > Modern cell culture-based technology eliminates vaccine manufactures reliance on embryonated chicken eggs, which may become compromised during an avian influenza pandemic. Four studies (total N = 6230) assessed the immunogenicity and safety of mammalian cell-based, MF59<sup>®</sup>-adjuvanted, A/H5N1 vaccine (aH5N1c; AUDENZ™) as two doses administered on Days 1 and 22 in children (NCT01776554), adults (NCT01776541; NCT02839330), and older adults (NCT01766921; NCT02839330). Immunogenicity of formulations at 7.5 μg and 3.75 μg antigen per dose were assessed by hemagglutination inhibition and microneutralization assays on Days 1, 22, 43, and 183 or 387. Solicited local and systemic adverse events (AEs) were recorded for 7 days after each vaccination. Unsolicited AEs were collected for 21 days after each vaccination, and serious and other selected AEs were recorded for one year. Antibody responses after two 7.5 μg doses met CBER licensure criteria in all age groups. Overall, an age-related response was evident, with the highest responses observed in children &lt;3 years old. In children, antibody titers met seroconversion criteria 12 months after vaccination. MF59 allowed for antigen dose sparing. Solicited AEs were mild to moderate in nature, of short duration, and less frequent after the second dose than the first, demonstrating a favorable risk-benefit profile. Full article </div> </div> <div > (This article belongs to the Section Influenza Virus Vaccines) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 176 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> COVID-19 Immunisation, Willingness to Be Vaccinated and Vaccination Strategies to Improve Vaccine Uptake in Australia <div > by <span ><div >Bing Wang</div>, </span><span ><div >Rebecca Nolan</div> and </span><span ><div >Helen Marshall</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1467; https://doi.org/10.3390/vaccines9121467 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > The COVID-19 vaccine rollout is crucial to lifting community and economic restrictions. This cross-sectional study aimed to assess: (a) COVID-19 vaccine uptake and associated factors; (b) COVID-19 vaccine intentions and associated factors; (c) community support for COVID-19 vaccination strategies and associated factors. The [...] Read more. </div> <div > The COVID-19 vaccine rollout is crucial to lifting community and economic restrictions. This cross-sectional study aimed to assess: (a) COVID-19 vaccine uptake and associated factors; (b) COVID-19 vaccine intentions and associated factors; (c) community support for COVID-19 vaccination strategies and associated factors. The survey was conducted between May and July 2021 in Australia. Of 3003 participants, 30% reported they were already vaccinated and 39% indicated they would get vaccinated. Low socioeconomic and education levels, non-English speaking backgrounds and being parents were associated with decreased vaccine willingness and/or vaccination rates. High levels of support for vaccination strategies were demonstrated with mandatory vaccination being less preferable. Respondents from non-English speaking backgrounds were more likely to support a mandatory vaccination policy. Respondents with the highest socioeconomic level were more likely to support vaccination requirements for international travel, visiting nursing homes and working in healthcare settings. Respondents who were aged ≥70 years were more likely to support all proposed vaccination strategies. Targeted campaigns should be implemented for parents and those who live in socioeconomic disadvantaged areas and have lower educational attainment. Concise and clear vaccine information should be provided in lay and multiple languages to improve vaccine confidence. Vaccine enforcement policies should be considered and implemented with caution. Full article </div> </div> <div > (This article belongs to the Section COVID-19 Vaccines and Vaccination) </div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 186 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Equity in Vaccine Trials for Higher Weight People? A Rapid Review of Weight-Related Inclusion and Exclusion Criteria for COVID-19 Clinical Trials <div > by <span ><div >Jessica Campbell</div>, </span><span ><div >Juliet Sutherland</div>, </span><span ><div >Danielle Bucknall</div>, </span><span ><div >Lily O’Hara</div>, </span><span ><div >Anita Heywood</div>, </span><span ><div >Matthew Hobbs</div>, </span><span ><div >Angela Ballantyne</div> and </span><span ><div >Lesley Gray</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1466; https://doi.org/10.3390/vaccines9121466 (registering DOI) - 11 Dec 2021 </div> <div > Abstract <div > Higher weight status, defined as body mass index (BMI) ≥ 30 kg/m<sup>2</sup>, is frequently described as a risk factor for severity and susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (known as COVID-19). Therefore, study groups in COVID-19 vaccine [...] Read more. </div> <div > Higher weight status, defined as body mass index (BMI) ≥ 30 kg/m<sup>2</sup>, is frequently described as a risk factor for severity and susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (known as COVID-19). Therefore, study groups in COVID-19 vaccine trials should be representative of the weight spectrum across the global population. Appropriate subgroup analysis should be conducted to ensure equitable vaccine outcomes for higher weight people. In this study, inclusion and exclusion criteria of registered clinical trial protocols were reviewed to determine the proportion of trials including higher weight people, and the proportion of trials conducting subgroup analyses of efficacy by BMI. Eligibility criteria of 249 trial protocols (phase I, II, III and IV) were analysed; 51 protocols (20.5%) specified inclusion of BMI &gt; 30, 73 (29.3%) specified exclusion of BMI &gt; 30, and 125 (50.2%) did not specify whether BMI was an inclusion or exclusion criterion, or if BMI was included in any ‘health’ screenings or physical examinations during recruitment. Of the 58 protocols for trials in phase III and IV, only 2 (3.4%) indicated an intention to report subgroup analysis of vaccine efficacy by weight status. Higher weight people appear to be significantly under-represented in the majority of vaccine trials. This may result in reduced efficacy and acceptance of COVID-19 vaccines for higher weight people and exacerbation of health inequities within this population group. Explicit inclusion of higher weight people in COVID-19 vaccine trials is required to reduce health inequities. Full article </div> </div> <div > (This article belongs to the Special Issue Vaccines: Uptake and Equity in Times of the COVID-19 Pandemic) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 4358 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessReview</div> Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review <div > by <span ><div >Adinda Kok</div>, </span><span ><div >Ron A. M. Fouchier</div> and </span><span ><div >Mathilde Richard</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1465; https://doi.org/10.3390/vaccines9121465 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > Avian influenza viruses from the A/H5 A/goose/Guangdong/1/1996 (GsGd) lineage pose a continuing threat to animal and human health. Since their emergence in 1997, these viruses have spread across multiple continents and have become enzootic in poultry. Additionally, over 800 cases of human infection [...] Read more. </div> <div > Avian influenza viruses from the A/H5 A/goose/Guangdong/1/1996 (GsGd) lineage pose a continuing threat to animal and human health. Since their emergence in 1997, these viruses have spread across multiple continents and have become enzootic in poultry. Additionally, over 800 cases of human infection with A/H5 GsGd viruses have been reported to date, which raises concerns about the potential for a new influenza virus pandemic. The continuous circulation of A/H5 GsGd viruses for over 20 years has resulted in the genetic and antigenic diversification of their hemagglutinin (HA) surface glycoprotein, which poses a serious challenge to pandemic preparedness and vaccine design. In the present article, clinical studies on A/H5 influenza vaccination strategies were reviewed to evaluate the breadth of antibody responses induced upon homologous and heterologous prime-boost vaccination strategies. Clinical data on immunological endpoints were extracted from studies and compiled into a dataset, which was used for the visualization and analysis of the height and breadth of humoral immune responses. Several aspects leading to high immunogenicity and/or cross-reactivity were identified, although the analysis was limited by the heterogeneity in study design and vaccine type used in the included studies. Consequently, crucial questions remain to be addressed in future studies on A/H5 GsGd vaccination strategies. Full article </div> </div> <div > (This article belongs to the Special Issue Immune Responses to Influenza Virus Antigens) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> mRNA Vaccine Protects against Zika Virus <div > by <span ><div >Lex G. Medina-Magües</div>, </span><span ><div >Janina Gergen</div>, </span><span ><div >Edith Jasny</div>, </span><span ><div >Benjamin Petsch</div>, </span><span ><div >Jaime Lopera-Madrid</div>, </span><span ><div >Emily S. Medina-Magües</div>, </span><span ><div >Cristhian Salas-Quinchucua</div> and </span><span ><div >Jorge E. Osorio</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1464; https://doi.org/10.3390/vaccines9121464 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > Zika virus (ZIKV), a mosquito-borne flavivirus, has recently triggered global concern due to severe health complications. In 2015, a large ZIKV outbreak occurred in the Americas and established a link between ZIKV and microcephaly in newborn babies, spontaneous abortion, persistent viremia, and Guillain–Barré [...] Read more. </div> <div > Zika virus (ZIKV), a mosquito-borne flavivirus, has recently triggered global concern due to severe health complications. In 2015, a large ZIKV outbreak occurred in the Americas and established a link between ZIKV and microcephaly in newborn babies, spontaneous abortion, persistent viremia, and Guillain–Barré syndrome. While antivirals are being developed and prevention strategies focus on vector control, a safe and effective Zika vaccine remains unavailable. Messenger RNA (mRNA) vaccine technology has arisen as a flexible, simplified, and fast vaccine production platform. Here, we report on an mRNA vaccine candidate that encodes the pre-membrane and envelope (prM–E) glycoproteins of ZIKV strain Brazil SPH2015 and is encapsulated in lipid nanoparticles (LNPs). Our ZIKV prM–E mRNA-LNP vaccine candidate induced antibody responses that protected in AG129 mice deficient in interferon (IFN) alpha/beta/gamma (IFN-α/β/γ) receptors. Notably, a single administration of ZIKV prM–E mRNA-LNP protected against a lethal dose of ZIKV, while a two-dose strategy induced strong protective immunity. E-specific double-positive IFN-γ and TNF-α T-cells were induced in BALB/c mice after immunizations with a two-dose strategy. With the success of mRNA vaccine technology in facing the coronavirus (COVID-19) pandemic, our data support the development of prM–E RNActive<sup>®</sup> as a promising mRNA vaccine against Zika to counter future epidemics. Full article </div> </div> <div > (This article belongs to the Topic Animal Model in Biomedical Research) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 215 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page </div> </div> <div >Open AccessArticle</div> Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection <div > by <span ><div >Oleguer Parés-Badell</div>, </span><span ><div >Xavier Martínez-Gómez</div>, </span><span ><div >Laia Pinós</div>, </span><span ><div >Blanca Borras-Bermejo</div>, </span><span ><div >Sonia Uriona</div>, </span><span ><div >Susana Otero-Romero</div>, </span><span ><div >José Ángel Rodrigo-Pendás</div>, </span><span ><div >Yolima Cossio-Gil</div>, </span><span ><div >Antònia Agustí</div>, </span><span ><div >Cristina Aguilera</div> and </span><span ><div >Magda Campins</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1463; https://doi.org/10.3390/vaccines9121463 (registering DOI) - 10 Dec 2021 </div> <div > Abstract <div > The aim of this study was to assess adverse reactions to COVID-19 vaccines, comparing the BNT162b2 or the mRNA-1273 COVID-19 vaccines and the presence and seriousness of a previous COVID-19 infection. We conducted a cross-sectional online survey of vaccinated healthcare workers at a [...] Read more. </div> <div > The aim of this study was to assess adverse reactions to COVID-19 vaccines, comparing the BNT162b2 or the mRNA-1273 COVID-19 vaccines and the presence and seriousness of a previous COVID-19 infection. We conducted a cross-sectional online survey of vaccinated healthcare workers at a tertiary hospital in Barcelona (Spain). Thirty-eight percent of vaccine recipients responded to the questionnaire. We compared the prevalence of adverse reactions by vaccine type and history of COVID-19 infections. A total of 2373 respondents had received the BNT162b2 vaccine, and 506 the mRNA-1273 vaccine. The prevalence of at least one adverse reaction with doses 1 and 2 was 41% and 70%, respectively, in the BNT162b2 group, and 60% and 92% in the mRNA-1273 group (<i>p </i>&lt; 0.001). The BNT162b2 group reported less prevalence of all adverse reactions. Need for medical leave was significantly more frequent among the mRNA-1273 group (12% versus 4.6% <i>p </i>&lt; 0.001). Interestingly, respondents with a history of allergies or chronic illnesses did not report more adverse reactions. The frequency of adverse reactions with dose 2 was 96% (95% CI 88–100%) for those with a history of COVID-19 related hospitalization, and 86% (95% CI 83–89%) for those with mild or moderate symptomatic COVID-19, significantly higher than for participants with no history of COVID-19 infections (67%, 95% CI 65–69%). Our results could help inform vaccine recipients of the probability of their having adverse reactions to COVID-19 vaccines. Full article </div> </div> <div > (This article belongs to the Special Issue Recombinant Vaccines Produced in Emerging Expression Systems for Human and Animal Health) </div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Expected Evolution of COVID-19 Epidemic in France for Several Combinations of Vaccination Strategies and Barrier Measures <div > by <span ><div >Simon Pageaud</div>, </span><span ><div >Catherine Pothier</div>, </span><span ><div >Christophe Rigotti</div>, </span><span ><div >Anne Eyraud-Loisel</div>, </span><span ><div >Jean-Pierre Bertoglio</div>, </span><span ><div >Alexis Bienvenüe</div>, </span><span ><div >Nicolas Leboisne</div>, </span><span ><div >Nicolas Ponthus</div>, </span><span ><div >Romain Gauchon</div>, </span><span ><div >François Gueyffier</div>, </span><span ><div >Philippe Vanhems</div>, </span><span ><div >Jean Iwaz</div>, </span><span ><div >Stéphane Loisel</div>, </span><span ><div >Pascal Roy</div> and </span>on behalf of the Group CovDyn (Covid Dynamics) </div> <div > Vaccines <b>2021</b>, 9(12), 1462; https://doi.org/10.3390/vaccines9121462 - 10 Dec 2021 </div> <div > Abstract <div > The outbreak of the SARS-CoV-2 virus, enhanced by rapid spreads of variants, has caused a major international health crisis, with serious public health and economic consequences. An agent-based model was designed to simulate the evolution of the epidemic in France over 2021 and [...] Read more. </div> <div > The outbreak of the SARS-CoV-2 virus, enhanced by rapid spreads of variants, has caused a major international health crisis, with serious public health and economic consequences. An agent-based model was designed to simulate the evolution of the epidemic in France over 2021 and the first six months of 2022. The study compares the efficiencies of four theoretical vaccination campaigns (over 6, 9, 12, and 18 months), combined with various non-pharmaceutical interventions. In France, with the emergence of the Alpha variant, without vaccination and despite strict barrier measures, more than 600,000 deaths would be observed. An efficient vaccination campaign (i.e., total coverage of the French population) over six months would divide the death toll by 10. A vaccination campaign of 12, instead of 6, months would slightly increase the disease-related mortality (+6%) but require a 77% increase in ICU bed–days. A campaign over 18 months would increase the disease-related mortality by 17% and require a 244% increase in ICU bed–days. Thus, it seems mandatory to vaccinate the highest possible percentage of the population within 12, or better yet, 9 months. The race against the epidemic and virus variants is really a matter of vaccination strategy. Full article </div> </div> <div > (This article belongs to the Section COVID-19 Vaccines and Vaccination) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Public Perceptions and Acceptance of COVID-19 Booster Vaccination in China: A Cross-Sectional Study <div > by <span ><div >Xiaozhen Lai</div>, </span><span ><div >He Zhu</div>, </span><span ><div >Jiahao Wang</div>, </span><span ><div >Yingzhe Huang</div>, </span><span ><div >Rize Jing</div>, </span><span ><div >Yun Lyu</div>, </span><span ><div >Haijun Zhang</div>, </span><span ><div >Huangyufei Feng</div>, </span><span ><div >Jia Guo</div> and </span><span ><div >Hai Fang</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1461; https://doi.org/10.3390/vaccines9121461 - 10 Dec 2021 </div> <div > Abstract <div > Coronavirus disease 2019 (COVID-19) booster vaccination has been proposed in response to the new challenges of highly contagious variants, yet few studies have examined public acceptance of boosters. This study examined public acceptance of COVID-19 booster vaccination and its influencing factors by using [...] Read more. </div> <div > Coronavirus disease 2019 (COVID-19) booster vaccination has been proposed in response to the new challenges of highly contagious variants, yet few studies have examined public acceptance of boosters. This study examined public acceptance of COVID-19 booster vaccination and its influencing factors by using the data from a self-administered online cross-sectional survey conducted in June 2021 in China. Multiple logistic analysis was used to examine the influencing factors of booster acceptance based on the health belief model (HBM). Among 1145 respondents, 84.80% reported to accept COVID-19 booster vaccination. Having COVID-19 vaccination history, perceiving high benefits and low barriers to booster vaccination, being younger (18–30 vs. 41–50), having a lower education level, being employed, and belonging to priority groups for vaccination were associated with increased odds of booster acceptance. The primary reason for refusing booster vaccination was concern about vaccine safety. The vast majority (92.8%) of respondents reported an annual willingness to pay between 0 and 300 CNY (0–46.29 USD) if the booster was not free. Our findings suggest that the acceptance rate of booster vaccination is relatively high in China, and the HBM-based analysis reveals that more efforts are needed to increase perceived benefits and reduce perceived barriers of vaccination to design effective and proper vaccination extension strategies when boosters become widely recommended. Full article </div> </div> <div > (This article belongs to the Section COVID-19 Vaccines and Vaccination) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 1651 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Model-Based Planning and Delivery of Mass Vaccination Campaigns against Infectious Disease: Application to the COVID-19 Pandemic in the UK <div > by <span ><div >Dauda Ibrahim</div>, </span><span ><div >Zoltán Kis</div>, </span><span ><div >Kyungjae Tak</div>, </span><span ><div >Maria M. Papathanasiou</div>, </span><span ><div >Cleo Kontoravdi</div>, </span><span ><div >Benoît Chachuat</div> and </span><span ><div >Nilay Shah</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1460; https://doi.org/10.3390/vaccines9121460 - 10 Dec 2021 </div> <div > Abstract <div > Vaccination plays a key role in reducing morbidity and mortality caused by infectious diseases, including the recent COVID-19 pandemic. However, a comprehensive approach that allows the planning of vaccination campaigns and the estimation of the resources required to deliver and administer COVID-19 vaccines [...] Read more. </div> <div > Vaccination plays a key role in reducing morbidity and mortality caused by infectious diseases, including the recent COVID-19 pandemic. However, a comprehensive approach that allows the planning of vaccination campaigns and the estimation of the resources required to deliver and administer COVID-19 vaccines is lacking. This work implements a new framework that supports the planning and delivery of vaccination campaigns. Firstly, the framework segments and priorities target populations, then estimates vaccination timeframe and workforce requirements, and lastly predicts logistics costs and facilitates the distribution of vaccines from manufacturing plants to vaccination centres. The outcomes from this study reveal the necessary resources required and their associated costs ahead of a vaccination campaign. Analysis of results shows that by integrating demand stratification, administration, and the supply chain, the synergy amongst these activities can be exploited to allow planning and cost-effective delivery of a vaccination campaign against COVID-19 and demonstrates how to sustain high rates of vaccination in a resource-efficient fashion. Full article </div> </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 1060 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population <div > by <span ><div >Marsia Gustiananda</div>, </span><span ><div >Bobby Prabowo Sulistyo</div>, </span><span ><div >David Agustriawan</div> and </span><span ><div >Sita Andarini</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1459; https://doi.org/10.3390/vaccines9121459 - 09 Dec 2021 </div> <div > Abstract <div > SARS-CoV-2 and its variants caused the COVID-19 pandemic. Vaccines that target conserved regions of SARS-CoV-2 and stimulate protective T-cell responses are important for reducing symptoms and limiting the infection. Seven cytotoxic (CTL) and five helper T-cells (HTL) epitopes from ORF1ab were identified using [...] Read more. </div> <div > SARS-CoV-2 and its variants caused the COVID-19 pandemic. Vaccines that target conserved regions of SARS-CoV-2 and stimulate protective T-cell responses are important for reducing symptoms and limiting the infection. Seven cytotoxic (CTL) and five helper T-cells (HTL) epitopes from ORF1ab were identified using NetCTLpan and NetMHCIIpan algorithms, respectively. These epitopes were generated from ORF1ab regions that are evolutionary stable as reflected by zero Shannon’s entropy and are presented by 56 human leukocyte antigen (HLA) Class I and 22 HLA Class II, ensuring good coverage for the Indonesian and world population. Having fulfilled other criteria such as immunogenicity, IFNγ inducing ability, and non-homology to human and microbiome peptides, the epitopes were assembled into a vaccine construct (VC) together with β-defensin as adjuvant and appropriate linkers. The VC was shown to have good physicochemical characteristics and capability of inducing CTL as well as HTL responses, which stem from the engagement of the vaccine with toll-like receptor 4 (TLR4) as revealed by docking simulations. The most promiscuous peptide <sup>899</sup>WSMATYYLF<sup>907</sup> was shown via docking simulation to interact well with HLA-A*24:07, the most predominant allele in Indonesia. The data presented here will contribute to the in vitro study of T-cell epitope mapping and vaccine design in Indonesia. Full article </div> </div> <div > (This article belongs to the Section COVID-19 Vaccines and Vaccination) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 591 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity <div > by <span ><div >Ying Liu</div>, </span><span ><div >Junyan Han</div>, </span><span ><div >Xin Li</div>, </span><span ><div >Danying Chen</div>, </span><span ><div >Xuesen Zhao</div>, </span><span ><div >Yaruo Qiu</div>, </span><span ><div >Leidan Zhang</div>, </span><span ><div >Jing Xiao</div>, </span><span ><div >Bei Li</div> and </span><span ><div >Hongxin Zhao</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1458; https://doi.org/10.3390/vaccines9121458 - 09 Dec 2021 </div> <div > Abstract <div > The administration of COVID-19 vaccines is the primary strategy used to prevent further infections by COVID-19, especially in people living with HIV (PLWH), who are at increased risk for severe symptoms and mortality. However, the vaccine hesitancy, safety, and immunogenicity of COVID-19 vaccines [...] Read more. </div> <div > The administration of COVID-19 vaccines is the primary strategy used to prevent further infections by COVID-19, especially in people living with HIV (PLWH), who are at increased risk for severe symptoms and mortality. However, the vaccine hesitancy, safety, and immunogenicity of COVID-19 vaccines among PLWH have not been fully characterized. We estimated vaccine hesitancy and status of COVID-19 vaccination in Chinese PLWH, explored the safety and impact on antiviral therapy (ART) efficacy and compared the immunogenicity of an inactivated vaccine between PLWH and healthy controls (HC). In total, 27.5% (104/378) of PLWH hesitated to take the vaccine. The barriers included concerns about safety and efficacy, and physician counselling might help patients overcome this vaccine hesitancy. A COVID-19 vaccination did not cause severe side effects and had no negative impact on CD4<sup>+</sup> T cell counts and HIV RNA viral load. Comparable spike receptor binding domain IgG titer were elicited in PLWH and HC after a second dose of the CoronaVac vaccine, but antibody responses were lower in poor immunological responders (CD4<sup>+</sup> T cell counts &lt; 350 cells/µL) compared with immunological responders (CD4<sup>+</sup> T cell counts ≥ 350 cells/µL). These data showed that PLWH have comparable safety and immune response following inactivated COVID-19 vaccination compared with HC, but the poor immunological response in PLWH is associated with impaired humoral response. Full article </div> </div> <div > (This article belongs to the Special Issue SARS-CoV-2 (COVID-19) Vaccination and Compliance/Hesitancy) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 789 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Comparative Evaluation of Immune Responses and Protection of Chitosan Nanoparticles and Oil-Emulsion Adjuvants in Avian Coronavirus Inactivated Vaccines in Chickens <div > by <span ><div >Priscila Diniz Lopes</div>, </span><span ><div >Cintia Hiromi Okino</div>, </span><span ><div >Filipe Santos Fernando</div>, </span><span ><div >Caren Pavani</div>, </span><span ><div >Viviane Casagrande Mariguela</div>, </span><span ><div >Maria de Fátima Silva Montassier</div> and </span><span ><div >Hélio José Montassier</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1457; https://doi.org/10.3390/vaccines9121457 - 09 Dec 2021 </div> <div > Abstract <div > Efficient vaccines are the main strategy to control the avian coronavirus (AvCoV), although several drawbacks related to traditional attenuated and inactivated vaccines have been reported. These counterpoints highlight the importance of developing new alternative vaccines against AvCoV, especially those able to induce long-lasting [...] Read more. </div> <div > Efficient vaccines are the main strategy to control the avian coronavirus (AvCoV), although several drawbacks related to traditional attenuated and inactivated vaccines have been reported. These counterpoints highlight the importance of developing new alternative vaccines against AvCoV, especially those able to induce long-lasting immune responses. This study evaluated and compared two inactivated vaccines formulated with AvCoV BR-I variants, one composed of chitosan nanoparticles (AvCoV-CS) and the second by Montanide oily adjuvant (AvCoV-O). Both developed vaccines were administered in a single dose or associated with the traditional Mass attenuated vaccine. The AvCoV-CS vaccine administered alone or associated with the Mass vaccine was able to induce strong humoral and cell-mediated immune (CMI) responses and complete protection against IBV virulent infection, wherein single administration was characterized by high IgA antibody levels in the mucosa, whereas when associated with the Mass vaccine, the serum IgG antibody was predominantly observed. On the other hand, single administration of the oily vaccine presented poor humoral and CMI responses and consequently incomplete protection against virulent challenge, but when associated with the Mass vaccine, immune responses were developed, and complete protection against infection was observed. Both of our experimental vaccines were able to induce full protection against virulent IBV challenge. A single dose of AvCoV-CS vaccine was sufficient to achieve complete protection, while AvCoV-O required a previous priming by a Mass strain to complete the protection. Full article </div> </div> <div > (This article belongs to the Section Veterinary Vaccines) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Myelin Peptide–Mannan Conjugate Multiple Sclerosis Vaccines: Conjugation Efficacy and Stability of Vaccine Ingredient <div > by <span ><div >John Matsoukas</div>, </span><span ><div >George Deraos</div>, </span><span ><div >Kostas Kelaidonis</div>, </span><span ><div >Md Kamal Hossain</div>, </span><span ><div >Jack Feehan</div>, </span><span ><div >Andreas G. Tzakos</div>, </span><span ><div >Elizabeth Matsoukas</div>, </span><span ><div >Emmanuel Topoglidis</div> and </span><span ><div >Vasso Apostolopoulos</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1456; https://doi.org/10.3390/vaccines9121456 - 08 Dec 2021 </div> <div > Abstract <div > Myelin peptide–mannan conjugates have been shown to be potential vaccines in the immunotherapy of multiple sclerosis. The conjugates are comprised from the epitope peptide and the polysaccharide mannan which transfers as a carrier the antigenic peptide to dendritic cells that process and present [...] Read more. </div> <div > Myelin peptide–mannan conjugates have been shown to be potential vaccines in the immunotherapy of multiple sclerosis. The conjugates are comprised from the epitope peptide and the polysaccharide mannan which transfers as a carrier the antigenic peptide to dendritic cells that process and present antigenic peptides at their surface in complex with MHC class I or class II resulting in T-cell stimulation. The conjugation of antigenic peptide with mannan occurs through the linker (Lys–Gly)5, which connects the peptide with the oxidized mannose units of mannan. This study describes novel methods for the quantification of the vaccine ingredient peptide within the conjugate, a prerequisite for approval of clinical trials in the pursuit of multiple sclerosis therapeutics. Myelin peptides, such as MOG<sub>35–55</sub>, MBP<sub>83–99</sub>, and PLP<sub>131–145</sub> in linear or cyclic form, as altered peptide ligands or conjugated to appropriate carriers, possess immunomodulatory properties in experimental models and are potential candidates for clinical trials. Full article </div> </div> <div > (This article belongs to the Special Issue Multiple Sclerosis, Complications and Therapeutics 2.0) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Educational Interventions on Pregnancy Vaccinations during Childbirth Classes Improves Vaccine Coverages among Pregnant Women in Palermo’s Province <div > by <span ><div >Claudio Costantino</div>, </span><span ><div >Walter Mazzucco</div>, </span><span ><div >Nicole Bonaccorso</div>, </span><span ><div >Livia Cimino</div>, </span><span ><div >Arianna Conforto</div>, </span><span ><div >Martina Sciortino</div>, </span><span ><div >Gabriele Catalano</div>, </span><span ><div >Maria Rosa D’Anna</div>, </span><span ><div >Antonio Maiorana</div>, </span><span ><div >Renato Venezia</div>, </span><span ><div >Giovanni Corsello</div> and </span><span ><div >Francesco Vitale</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1455; https://doi.org/10.3390/vaccines9121455 - 08 Dec 2021 </div> <div > Abstract <div > Maternal immunization is considered the best intervention in order to prevent influenza infection of pregnant women and influenza and pertussis infection of newborns. Despite the existing recommendations, vaccination coverage rates in Italy remain very low. Starting from August 2018, maternal immunization against influenza [...] Read more. </div> <div > Maternal immunization is considered the best intervention in order to prevent influenza infection of pregnant women and influenza and pertussis infection of newborns. Despite the existing recommendations, vaccination coverage rates in Italy remain very low. Starting from August 2018, maternal immunization against influenza and diphtheria-tetanus-pertussis were strongly recommended by the Italian Ministry of Health. We conducted a cross sectional study to estimate the effectiveness of an educational intervention, conducted during childbirth classes in three general hospitals in the Palermo metropolitan area, Italy, on vaccination adherence during pregnancy. To this end, a questionnaire on knowledge, attitudes, and immunization practices was structured and self-administered to a sample of pregnant women attending childbirth classes. Then, an educational intervention on maternal immunization, followed by a counseling, was conducted by a Public Health medical doctor. After 30 days following the interventions, the adherence to the recommended vaccinations (influenza and pertussis) was evaluated. At the end of the study 326 women were enrolled and 201 responded to the follow-up survey. After the intervention, among the responding pregnant women 47.8% received influenza vaccination (+44.8%), 57.7% diphtheria-tetanus-pertussis vaccination (+50.7%) and 64.2% both the recommended vaccinations (+54.8%). A significant association was found between pregnant women that received at least one vaccination during pregnancy and higher educational level (graduation degree/master’s degree), employment status (employed part/full-time) and influenza vaccination adherence during past seasons (at least one during last five years). The implementation of vaccination educational interventions, including counseling by healthcare professionals (HCPs), on maternal immunization during childbirth courses improved considerably the vaccination adherence during pregnancy. Full article </div> </div> <div > (This article belongs to the Special Issue Measure to Improve Vaccination Coverage In at Risk Categories: Pregnant Women, Healthcare Workers and Patients with Chronic Diseases) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Liver Transplant Recipients—Is It Related to Immunosuppression Only? <div > by <span ><div >Paulina Nazaruk</div>, </span><span ><div >Marta Monticolo</div>, </span><span ><div >Anna Maria Jędrzejczak</div>, </span><span ><div >Natalia Krata</div>, </span><span ><div >Barbara Moszczuk</div>, </span><span ><div >Joanna Sańko-Resmer</div>, </span><span ><div >Tomasz Pilecki</div>, </span><span ><div >Arkadiusz Urbanowicz</div>, </span><span ><div >Michał Florczak</div>, </span><span ><div >Leszek Pączek</div>, </span><span ><div >Bartosz Foroncewicz</div> and </span><span ><div >Krzysztof Mucha</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1454; https://doi.org/10.3390/vaccines9121454 - 08 Dec 2021 </div> <div > Abstract <div > The BNT162b2 vaccine is reportedly effective in preventing severe disease in more than 90% of the general population, but its efficacy in transplant recipients remains controversial. We aimed to determine the immune response to the BNT162b2 vaccine in kidney (KTRs) and liver transplant [...] Read more. </div> <div > The BNT162b2 vaccine is reportedly effective in preventing severe disease in more than 90% of the general population, but its efficacy in transplant recipients remains controversial. We aimed to determine the immune response to the BNT162b2 vaccine in kidney (KTRs) and liver transplant recipients (LTRs). In this retrospective cohort study, we included randomly 65 KTRs and 65 LTRs, who received two 30 μg doses of BNT162b2 vaccine in 3-to6-week intervals. We analyzed the anti-SARS-CoV-2 spike protein IgG antibody (anti-S1 Ab) titer, biochemical liver and renal tests, immunosuppressive drug trough level, and clinical follow up 4–6 weeks after the first dose and 4–8 weeks after the second dose. The level of protective antibodies was 57.1% in KTRs and 88.9% in LTRs after the second dose. The anti-S1 Ab response was significantly associated with sex, age, and history of COVID-19. A tacrolimus dose at vaccination but not its trough level was significantly correlated with the increase in anti-S1 Ab titer after the second vaccine dose in LTRs. Rejection episodes did not occur after vaccination. Our results showed a higher than previously reported humoral response to the BNT162b2 vaccine in KTRs and LTRs, which was dependent upon age, type of transplanted organ, and immunosuppression. Full article </div> </div> <div > (This article belongs to the Special Issue Assessment of Post-COVID-19 Complications and Vaccination Efficacy) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessFeature PaperArticle</div> <a >Mimicking Native Display of CD0873 on Liposomes Augments Its Potency as an Oral Vaccine against <i>Clostridioides difficile</i></a> <div > by <span ><div >Cansu Karyal</div>, </span><span ><div >Panayiota Palazi</div>, </span><span ><div >Jaime Hughes</div>, </span><span ><div >Rhys C. Griffiths</div>, </span><span ><div >Ruby R. Persaud</div>, </span><span ><div >Patrick J. Tighe</div>, </span><span ><div >Nicholas J. Mitchell</div> and </span><span ><div >Ruth Griffin</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1453; https://doi.org/10.3390/vaccines9121453 - 08 Dec 2021 </div> <div > Abstract <div > Mucosal vaccination aims to prevent infection mainly by inducing secretory IgA (sIgA) antibody, which neutralises pathogens and enterotoxins by blocking their attachment to epithelial cells. We previously demonstrated that encapsulated protein antigen CD0873 given orally to hamsters induces neutralising antibodies locally as well [...] Read more. </div> <div > Mucosal vaccination aims to prevent infection mainly by inducing secretory IgA (sIgA) antibody, which neutralises pathogens and enterotoxins by blocking their attachment to epithelial cells. We previously demonstrated that encapsulated protein antigen CD0873 given orally to hamsters induces neutralising antibodies locally as well as systemically, affording partial protection against <i>Clostridioides difficile</i> infection. The aim of this study was to determine whether displaying CD0873 on liposomes, mimicking native presentation, would drive a stronger antibody response. The recombinant form we previously tested resembles the naturally cleaved lipoprotein commencing with a cysteine but lacking lipid modification. A synthetic lipid (DHPPA-Mal) was designed for conjugation of this protein via its N-terminal cysteine to the maleimide headgroup. DHPPA-Mal was first formulated with liposomes to produce MalLipo; then, CD0873 was conjugated to headgroups protruding from the outer envelope to generate CD0873-MalLipo. The immunogenicity of CD0873-MalLipo was compared to CD0873 in hamsters. Intestinal sIgA and CD0873-specific serum IgG were induced in all vaccinated animals; however, neutralising activity was greatest for the CD0873-MalLipo group. Our data hold great promise for development of a novel oral vaccine platform driving intestinal and systemic immune responses. Full article </div> </div> <div > (This article belongs to the Special Issue Decoding Host and Microbial Communications in Infection and Vaccination) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >attachment</i> </a> <div > Supplementary material: Supplementary File 1 (ZIP, 250 KiB) </div> </div> <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessReview</div> Does Influenza Vaccination during Pregnancy Have Effects on Non-Influenza Infectious Morbidity? A Systematic Review and Meta-Analysis of Randomised Controlled Trials <div > by <span ><div >Katrine Pedersbæk Hansen</div>, </span><span ><div >Christine Stabell Benn</div>, </span><span ><div >Thomas Aamand</div>, </span><span ><div >Martin Buus</div>, </span><span ><div >Isaquel da Silva</div>, </span><span ><div >Peter Aaby</div>, </span><span ><div >Ane Bærent Fisker</div> and </span><span ><div >Sanne Marie Thysen</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1452; https://doi.org/10.3390/vaccines9121452 - 08 Dec 2021 </div> <div > Abstract <div > The recommendation to provide inactivated influenza vaccine (IIV) to pregnant women is based on observed protection against influenza-related morbidity in mother and infant. Non-live vaccines may have non-specific effects (NSEs), increasing the risk of non-targeted infections in females. We reviewed the evidence from [...] Read more. </div> <div > The recommendation to provide inactivated influenza vaccine (IIV) to pregnant women is based on observed protection against influenza-related morbidity in mother and infant. Non-live vaccines may have non-specific effects (NSEs), increasing the risk of non-targeted infections in females. We reviewed the evidence from available randomised controlled trials (RCTs) of IIV to pregnant women, to assess whether IIV may have NSEs. Four RCTs, all conducted in low- and middle-income settings, were identified. We extracted information on all-cause and infectious mortality and adverse events in women and their infants. We conducted meta-analyses providing risk ratios (RR). The meta-analysis for maternal all-cause mortality provided a RR of 1.48 (95% CI = 0.52–4.16). The estimates for miscarriage/stillbirth and infant all-cause mortality up to 6 months of age were 1.06 (0.78–1.44) and 1.11 (0.87–1.41), respectively. IIV was associated with a higher risk of non-influenza infectious adverse events, with meta-estimates of 2.01 (1.15–3.50) in women and 1.36 (1.12–1.67) in infants up to 6 months of age. Thus, following a pattern seen for other non-live vaccines, IIV was associated with a higher risk of non-influenza infectious adverse events. To ensure that scarce resources are used well, and no harm is inflicted, further RCTs are warranted. Full article </div> </div> <div > (This article belongs to the Special Issue Non-specific Protections in Response to Vaccination and Other Stimulations of the Immune System) </div> ►▼ Show Figures <div ><div ><div ><p>Figure 1</p></div></div></div> </div> </div> </div> <div > <div > <div > <div > <a > <i >get_app</i> </a> </div> <div > <a > <i >subject</i> </a> <div > View online as: Abstract Page Full-Text HTML </div> </div> <div >Open AccessArticle</div> COVID-19 Vaccination Acceptance among Health Science Students in Morocco: A Cross-Sectional Study <div > by <span ><div >Mohamed Khalis</div>, </span><span ><div >Mouna Boucham</div>, </span><span ><div >Amy Luo</div>, </span><span ><div >Abdelghafour Marfak</div>, </span><span ><div >Soukaina Saad</div>, </span><span ><div >Camara Mariama Aboubacar</div>, </span><span ><div >Soukaina Ait El Haj</div>, </span><span ><div >Manar Jallal</div>, </span><span ><div >Fatima-Zahra Aazi</div>, </span><span ><div >Hafida Charaka</div> and </span><span ><div >Chakib Nejjari</div></span> </div> <div > Vaccines <b>2021</b>, 9(12), 1451; https://doi.org/10.3390/vaccines9121451 - 08 Dec 2021 </div> <div > Abstract <div > While students in the health sciences occupy pivotal roles in the Moroccan COVID-19 response and vaccination campaigns, factors associated with COVID-19 vaccine acceptability among students have not been reported. This study aimed to determine the willingness and identify predictive attitudes and beliefs of [...] Read more. </div> <div > While students in the health sciences occupy pivotal roles in the Moroccan COVID-19 response and vaccination campaigns, factors associated with COVID-19 vaccine acceptability among students have not been reported. This study aimed to determine the willingness and identify predictive attitudes and beliefs of COVID-19 vaccine acceptance among health science students in Morocco. A cross-sectional, self-administered online questionnaire was conducted among students of the Mohammed VI University of Health Sciences in Casablanca, Morocco in January 2021. In total, 1272 students participated. Univariate and multivariate logistic regression models were used to calculate odds ratios and 95% confidence intervals. Overall, 26.9% of participants reported being willing to receive the COVID-19 vaccine. Between genders, male students were more likely to accept the vaccine. Regarding individual attitudes and beliefs about COVID-19 infection, students with greater confidence in COVID-19 information, and higher perceived likelihood and perceived severity of infection were more likely to be willing to get the vaccine. Concerning a COVID-19 vaccine, students who reported lower levels of perceived harm and higher levels of perceived vaccine effectiveness were more willing to get vaccinated. Our findings help guide future efforts to tailor communication and identify strategies to increase COVID-19 vaccine uptake among students. Full article </div> </div> <div > (This article belongs to the Special Issue COVID-19 Vaccine Acceptance and Uptake: Insights from Behavioural and Social Sciences) </div> </div> </div> </div> </div> <div > More Articles... </div> </div> </div> </div> <div > <div > <div > <div > <a > Submit to <i>Vaccines</i> </a> Review for Vaccines <div > Share </div> </div> <div > <h2 >Journal Menu</h2> ► ▼ Journal Menu <ul > <li > <ul> <li > Vaccines Home </li> <li > Aims Scope </li> <li > Editorial Board </li> <li > Reviewer Board </li> <li > Topical Advisory Panel </li> <li > Instructions for Authors </li> <li > Special Issues </li> <li > Sections Collections </li> <li > Article Processing Charge </li> <li > Indexing Archiving </li> <li > Editor's Choice Articles </li> <li > Most Cited Viewed </li> <li > Journal Statistics </li> <li > Journal History </li> <li > Journal Awards </li> <li > Society Collaborations </li> <li > Conferences </li> <li > Editorial Office </li> </ul> </li> </ul> </div> <h2 >Journal Browser</h2> ► ▼ Journal Browser <div > <div > <ul > <li > <a > <i > arrow_forward_ios </i> Forthcoming issue </a> <a > <i > arrow_forward_ios </i> Current issue </a> </li> <div > <div > <div > <li > Vol. 9 (2021) </li> <li > Vol. 8 (2020) </li> <li > Vol. 7 (2019) </li> <li > Vol. 6 (2018) </li> <li > Vol. 5 (2017) </li> <li > Vol. 4 (2016) </li> <li > Vol. 3 (2015) </li> <li > Vol. 2 (2014) </li> <li > Vol. 1 (2013) </li> </div> </div> </div> </ul> </div> </div> </div> </div> <div > <div > <h2>Highly Accessed Articles</h2> </div> <div > <div > View More... </div> </div> </div> <div > <div > <h2>Latest Books</h2> </div> <div > <div > More Open Access Books... </div> </div> </div> </div> <div > <div > <div > <h2>E-Mail Alert</h2> </div> </div> <div > <div > <h2>News</h2> </div> <div > <div > 3 December 2021 The 2nd International Electronic Conference on Healthcare (IECH2022)—Submissions Deadline Extension </div> <div > 22 November 2021 720 MDPI Editorial Board Members Receiving "2021 Highly Cited Researchers" Distinction </div> <div > 16 November 2021 Topical Advisory Panel Established to Support Editorial Board </div> <div > More News Announcements... </div> </div> </div> <div > <div > <h2>Topics</h2> </div> <div > <div ><div> Topic in Biomedicines, Pharmaceutics, Pharmaceuticals, Cancers, Vaccines</div> Animal Model in Biomedical Research Editor-in-Chief: Marc EkkerDeadline: 31 December 2021</div> <div ><div> Topic in Vaccines, Biology, Pathogens, Biologics, MPs</div> Global Analysis of SARS-CoV-2 Serology Editors-in-Chief: Ger Rijkers, Jean-Luc MurkDeadline: 20 April 2022</div> </div> </div> <div > <div > <h2>Conferences</h2> </div> <div > <div > Announce Your Conference </div> <div > 17 February–3 March 2022 2nd International Electronic Conference on Healthcare (IECH2022)</div> <div > More Conferences... </div> </div> </div> <div > <div > <h2>Special Issues</h2> </div> <div > <div > Edit a Special Issue </div> <div ><div> Special Issue in Vaccines</div> New Vaccine Technologies and Approaches 2.0 Guest Editors: Stephen A. Morris, Camila CoelhoDeadline: 15 December 2021</div> <div ><div> Special Issue in Vaccines</div> Feature Papers Collection on Influenza Vaccines Guest Editors: Luis Martinez-Sobrido, Ralph A. Tripp, Aitor NogalesDeadline: 30 December 2021</div> <div ><div> Special Issue in Vaccines</div> Frontiers in Shigella Vaccine Development Guest Editors: Duncan Steele, Calman A. MacLennanDeadline: 1 January 2022</div> <div ><div> Special Issue in Vaccines</div> Microbial Antigen Identification and Vaccine Delivery Systems Guest Editors: Jorge H. Leitão, Paulo BettencourtDeadline: 10 January 2022</div> <div > More Special Issues </div> </div> </div> <div > <div > <h2>Topical Collections</h2> </div> <div > <div ><div> Topical Collection in Vaccines</div> Research on Monoclonal Antibodies and Antibody Engineering Collection Editor: Tatsuya Yamazaki</div> <div ><div> Topical Collection in Vaccines</div> COVID-19 Vaccines and Vaccination Collection Editors: Ralph Tripp, Steven B. Bradfute, Scott Anthony</div> <div ><div> Topical Collection in Vaccines</div> Vaccines against Infectious Diseases Collection Editor: E.Diane Williamson</div> <div ><div> Topical Collection in Vaccines</div> Vaccines against Chronic and Persistent Bacterial Infections </div> </div> </div> <div > <div > <h2>Jobs in Research</h2> </div> <div > <div > Post New Job Opening </div> </div> </div> </div> </div> </div> </section> <div > <div > Vaccines, EISSN 2076-393X, Published by MDPI <span> Disclaimer <div > The statements, opinions and data contained in the journal Vaccines are solely those of the individual authors and contributors and not of the publisher and the editor(s). MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. </div> </span> <div > RSS Content Alert </div> </div> <div > <div > <h3> Further Information </h3> Article Processing Charges Pay an Invoice <a > Open Access Policy </a> <a > Contact MDPI </a> <a > Jobs at MDPI </a> </div> <div > <h3> Guidelines </h3> <a > For Authors </a> <a > For Reviewers </a> <a > For Editors </a> <a > For Librarians </a> <a > For Publishers </a> <a > For Societies </a> </div> <div > <h3> MDPI Initiatives </h3> <a > Sciforum </a> <a > MDPI Books </a> <a > Preprints </a> <a > Scilit </a> <a > SciProfiles </a> <a > Encyclopedia </a> <a > JAMS </a> <a > Proceedings Series </a> </div> <div > <h3> Follow MDPI </h3> <a > LinkedIn </a> <a > Facebook </a> <a > Twitter </a> </div> </div> <div > <div > <div > © 1996-2021 MDPI (Basel, Switzerland) unless otherwise stated </div> <div > <a > Disclaimer </a> <div > The statements, opinions and data contained in the journals are solely those of the individual authors and contributors and not of the publisher and the editor(s). MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. </div> <a > Terms and Conditions </a> <a > Privacy Policy </a> </div> </div> </div> </div> <div > <div > We use cookies on our website to ensure you get the best experience. Read more about our cookies <a >here</a>. </div> <div > <a >Accept</a> </div> </div> <div > <div > We have just recently launched a new version of our website. Help us to further improve by taking part in this short 5 minute survey here. here. </div> <div > <a >Never show this again</a> </div> </div> </div> <div > <div > <div > <h2 >Share Link</h2> </div> <div > <a >Copy</a> </div> </div> <a > <i >clear</i> </a> </div> <div > <div > <div > <h2 >Share</h2> </div> </div> <a > <i >clear</i> </a> </div> <a >Back to TopTop</a> </body>'</script>

      </head>
        <body class="valid" valid="valid" title="valid: True, node: 1, tag: body, level: 1" node_number="1"> <div class="valid" valid="valid" title="valid: True, node: 2, tag: div, level: 2" node_number="2"> <div class="valid" valid="valid" title="valid: True, node: 3, tag: div, level: 3" node_number="3"> <div class="valid" valid="valid" title="valid: True, node: 4, tag: div, level: 4" node_number="4"> <a class="valid" valid="valid" title="valid: True, node: 5, tag: a, level: 5" node_number="5"> <h2 class="valid" valid="valid" title="valid: True, node: 6, tag: h2, level: 6" node_number="6">25th Anniversary</h2> </a> <a class="valid" valid="valid" title="valid: True, node: 7, tag: a, level: 5" node_number="7"> <h2 class="valid" valid="valid" title="valid: True, node: 8, tag: h2, level: 6" node_number="8">Journals</h2> </a> <div class="valid" valid="valid" title="valid: True, node: 9, tag: div, level: 5" node_number="9"> <div class="valid" valid="valid" title="valid: True, node: 10, tag: div, level: 6" node_number="10"> <h2 class="valid" valid="valid" title="valid: True, node: 11, tag: h2, level: 7" node_number="11">Information</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 12, tag: div, level: 6" node_number="12"> <div class="valid" valid="valid" title="valid: True, node: 13, tag: div, level: 7" node_number="13"> <div class="valid" valid="valid" title="valid: True, node: 14, tag: div, level: 8" node_number="14"> <a class="valid" valid="valid" title="valid: True, node: 15, tag: a, level: 9" node_number="15">For Authors</a> <a class="valid" valid="valid" title="valid: True, node: 16, tag: a, level: 9" node_number="16">For Reviewers</a> <a class="valid" valid="valid" title="valid: True, node: 17, tag: a, level: 9" node_number="17">For Editors</a> <a class="valid" valid="valid" title="valid: True, node: 18, tag: a, level: 9" node_number="18">For Librarians</a> <a class="valid" valid="valid" title="valid: True, node: 19, tag: a, level: 9" node_number="19">For Publishers</a> <a class="valid" valid="valid" title="valid: True, node: 20, tag: a, level: 9" node_number="20">For Societies</a> </div> <div class="valid" valid="valid" title="valid: True, node: 21, tag: div, level: 8" node_number="21"> <a class="valid" valid="valid" title="valid: True, node: 22, tag: a, level: 9" node_number="22">Article Processing Charges</a> <a class="valid" valid="valid" title="valid: True, node: 23, tag: a, level: 9" node_number="23">Open Access Policy</a> <a class="valid" valid="valid" title="valid: True, node: 24, tag: a, level: 9" node_number="24">Institutional Open Access Program</a> <a class="valid" valid="valid" title="valid: True, node: 25, tag: a, level: 9" node_number="25">Editorial Process</a> <a class="valid" valid="valid" title="valid: True, node: 26, tag: a, level: 9" node_number="26">Awards</a> <a class="valid" valid="valid" title="valid: True, node: 27, tag: a, level: 9" node_number="27">Research and Publication Ethics</a> </div> </div> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 28, tag: a, level: 5" node_number="28"> <h2 class="valid" valid="valid" title="valid: True, node: 29, tag: h2, level: 6" node_number="29">Author Services</h2> </a> <div class="valid" valid="valid" title="valid: True, node: 30, tag: div, level: 5" node_number="30"> <div class="valid" valid="valid" title="valid: True, node: 31, tag: div, level: 6" node_number="31"> <h2 class="valid" valid="valid" title="valid: True, node: 32, tag: h2, level: 7" node_number="32">Initiatives</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 33, tag: div, level: 6" node_number="33"> <div class="valid" valid="valid" title="valid: True, node: 34, tag: div, level: 7" node_number="34"> <div class="valid" valid="valid" title="valid: True, node: 35, tag: div, level: 8" node_number="35"> <a class="valid" valid="valid" title="valid: True, node: 36, tag: a, level: 9" node_number="36">Sciforum</a> <a class="valid" valid="valid" title="valid: True, node: 37, tag: a, level: 9" node_number="37">MDPI Books</a> <a class="valid" valid="valid" title="valid: True, node: 38, tag: a, level: 9" node_number="38">Preprints</a> <a class="valid" valid="valid" title="valid: True, node: 39, tag: a, level: 9" node_number="39">Scilit</a> <a class="valid" valid="valid" title="valid: True, node: 40, tag: a, level: 9" node_number="40">SciProfiles</a> <a class="valid" valid="valid" title="valid: True, node: 41, tag: a, level: 9" node_number="41">Encyclopedia</a> <a class="valid" valid="valid" title="valid: True, node: 42, tag: a, level: 9" node_number="42">JAMS</a> <a class="valid" valid="valid" title="valid: True, node: 43, tag: a, level: 9" node_number="43">Proceedings Series</a> </div> </div> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 44, tag: a, level: 5" node_number="44"> <h2 class="valid" valid="valid" title="valid: True, node: 45, tag: h2, level: 6" node_number="45">About</h2> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 46, tag: div, level: 4" node_number="46"> <a class="valid" valid="valid" title="valid: True, node: 47, tag: a, level: 5" node_number="47">Sign In / Sign Up</a> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 48, tag: div, level: 2" node_number="48"> <h2 class="valid" valid="valid" title="valid: True, node: 49, tag: h2, level: 3" node_number="49">Notice</h2> <a class="valid" valid="valid" title="valid: True, node: 50, tag: a, level: 3" node_number="50"> <i class="valid" valid="valid" title="valid: True, node: 51, tag: i, level: 4" node_number="51">clear</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 52, tag: div, level: 2" node_number="52"> <div class="valid" valid="valid" title="valid: True, node: 53, tag: div, level: 3" node_number="53"> <div class="valid" valid="valid" title="valid: True, node: 54, tag: div, level: 4" node_number="54"> <h2 class="valid" valid="valid" title="valid: True, node: 55, tag: h2, level: 5" node_number="55">Notice</h2> <p class="valid" valid="valid" title="valid: True, node: 56, tag: p, level: 5" node_number="56"> You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader. </p> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 57, tag: div, level: 3" node_number="57"> <div class="valid" valid="valid" title="valid: True, node: 58, tag: div, level: 4" node_number="58"> <a class="valid" valid="valid" title="valid: True, node: 59, tag: a, level: 5" node_number="59">Continue</a> <a class="valid" valid="valid" title="valid: True, node: 60, tag: a, level: 5" node_number="60">Cancel</a> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 61, tag: a, level: 3" node_number="61"> <i class="valid" valid="valid" title="valid: True, node: 62, tag: i, level: 4" node_number="62">clear</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 63, tag: div, level: 2" node_number="63"> <p class="valid" valid="valid" title="valid: True, node: 64, tag: p, level: 3" node_number="64"> All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. </p> </div> <div class="valid" valid="valid" title="valid: True, node: 65, tag: div, level: 2" node_number="65"> <p class="valid" valid="valid" title="valid: True, node: 66, tag: p, level: 3" node_number="66"> Feature Papers represent the most advanced research with significant potential for high impact in the field. Feature Papers are submitted upon individual invitation or recommendation by the scientific editors and undergo peer review prior to publication. </p> <p class="valid" valid="valid" title="valid: True, node: 67, tag: p, level: 3" node_number="67"> The Feature Paper can be either an original research article, a substantial novel research study that often involves several techniques or approaches, or a comprehensive review paper with concise and precise updates on the latest progress in the field that systematically reviews the most exciting advances in scientific literature. This type of paper provides an outlook on future directions of research or possible applications. </p> </div> <div class="valid" valid="valid" title="valid: True, node: 68, tag: div, level: 2" node_number="68"> <p class="valid" valid="valid" title="valid: True, node: 69, tag: p, level: 3" node_number="69"> Editor&#8217;s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to authors, or important in this field. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal. </p> </div> <div class="valid" valid="valid" title="valid: True, node: 70, tag: div, level: 2" node_number="70"> <div class="valid" valid="valid" title="valid: True, node: 71, tag: div, level: 3" node_number="71">  </div> <section class="valid" valid="valid" title="valid: True, node: 72, tag: section, level: 3" node_number="72"> <header class="valid" valid="valid" title="valid: True, node: 73, tag: header, level: 4" node_number="73"> <div class="valid" valid="valid" title="valid: True, node: 74, tag: div, level: 5" node_number="74"> <div class="valid" valid="valid" title="valid: True, node: 75, tag: div, level: 6" node_number="75"> <div class="valid" valid="valid" title="valid: True, node: 76, tag: div, level: 7" node_number="76"> <ul class="valid" valid="valid" title="valid: True, node: 77, tag: ul, level: 8" node_number="77"> <li class="valid" valid="valid" title="valid: True, node: 78, tag: li, level: 9" node_number="78"> <a class="valid" valid="valid" title="valid: True, node: 79, tag: a, level: 10" node_number="79">25th Anniversary</a> </li> <li class="valid" valid="valid" title="valid: True, node: 80, tag: li, level: 9" node_number="80"> <a class="valid" valid="valid" title="valid: True, node: 81, tag: a, level: 10" node_number="81">Journals</a> </li> <li class="valid" valid="valid" title="valid: True, node: 82, tag: li, level: 9" node_number="82"> <a class="valid" valid="valid" title="valid: True, node: 83, tag: a, level: 10" node_number="83">Information</a> <ul class="valid" valid="valid" title="valid: True, node: 84, tag: ul, level: 10" node_number="84"> <li class="valid" valid="valid" title="valid: True, node: 85, tag: li, level: 11" node_number="85"> <div class="valid" valid="valid" title="valid: True, node: 86, tag: div, level: 12" node_number="86"> <div class="valid" valid="valid" title="valid: True, node: 87, tag: div, level: 13" node_number="87"> <ul class="valid" valid="valid" title="valid: True, node: 88, tag: ul, level: 14" node_number="88"> <li title="valid: False, node: 89, tag: li, level: 15" node_number="89"> <a title="valid: False, node: 90, tag: a, level: 16" node_number="90">For Authors</a> </li> <li title="valid: False, node: 91, tag: li, level: 15" node_number="91"> <a title="valid: False, node: 92, tag: a, level: 16" node_number="92">For Reviewers</a> </li> <li title="valid: False, node: 93, tag: li, level: 15" node_number="93"> <a title="valid: False, node: 94, tag: a, level: 16" node_number="94">For Editors</a> </li> <li title="valid: False, node: 95, tag: li, level: 15" node_number="95"> <a title="valid: False, node: 96, tag: a, level: 16" node_number="96">For Librarians</a> </li> <li title="valid: False, node: 97, tag: li, level: 15" node_number="97"> <a title="valid: False, node: 98, tag: a, level: 16" node_number="98">For Publishers</a> </li> <li title="valid: False, node: 99, tag: li, level: 15" node_number="99"> <a title="valid: False, node: 100, tag: a, level: 16" node_number="100">For Societies</a> </li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 101, tag: div, level: 13" node_number="101"> <ul class="valid" valid="valid" title="valid: True, node: 102, tag: ul, level: 14" node_number="102"> <li title="valid: False, node: 103, tag: li, level: 15" node_number="103"> <a title="valid: False, node: 104, tag: a, level: 16" node_number="104">Article Processing Charges</a> </li> <li title="valid: False, node: 105, tag: li, level: 15" node_number="105"> <a title="valid: False, node: 106, tag: a, level: 16" node_number="106">Open Access Policy</a> </li> <li title="valid: False, node: 107, tag: li, level: 15" node_number="107"> <a title="valid: False, node: 108, tag: a, level: 16" node_number="108">Institutional Open Access Program</a> </li> <li title="valid: False, node: 109, tag: li, level: 15" node_number="109"> <a title="valid: False, node: 110, tag: a, level: 16" node_number="110">Editorial Process</a> </li> <li title="valid: False, node: 111, tag: li, level: 15" node_number="111"> <a title="valid: False, node: 112, tag: a, level: 16" node_number="112">Awards</a> </li> <li title="valid: False, node: 113, tag: li, level: 15" node_number="113"> <a title="valid: False, node: 114, tag: a, level: 16" node_number="114">Research and Publication Ethics</a> </li> </ul> </div> </div> </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 115, tag: li, level: 9" node_number="115"> <a class="valid" valid="valid" title="valid: True, node: 116, tag: a, level: 10" node_number="116">Author Services</a> </li> <li class="valid" valid="valid" title="valid: True, node: 117, tag: li, level: 9" node_number="117"> <a class="valid" valid="valid" title="valid: True, node: 118, tag: a, level: 10" node_number="118">Initiatives</a> <ul class="valid" valid="valid" title="valid: True, node: 119, tag: ul, level: 10" node_number="119"> <li class="valid" valid="valid" title="valid: True, node: 120, tag: li, level: 11" node_number="120"> <div class="valid" valid="valid" title="valid: True, node: 121, tag: div, level: 12" node_number="121"> <div class="valid" valid="valid" title="valid: True, node: 122, tag: div, level: 13" node_number="122"> <ul class="valid" valid="valid" title="valid: True, node: 123, tag: ul, level: 14" node_number="123"> <li title="valid: False, node: 124, tag: li, level: 15" node_number="124"> <a title="valid: False, node: 125, tag: a, level: 16" node_number="125"> Sciforum </a> </li> <li title="valid: False, node: 126, tag: li, level: 15" node_number="126"> <a title="valid: False, node: 127, tag: a, level: 16" node_number="127"> MDPI Books </a> </li> <li title="valid: False, node: 128, tag: li, level: 15" node_number="128"> <a title="valid: False, node: 129, tag: a, level: 16" node_number="129"> Preprints </a> </li> <li title="valid: False, node: 130, tag: li, level: 15" node_number="130"> <a title="valid: False, node: 131, tag: a, level: 16" node_number="131"> Scilit </a> </li> <li title="valid: False, node: 132, tag: li, level: 15" node_number="132"> <a title="valid: False, node: 133, tag: a, level: 16" node_number="133"> SciProfiles </a> </li> <li title="valid: False, node: 134, tag: li, level: 15" node_number="134"> <a title="valid: False, node: 135, tag: a, level: 16" node_number="135"> Encyclopedia </a> </li> <li title="valid: False, node: 136, tag: li, level: 15" node_number="136"> <a title="valid: False, node: 137, tag: a, level: 16" node_number="137"> JAMS </a> </li> <li title="valid: False, node: 138, tag: li, level: 15" node_number="138"> <a title="valid: False, node: 139, tag: a, level: 16" node_number="139"> Proceedings Series </a> </li> </ul> </div> </div> </li> </ul> </li> <li class="valid" valid="valid" title="valid: True, node: 140, tag: li, level: 9" node_number="140"> <a class="valid" valid="valid" title="valid: True, node: 141, tag: a, level: 10" node_number="141">About</a> </li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 142, tag: div, level: 7" node_number="142"> <div class="valid" valid="valid" title="valid: True, node: 143, tag: div, level: 8" node_number="143"> <a class="valid" valid="valid" title="valid: True, node: 144, tag: a, level: 9" node_number="144">Sign In / Sign Up</a> <a class="valid" valid="valid" title="valid: True, node: 145, tag: a, level: 9" node_number="145">Submit</a> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 146, tag: div, level: 5" node_number="146"> <div class="valid" valid="valid" title="valid: True, node: 147, tag: div, level: 6" node_number="147"> <div class="valid" valid="valid" title="valid: True, node: 148, tag: div, level: 7" node_number="148"> <div class="valid" valid="valid" title="valid: True, node: 149, tag: div, level: 8" node_number="149"> <a class="valid" valid="valid" title="valid: True, node: 150, tag: a, level: 9" node_number="150"> Covered in: PubMed </a> </div></div> <div class="valid" valid="valid" title="valid: True, node: 151, tag: div, level: 7" node_number="151"> <div class="valid" valid="valid" title="valid: True, node: 152, tag: div, level: 8" node_number="152"> <a class="valid" valid="valid" title="valid: True, node: 153, tag: a, level: 9" node_number="153"> IMPACTFACTOR 4.422 </a> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 154, tag: div, level: 6" node_number="154"> Journals </div> <div class="valid" valid="valid" title="valid: True, node: 155, tag: div, level: 6" node_number="155"> Vaccines </div> </div> </header> <div class="valid" valid="valid" title="valid: True, node: 156, tag: div, level: 4" node_number="156"> <div class="valid" valid="valid" title="valid: True, node: 157, tag: div, level: 5" node_number="157"> <div class="valid" valid="valid" title="valid: True, node: 158, tag: div, level: 6" node_number="158"> <div class="valid" valid="valid" title="valid: True, node: 159, tag: div, level: 7" node_number="159"> <div class="valid" valid="valid" title="valid: True, node: 160, tag: div, level: 8" node_number="160"> <ul class="valid" valid="valid" title="valid: True, node: 161, tag: ul, level: 9" node_number="161"> <li class="valid" valid="valid" title="valid: True, node: 162, tag: li, level: 10" node_number="162"> <a class="valid" valid="valid" title="valid: True, node: 163, tag: a, level: 11" node_number="163"> <div class="valid" valid="valid" title="valid: True, node: 164, tag: div, level: 12" node_number="164"> Less Isn't Always More: Antibody Dynamics Following Cocktail Vaccination </div> </a> </li> <li class="valid" valid="valid" title="valid: True, node: 165, tag: li, level: 10" node_number="165"> <a class="valid" valid="valid" title="valid: True, node: 166, tag: a, level: 11" node_number="166"> <div class="valid" valid="valid" title="valid: True, node: 167, tag: div, level: 12" node_number="167"> COVID-19 Vaccination Willingness&#8212;Illness and Treatment Perceptions as Predictors </div> </a> </li> <li class="valid" valid="valid" title="valid: True, node: 168, tag: li, level: 10" node_number="168"> <a class="valid" valid="valid" title="valid: True, node: 169, tag: a, level: 11" node_number="169"> <div class="valid" valid="valid" title="valid: True, node: 170, tag: div, level: 12" node_number="170"> TB and SIV Coinfection; a Model for Evaluating Vaccine Strategies against TB Reactivation: A Pilot Study Using BCG Vaccination </div> </a> </li> <li class="valid" valid="valid" title="valid: True, node: 171, tag: li, level: 10" node_number="171"> <a class="valid" valid="valid" title="valid: True, node: 172, tag: a, level: 11" node_number="172"> <div class="valid" valid="valid" title="valid: True, node: 173, tag: div, level: 12" node_number="173"> Structurally Sound&#8212;Focused Subunit Vaccine Designed to Maximize Fc-Effector Activities Against HIV </div> </a> </li> <li class="valid" valid="valid" title="valid: True, node: 174, tag: li, level: 10" node_number="174"> <a class="valid" valid="valid" title="valid: True, node: 175, tag: a, level: 11" node_number="175"> <div class="valid" valid="valid" title="valid: True, node: 176, tag: div, level: 12" node_number="176"> Interests of the Non-Human Primate Models for HIV Cure Research </div> </a> </li> </ul> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 177, tag: div, level: 7" node_number="177"> <div class="valid" valid="valid" title="valid: True, node: 178, tag: div, level: 8" node_number="178"> <h2 class="valid" valid="valid" title="valid: True, node: 179, tag: h2, level: 9" node_number="179">Journal Description</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 180, tag: div, level: 8" node_number="180"> <div class="valid" valid="valid" title="valid: True, node: 181, tag: div, level: 9" node_number="181"> <h1 class="valid" valid="valid" title="valid: True, node: 182, tag: h1, level: 10" node_number="182"> Vaccines </h1> <div class="valid" valid="valid" title="valid: True, node: 183, tag: div, level: 10" node_number="183"> Vaccines is an international,&#160;<a class="valid" valid="valid" title="valid: True, node: 184, tag: a, level: 11" node_number="184">peer-reviewed</a>, open access journal published&#160;monthly online by MDPI. <a class="valid" valid="valid" title="valid: True, node: 185, tag: a, level: 11" node_number="185">The American Society for Virology (ASV)</a> is affiliated with Vaccines and their members receive a discount on the article processing charges. <ul class="valid" valid="valid" title="valid: True, node: 186, tag: ul, level: 11" node_number="186"> <li class="valid" valid="valid" title="valid: True, node: 187, tag: li, level: 12" node_number="187">Open Access&#8212; free for readers, with <a class="valid" valid="valid" title="valid: True, node: 188, tag: a, level: 13" node_number="188">article processing charges (APC)</a> paid by authors or their institutions.</li> <li class="valid" valid="valid" title="valid: True, node: 189, tag: li, level: 12" node_number="189">High Visibility:&#160;indexed within <a class="valid" valid="valid" title="valid: True, node: 190, tag: a, level: 13" node_number="190">Scopus</a>, <a class="valid" valid="valid" title="valid: True, node: 191, tag: a, level: 13" node_number="191">SCIE (Web of Science)</a>, <a class="valid" valid="valid" title="valid: True, node: 192, tag: a, level: 13" node_number="192">PubMed</a>, <a class="valid" valid="valid" title="valid: True, node: 193, tag: a, level: 13" node_number="193">PMC</a>, <a class="valid" valid="valid" title="valid: True, node: 194, tag: a, level: 13" node_number="194">Embase</a>, <a class="valid" valid="valid" title="valid: True, node: 195, tag: a, level: 13" node_number="195">CAPlus / SciFinder</a>, and many <a class="valid" valid="valid" title="valid: True, node: 196, tag: a, level: 13" node_number="196">other databases</a>.</li> <li class="valid" valid="valid" title="valid: True, node: 197, tag: li, level: 12" node_number="197">Journal Rank:&#160;JCR&#160;- Q2 (Immunology)</li> <li class="valid" valid="valid" title="valid: True, node: 198, tag: li, level: 12" node_number="198">Rapid Publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 3.8 days (median values for papers published in this journal in the first half of 2021).</li> <li class="valid" valid="valid" title="valid: True, node: 199, tag: li, level: 12" node_number="199">Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.</li> </ul> </div> <div class="valid" valid="valid" title="valid: True, node: 200, tag: div, level: 10" node_number="200"> Impact Factor: 4.422 (2020) ; 5-Year Impact Factor: 5.513 (2020) </div> <div class="valid" valid="valid" title="valid: True, node: 201, tag: div, level: 10" node_number="201"> <a class="valid" valid="valid" title="valid: True, node: 202, tag: a, level: 11" node_number="202"> <i class="valid" valid="valid" title="valid: True, node: 203, tag: i, level: 12" node_number="203">subject</i> Imprint Information </a> <a class="valid" valid="valid" title="valid: True, node: 204, tag: a, level: 11" node_number="204"> <i class="valid" valid="valid" title="valid: True, node: 205, tag: i, level: 12" node_number="205">get_app</i> Journal Flyer </a> <a class="valid" valid="valid" title="valid: True, node: 206, tag: a, level: 11" node_number="206"> Open Access </a> ISSN: 2076-393X </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 207, tag: div, level: 7" node_number="207"> <div class="valid" valid="valid" title="valid: True, node: 208, tag: div, level: 8" node_number="208"> <h2 class="valid" valid="valid" title="valid: True, node: 209, tag: h2, level: 9" node_number="209">Latest Articles</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 210, tag: div, level: 8" node_number="210"> <div class="valid" valid="valid" title="valid: True, node: 211, tag: div, level: 9" node_number="211"> <div class="valid" valid="valid" title="valid: True, node: 212, tag: div, level: 10" node_number="212"> <div class="valid" valid="valid" title="valid: True, node: 213, tag: div, level: 11" node_number="213"> <div class="valid" valid="valid" title="valid: True, node: 214, tag: div, level: 12" node_number="214"> <a class="valid" valid="valid" title="valid: True, node: 215, tag: a, level: 13" node_number="215"> <i class="valid" valid="valid" title="valid: True, node: 216, tag: i, level: 14" node_number="216">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 217, tag: div, level: 12" node_number="217"> <a class="valid" valid="valid" title="valid: True, node: 218, tag: a, level: 13" node_number="218"> <i class="valid" valid="valid" title="valid: True, node: 219, tag: i, level: 14" node_number="219">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 220, tag: div, level: 13" node_number="220"> View online as: Abstract Page <a class="valid" valid="valid" title="valid: True, node: 221, tag: a, level: 14" node_number="221">Full-Text HTML</a> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 222, tag: div, level: 12" node_number="222">Open AccessArticle</div> Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis <div class="valid" valid="valid" title="valid: True, node: 223, tag: div, level: 12" node_number="223"> by <span class="valid" valid="valid" title="valid: True, node: 224, tag: span, level: 13" node_number="224"><div class="valid" valid="valid" title="valid: True, node: 225, tag: div, level: 14" node_number="225">Lutz Achtnichts</div>, </span><span class="valid" valid="valid" title="valid: True, node: 226, tag: span, level: 13" node_number="226"><div class="valid" valid="valid" title="valid: True, node: 227, tag: div, level: 14" node_number="227">Barbara Jakopp</div>, </span><span class="valid" valid="valid" title="valid: True, node: 228, tag: span, level: 13" node_number="228"><div class="valid" valid="valid" title="valid: True, node: 229, tag: div, level: 14" node_number="229">Michael Oberle</div>, </span><span class="valid" valid="valid" title="valid: True, node: 230, tag: span, level: 13" node_number="230"><div class="valid" valid="valid" title="valid: True, node: 231, tag: div, level: 14" node_number="231">Krassen Nedeltchev</div>, </span><span class="valid" valid="valid" title="valid: True, node: 232, tag: span, level: 13" node_number="232"><div class="valid" valid="valid" title="valid: True, node: 233, tag: div, level: 14" node_number="233">Christoph Andreas Fux</div>, </span><span class="valid" valid="valid" title="valid: True, node: 234, tag: span, level: 13" node_number="234"><div class="valid" valid="valid" title="valid: True, node: 235, tag: div, level: 14" node_number="235">Johann Sellner</div> and </span><span class="valid" valid="valid" title="valid: True, node: 236, tag: span, level: 13" node_number="236"><div class="valid" valid="valid" title="valid: True, node: 237, tag: div, level: 14" node_number="237">Oliver Findling</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 238, tag: div, level: 12" node_number="238"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 239, tag: b, level: 13" node_number="239">2021</b>, 9(12), 1470; https://doi.org/10.3390/vaccines9121470 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 240, tag: div, level: 12" node_number="240"> Abstract <div class="valid" valid="valid" title="valid: True, node: 241, tag: div, level: 13" node_number="241"> CD20 depletion is a risk factor for unfavorable outcomes of COVID-19 in people with MS (pwMS). Evidence suggests that protective IgG response to mRNA-based vaccines in B cell-depleted individuals is limited. We studied the seroconversion after the third mRNA SARS-CoV-2 vaccine in B [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 242, tag: div, level: 13" node_number="242"> CD20 depletion is a risk factor for unfavorable outcomes of COVID-19 in people with MS (pwMS). Evidence suggests that protective IgG response to mRNA-based vaccines in B cell-depleted individuals is limited. We studied the seroconversion after the third mRNA SARS-CoV-2 vaccine in B cell-depleted pwMS with limited or no IgG response after the standard immunization. Sixteen pwMS treated with ocrelizumab or rituximab received a third homologous SARS-CoV-2 mRNA vaccine, either the Moderna mRNA-1273 or Pfizer-BioNTech&#8217;s BNT162b2 vaccine. We quantified the response of IgG antibodies against the spike receptor-binding domain of SARS-CoV-2 four weeks later. An antibody titer of 100 AU/mL or more was considered clinically relevant. The median time between the last infusion of the anti-CD20 treatment and the third vaccination was 22.9 weeks (range 15.1&#8211;31.3). After the third vaccination, one out of 16 patients showed an IgG titer deemed clinically relevant. Only the seroconverted patient had measurable B-cell counts at the time of the third vaccination. The development of a humoral immune response remains rare in pwMS on anti-CD20 therapy, even after third dose of the homologous SARS-CoV-2 mRNA vaccine. It remains to be determined whether T-cell responses can compensate for the lack of seroconversion and provide sufficient protection against CoV-2 infections. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 243, tag: div, level: 12" node_number="243"> (This article belongs to the Section COVID-19 Vaccines and Vaccination) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 244, tag: div, level: 12" node_number="244"><div class="valid" valid="valid" title="valid: True, node: 245, tag: div, level: 13" node_number="245"><div class="valid" valid="valid" title="valid: True, node: 246, tag: div, level: 14" node_number="246"><p title="valid: False, node: 247, tag: p, level: 15" node_number="247">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 248, tag: div, level: 9" node_number="248"> <div class="valid" valid="valid" title="valid: True, node: 249, tag: div, level: 10" node_number="249"> <div class="valid" valid="valid" title="valid: True, node: 250, tag: div, level: 11" node_number="250"> <div class="valid" valid="valid" title="valid: True, node: 251, tag: div, level: 12" node_number="251"> <div class="valid" valid="valid" title="valid: True, node: 252, tag: div, level: 13" node_number="252"> <a class="valid" valid="valid" title="valid: True, node: 253, tag: a, level: 14" node_number="253"> <i title="valid: False, node: 254, tag: i, level: 15" node_number="254">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 255, tag: div, level: 13" node_number="255"> <a class="valid" valid="valid" title="valid: True, node: 256, tag: a, level: 14" node_number="256"> <i title="valid: False, node: 257, tag: i, level: 15" node_number="257">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 258, tag: div, level: 14" node_number="258"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 259, tag: div, level: 13" node_number="259">Open AccessArticle</div> Intention of Parents to Immunize Children against SARS-CoV-2 in Italy <div class="valid" valid="valid" title="valid: True, node: 260, tag: div, level: 13" node_number="260"> by <span class="valid" valid="valid" title="valid: True, node: 261, tag: span, level: 14" node_number="261"><div title="valid: False, node: 262, tag: div, level: 15" node_number="262">Luisa Russo</div>, </span><span class="valid" valid="valid" title="valid: True, node: 263, tag: span, level: 14" node_number="263"><div title="valid: False, node: 264, tag: div, level: 15" node_number="264">Ileana Croci</div>, </span><span class="valid" valid="valid" title="valid: True, node: 265, tag: span, level: 14" node_number="265"><div title="valid: False, node: 266, tag: div, level: 15" node_number="266">Ilaria Campagna</div>, </span><span class="valid" valid="valid" title="valid: True, node: 267, tag: span, level: 14" node_number="267"><div title="valid: False, node: 268, tag: div, level: 15" node_number="268">Elisabetta Pandolfi</div>, </span><span class="valid" valid="valid" title="valid: True, node: 269, tag: span, level: 14" node_number="269"><div title="valid: False, node: 270, tag: div, level: 15" node_number="270">Alberto Villani</div>, </span><span class="valid" valid="valid" title="valid: True, node: 271, tag: span, level: 14" node_number="271"><div title="valid: False, node: 272, tag: div, level: 15" node_number="272">Antonino Reale</div>, </span><span class="valid" valid="valid" title="valid: True, node: 273, tag: span, level: 14" node_number="273"><div title="valid: False, node: 274, tag: div, level: 15" node_number="274">Maria Antonietta Barbieri</div>, </span><span class="valid" valid="valid" title="valid: True, node: 275, tag: span, level: 14" node_number="275"><div title="valid: False, node: 276, tag: div, level: 15" node_number="276">Massimiliano Raponi</div>, </span><span class="valid" valid="valid" title="valid: True, node: 277, tag: span, level: 14" node_number="277"><div title="valid: False, node: 278, tag: div, level: 15" node_number="278">Francesco Gesualdo</div> and </span><span class="valid" valid="valid" title="valid: True, node: 279, tag: span, level: 14" node_number="279"><div title="valid: False, node: 280, tag: div, level: 15" node_number="280">Alberto Eugenio Tozzi</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 281, tag: div, level: 13" node_number="281"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 282, tag: b, level: 14" node_number="282">2021</b>, 9(12), 1469; https://doi.org/10.3390/vaccines9121469 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 283, tag: div, level: 13" node_number="283"> Abstract <div class="valid" valid="valid" title="valid: True, node: 284, tag: div, level: 14" node_number="284"> Several countries have targeted adolescents for immunization against SARS-CoV-2 to mitigate COVID-19 spread. In Italy, immunization for children &#8805; 12 years has been available starting from June 2021. We conducted a cross-sectional study to investigate the knowledge, attitude and intention to vaccinate children [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 285, tag: div, level: 14" node_number="285"> Several countries have targeted adolescents for immunization against SARS-CoV-2 to mitigate COVID-19 spread. In Italy, immunization for children &#8805; 12 years has been available starting from June 2021. We conducted a cross-sectional study to investigate the knowledge, attitude and intention to vaccinate children &lt; 18 years in Italian families. We used a multinomial logistic regression model to investigate factors associated with intention to vaccinate. We collected a total of 1696 responses. Among the 491 families of children &#8805; 12 years, 41.2% would not vaccinate their children and 21.2% were uncertain, while among the 1205 families of children &lt; 12 years, 36.1% would not vaccinate and 33.8% were uncertain. Determinants of intention to vaccinate both age groups were perceived safety and efficacy of vaccines and perceived risk of transmitting infection to adults. For children &lt; 12 years, additional determinants were perceived risk of being infected and being hospitalized because of COVID-19. In view of the expanding strategy to vaccinate adolescents and the availability of immunization for children &lt; 12 years, our results call for a communication strategy targeted at families of children focused on the safety and efficacy of COVID-19 vaccine in children and on the dynamics of infection spread across different age groups. As perceptions in families are volatile and may change rapidly over time, repeated surveys for measuring attitudes to vaccinate would be advisable. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 286, tag: div, level: 13" node_number="286"> (This article belongs to the Special Issue Factors Associated with Vaccine Hesitancy) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 287, tag: div, level: 13" node_number="287"><div class="valid" valid="valid" title="valid: True, node: 288, tag: div, level: 14" node_number="288"><div title="valid: False, node: 289, tag: div, level: 15" node_number="289"><p title="valid: False, node: 290, tag: p, level: 16" node_number="290">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 291, tag: div, level: 10" node_number="291"> <div class="valid" valid="valid" title="valid: True, node: 292, tag: div, level: 11" node_number="292"> <div class="valid" valid="valid" title="valid: True, node: 293, tag: div, level: 12" node_number="293"> <div class="valid" valid="valid" title="valid: True, node: 294, tag: div, level: 13" node_number="294"> <a class="valid" valid="valid" title="valid: True, node: 295, tag: a, level: 14" node_number="295"> <i title="valid: False, node: 296, tag: i, level: 15" node_number="296">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 297, tag: div, level: 13" node_number="297"> <a class="valid" valid="valid" title="valid: True, node: 298, tag: a, level: 14" node_number="298"> <i title="valid: False, node: 299, tag: i, level: 15" node_number="299">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 300, tag: div, level: 14" node_number="300"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 301, tag: div, level: 13" node_number="301">Open AccessArticle</div> Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults <div class="valid" valid="valid" title="valid: True, node: 302, tag: div, level: 13" node_number="302"> by <span class="valid" valid="valid" title="valid: True, node: 303, tag: span, level: 14" node_number="303"><div title="valid: False, node: 304, tag: div, level: 15" node_number="304">Eve Versage</div>, </span><span class="valid" valid="valid" title="valid: True, node: 305, tag: span, level: 14" node_number="305"><div title="valid: False, node: 306, tag: div, level: 15" node_number="306">Esther van Twuijver</div>, </span><span class="valid" valid="valid" title="valid: True, node: 307, tag: span, level: 14" node_number="307"><div title="valid: False, node: 308, tag: div, level: 15" node_number="308">Wim Jansen</div>, </span><span class="valid" valid="valid" title="valid: True, node: 309, tag: span, level: 14" node_number="309"><div title="valid: False, node: 310, tag: div, level: 15" node_number="310">Ad Theeuwes</div>, </span><span class="valid" valid="valid" title="valid: True, node: 311, tag: span, level: 14" node_number="311"><div title="valid: False, node: 312, tag: div, level: 15" node_number="312">Daphne Sawlwin</div> and </span><span class="valid" valid="valid" title="valid: True, node: 313, tag: span, level: 14" node_number="313"><div title="valid: False, node: 314, tag: div, level: 15" node_number="314">Matthew Hohenboken</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 315, tag: div, level: 13" node_number="315"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 316, tag: b, level: 14" node_number="316">2021</b>, 9(12), 1468; https://doi.org/10.3390/vaccines9121468 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 317, tag: div, level: 13" node_number="317"> Abstract <div class="valid" valid="valid" title="valid: True, node: 318, tag: div, level: 14" node_number="318"> Modern cell culture-based technology eliminates vaccine manufactures reliance on embryonated chicken eggs, which may become compromised during an avian influenza pandemic. Four studies (total N = 6230) assessed the immunogenicity and safety of mammalian cell-based, MF59<sup title="valid: False, node: 319, tag: sup, level: 15" node_number="319">&#174;</sup>-adjuvanted, A/H5N1 vaccine (aH5N1c; AUDENZ&#8482;) as [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 320, tag: div, level: 14" node_number="320"> Modern cell culture-based technology eliminates vaccine manufactures reliance on embryonated chicken eggs, which may become compromised during an avian influenza pandemic. Four studies (total N = 6230) assessed the immunogenicity and safety of mammalian cell-based, MF59<sup title="valid: False, node: 321, tag: sup, level: 15" node_number="321">&#174;</sup>-adjuvanted, A/H5N1 vaccine (aH5N1c; AUDENZ&#8482;) as two doses administered on Days 1 and 22 in children (NCT01776554), adults (NCT01776541; NCT02839330), and older adults (NCT01766921; NCT02839330). Immunogenicity of formulations at 7.5 &#956;g and 3.75 &#956;g antigen per dose were assessed by hemagglutination inhibition and microneutralization assays on Days 1, 22, 43, and 183 or 387. Solicited local and systemic adverse events (AEs) were recorded for 7 days after each vaccination. Unsolicited AEs were collected for 21 days after each vaccination, and serious and other selected AEs were recorded for one year. Antibody responses after two 7.5 &#956;g doses met CBER licensure criteria in all age groups. Overall, an age-related response was evident, with the highest responses observed in children &lt;3 years old. In children, antibody titers met seroconversion criteria 12 months after vaccination. MF59 allowed for antigen dose sparing. Solicited AEs were mild to moderate in nature, of short duration, and less frequent after the second dose than the first, demonstrating a favorable risk-benefit profile. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 322, tag: div, level: 13" node_number="322"> (This article belongs to the Section Influenza Virus Vaccines) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 323, tag: div, level: 13" node_number="323"><div class="valid" valid="valid" title="valid: True, node: 324, tag: div, level: 14" node_number="324"><div title="valid: False, node: 325, tag: div, level: 15" node_number="325"><p title="valid: False, node: 326, tag: p, level: 16" node_number="326">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 327, tag: div, level: 10" node_number="327"> <div class="valid" valid="valid" title="valid: True, node: 328, tag: div, level: 11" node_number="328"> <div class="valid" valid="valid" title="valid: True, node: 329, tag: div, level: 12" node_number="329"> <div class="valid" valid="valid" title="valid: True, node: 330, tag: div, level: 13" node_number="330"> <a class="valid" valid="valid" title="valid: True, node: 331, tag: a, level: 14" node_number="331"> <i title="valid: False, node: 332, tag: i, level: 15" node_number="332">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 333, tag: div, level: 14" node_number="333"> Supplementary material: Supplementary File 1 (ZIP, 176 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 334, tag: div, level: 13" node_number="334"> <a class="valid" valid="valid" title="valid: True, node: 335, tag: a, level: 14" node_number="335"> <i title="valid: False, node: 336, tag: i, level: 15" node_number="336">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 337, tag: div, level: 13" node_number="337"> <a class="valid" valid="valid" title="valid: True, node: 338, tag: a, level: 14" node_number="338"> <i title="valid: False, node: 339, tag: i, level: 15" node_number="339">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 340, tag: div, level: 14" node_number="340"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 341, tag: div, level: 13" node_number="341">Open AccessArticle</div> COVID-19 Immunisation, Willingness to Be Vaccinated and Vaccination Strategies to Improve Vaccine Uptake in Australia <div class="valid" valid="valid" title="valid: True, node: 342, tag: div, level: 13" node_number="342"> by <span class="valid" valid="valid" title="valid: True, node: 343, tag: span, level: 14" node_number="343"><div title="valid: False, node: 344, tag: div, level: 15" node_number="344">Bing Wang</div>, </span><span class="valid" valid="valid" title="valid: True, node: 345, tag: span, level: 14" node_number="345"><div title="valid: False, node: 346, tag: div, level: 15" node_number="346">Rebecca Nolan</div> and </span><span class="valid" valid="valid" title="valid: True, node: 347, tag: span, level: 14" node_number="347"><div title="valid: False, node: 348, tag: div, level: 15" node_number="348">Helen Marshall</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 349, tag: div, level: 13" node_number="349"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 350, tag: b, level: 14" node_number="350">2021</b>, 9(12), 1467; https://doi.org/10.3390/vaccines9121467 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 351, tag: div, level: 13" node_number="351"> Abstract <div class="valid" valid="valid" title="valid: True, node: 352, tag: div, level: 14" node_number="352"> The COVID-19 vaccine rollout is crucial to lifting community and economic restrictions. This cross-sectional study aimed to assess: (a) COVID-19 vaccine uptake and associated factors; (b) COVID-19 vaccine intentions and associated factors; (c) community support for COVID-19 vaccination strategies and associated factors. The [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 353, tag: div, level: 14" node_number="353"> The COVID-19 vaccine rollout is crucial to lifting community and economic restrictions. This cross-sectional study aimed to assess: (a) COVID-19 vaccine uptake and associated factors; (b) COVID-19 vaccine intentions and associated factors; (c) community support for COVID-19 vaccination strategies and associated factors. The survey was conducted between May and July 2021 in Australia. Of 3003 participants, 30% reported they were already vaccinated and 39% indicated they would get vaccinated. Low socioeconomic and education levels, non-English speaking backgrounds and being parents were associated with decreased vaccine willingness and/or vaccination rates. High levels of support for vaccination strategies were demonstrated with mandatory vaccination being less preferable. Respondents from non-English speaking backgrounds were more likely to support a mandatory vaccination policy. Respondents with the highest socioeconomic level were more likely to support vaccination requirements for international travel, visiting nursing homes and working in healthcare settings. Respondents who were aged &#8805;70 years were more likely to support all proposed vaccination strategies. Targeted campaigns should be implemented for parents and those who live in socioeconomic disadvantaged areas and have lower educational attainment. Concise and clear vaccine information should be provided in lay and multiple languages to improve vaccine confidence. Vaccine enforcement policies should be considered and implemented with caution. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 354, tag: div, level: 13" node_number="354"> (This article belongs to the Section COVID-19 Vaccines and Vaccination) </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 355, tag: div, level: 10" node_number="355"> <div class="valid" valid="valid" title="valid: True, node: 356, tag: div, level: 11" node_number="356"> <div class="valid" valid="valid" title="valid: True, node: 357, tag: div, level: 12" node_number="357"> <div class="valid" valid="valid" title="valid: True, node: 358, tag: div, level: 13" node_number="358"> <a class="valid" valid="valid" title="valid: True, node: 359, tag: a, level: 14" node_number="359"> <i title="valid: False, node: 360, tag: i, level: 15" node_number="360">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 361, tag: div, level: 14" node_number="361"> Supplementary material: Supplementary File 1 (ZIP, 186 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 362, tag: div, level: 13" node_number="362"> <a class="valid" valid="valid" title="valid: True, node: 363, tag: a, level: 14" node_number="363"> <i title="valid: False, node: 364, tag: i, level: 15" node_number="364">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 365, tag: div, level: 13" node_number="365"> <a class="valid" valid="valid" title="valid: True, node: 366, tag: a, level: 14" node_number="366"> <i title="valid: False, node: 367, tag: i, level: 15" node_number="367">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 368, tag: div, level: 14" node_number="368"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 369, tag: div, level: 13" node_number="369">Open AccessArticle</div> Equity in Vaccine Trials for Higher Weight People? A Rapid Review of Weight-Related Inclusion and Exclusion Criteria for COVID-19 Clinical Trials <div class="valid" valid="valid" title="valid: True, node: 370, tag: div, level: 13" node_number="370"> by <span class="valid" valid="valid" title="valid: True, node: 371, tag: span, level: 14" node_number="371"><div title="valid: False, node: 372, tag: div, level: 15" node_number="372">Jessica Campbell</div>, </span><span class="valid" valid="valid" title="valid: True, node: 373, tag: span, level: 14" node_number="373"><div title="valid: False, node: 374, tag: div, level: 15" node_number="374">Juliet Sutherland</div>, </span><span class="valid" valid="valid" title="valid: True, node: 375, tag: span, level: 14" node_number="375"><div title="valid: False, node: 376, tag: div, level: 15" node_number="376">Danielle Bucknall</div>, </span><span class="valid" valid="valid" title="valid: True, node: 377, tag: span, level: 14" node_number="377"><div title="valid: False, node: 378, tag: div, level: 15" node_number="378">Lily O&#8217;Hara</div>, </span><span class="valid" valid="valid" title="valid: True, node: 379, tag: span, level: 14" node_number="379"><div title="valid: False, node: 380, tag: div, level: 15" node_number="380">Anita Heywood</div>, </span><span class="valid" valid="valid" title="valid: True, node: 381, tag: span, level: 14" node_number="381"><div title="valid: False, node: 382, tag: div, level: 15" node_number="382">Matthew Hobbs</div>, </span><span class="valid" valid="valid" title="valid: True, node: 383, tag: span, level: 14" node_number="383"><div title="valid: False, node: 384, tag: div, level: 15" node_number="384">Angela Ballantyne</div> and </span><span class="valid" valid="valid" title="valid: True, node: 385, tag: span, level: 14" node_number="385"><div title="valid: False, node: 386, tag: div, level: 15" node_number="386">Lesley Gray</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 387, tag: div, level: 13" node_number="387"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 388, tag: b, level: 14" node_number="388">2021</b>, 9(12), 1466; https://doi.org/10.3390/vaccines9121466 (registering&#160;DOI) - 11 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 389, tag: div, level: 13" node_number="389"> Abstract <div class="valid" valid="valid" title="valid: True, node: 390, tag: div, level: 14" node_number="390"> Higher weight status, defined as body mass index (BMI) &#8805; 30 kg/m<sup title="valid: False, node: 391, tag: sup, level: 15" node_number="391">2</sup>, is frequently described as a risk factor for severity and susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (known as COVID-19). Therefore, study groups in COVID-19 vaccine [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 392, tag: div, level: 14" node_number="392"> Higher weight status, defined as body mass index (BMI) &#8805; 30 kg/m<sup title="valid: False, node: 393, tag: sup, level: 15" node_number="393">2</sup>, is frequently described as a risk factor for severity and susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (known as COVID-19). Therefore, study groups in COVID-19 vaccine trials should be representative of the weight spectrum across the global population. Appropriate subgroup analysis should be conducted to ensure equitable vaccine outcomes for higher weight people. In this study, inclusion and exclusion criteria of registered clinical trial protocols were reviewed to determine the proportion of trials including higher weight people, and the proportion of trials conducting subgroup analyses of efficacy by BMI. Eligibility criteria of 249 trial protocols (phase I, II, III and IV) were analysed; 51 protocols (20.5%) specified inclusion of BMI &gt; 30, 73 (29.3%) specified exclusion of BMI &gt; 30, and 125 (50.2%) did not specify whether BMI was an inclusion or exclusion criterion, or if BMI was included in any &#8216;health&#8217; screenings or physical examinations during recruitment. Of the 58 protocols for trials in phase III and IV, only 2 (3.4%) indicated an intention to report subgroup analysis of vaccine efficacy by weight status. Higher weight people appear to be significantly under-represented in the majority of vaccine trials. This may result in reduced efficacy and acceptance of COVID-19 vaccines for higher weight people and exacerbation of health inequities within this population group. Explicit inclusion of higher weight people in COVID-19 vaccine trials is required to reduce health inequities. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 394, tag: div, level: 13" node_number="394"> (This article belongs to the Special Issue Vaccines: Uptake and Equity in Times of the COVID-19 Pandemic) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 395, tag: div, level: 13" node_number="395"><div class="valid" valid="valid" title="valid: True, node: 396, tag: div, level: 14" node_number="396"><div title="valid: False, node: 397, tag: div, level: 15" node_number="397"><p title="valid: False, node: 398, tag: p, level: 16" node_number="398">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 399, tag: div, level: 10" node_number="399"> <div class="valid" valid="valid" title="valid: True, node: 400, tag: div, level: 11" node_number="400"> <div class="valid" valid="valid" title="valid: True, node: 401, tag: div, level: 12" node_number="401"> <div class="valid" valid="valid" title="valid: True, node: 402, tag: div, level: 13" node_number="402"> <a class="valid" valid="valid" title="valid: True, node: 403, tag: a, level: 14" node_number="403"> <i title="valid: False, node: 404, tag: i, level: 15" node_number="404">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 405, tag: div, level: 14" node_number="405"> Supplementary material: Supplementary File 1 (ZIP, 4358 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 406, tag: div, level: 13" node_number="406"> <a class="valid" valid="valid" title="valid: True, node: 407, tag: a, level: 14" node_number="407"> <i title="valid: False, node: 408, tag: i, level: 15" node_number="408">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 409, tag: div, level: 13" node_number="409"> <a class="valid" valid="valid" title="valid: True, node: 410, tag: a, level: 14" node_number="410"> <i title="valid: False, node: 411, tag: i, level: 15" node_number="411">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 412, tag: div, level: 14" node_number="412"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 413, tag: div, level: 13" node_number="413">Open AccessReview</div> Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review <div class="valid" valid="valid" title="valid: True, node: 414, tag: div, level: 13" node_number="414"> by <span class="valid" valid="valid" title="valid: True, node: 415, tag: span, level: 14" node_number="415"><div title="valid: False, node: 416, tag: div, level: 15" node_number="416">Adinda Kok</div>, </span><span class="valid" valid="valid" title="valid: True, node: 417, tag: span, level: 14" node_number="417"><div title="valid: False, node: 418, tag: div, level: 15" node_number="418">Ron A. M. Fouchier</div> and </span><span class="valid" valid="valid" title="valid: True, node: 419, tag: span, level: 14" node_number="419"><div title="valid: False, node: 420, tag: div, level: 15" node_number="420">Mathilde Richard</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 421, tag: div, level: 13" node_number="421"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 422, tag: b, level: 14" node_number="422">2021</b>, 9(12), 1465; https://doi.org/10.3390/vaccines9121465 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 423, tag: div, level: 13" node_number="423"> Abstract <div class="valid" valid="valid" title="valid: True, node: 424, tag: div, level: 14" node_number="424"> Avian influenza viruses from the A/H5 A/goose/Guangdong/1/1996 (GsGd) lineage pose a continuing threat to animal and human health. Since their emergence in 1997, these viruses have spread across multiple continents and have become enzootic in poultry. Additionally, over 800 cases of human infection [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 425, tag: div, level: 14" node_number="425"> Avian influenza viruses from the A/H5 A/goose/Guangdong/1/1996 (GsGd) lineage pose a continuing threat to animal and human health. Since their emergence in 1997, these viruses have spread across multiple continents and have become enzootic in poultry. Additionally, over 800 cases of human infection with A/H5 GsGd viruses have been reported to date, which raises concerns about the potential for a new influenza virus pandemic. The continuous circulation of A/H5 GsGd viruses for over 20 years has resulted in the genetic and antigenic diversification of their hemagglutinin (HA) surface glycoprotein, which poses a serious challenge to pandemic preparedness and vaccine design. In the present article, clinical studies on A/H5 influenza vaccination strategies were reviewed to evaluate the breadth of antibody responses induced upon homologous and heterologous prime-boost vaccination strategies. Clinical data on immunological endpoints were extracted from studies and compiled into a dataset, which was used for the visualization and analysis of the height and breadth of humoral immune responses. Several aspects leading to high immunogenicity and/or cross-reactivity were identified, although the analysis was limited by the heterogeneity in study design and vaccine type used in the included studies. Consequently, crucial questions remain to be addressed in future studies on A/H5 GsGd vaccination strategies. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 426, tag: div, level: 13" node_number="426"> (This article belongs to the Special Issue Immune Responses to Influenza Virus Antigens) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 427, tag: div, level: 13" node_number="427"><div class="valid" valid="valid" title="valid: True, node: 428, tag: div, level: 14" node_number="428"><div title="valid: False, node: 429, tag: div, level: 15" node_number="429"><p title="valid: False, node: 430, tag: p, level: 16" node_number="430">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 431, tag: div, level: 10" node_number="431"> <div class="valid" valid="valid" title="valid: True, node: 432, tag: div, level: 11" node_number="432"> <div class="valid" valid="valid" title="valid: True, node: 433, tag: div, level: 12" node_number="433"> <div class="valid" valid="valid" title="valid: True, node: 434, tag: div, level: 13" node_number="434"> <a class="valid" valid="valid" title="valid: True, node: 435, tag: a, level: 14" node_number="435"> <i title="valid: False, node: 436, tag: i, level: 15" node_number="436">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 437, tag: div, level: 13" node_number="437"> <a class="valid" valid="valid" title="valid: True, node: 438, tag: a, level: 14" node_number="438"> <i title="valid: False, node: 439, tag: i, level: 15" node_number="439">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 440, tag: div, level: 14" node_number="440"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 441, tag: div, level: 13" node_number="441">Open AccessArticle</div> mRNA Vaccine Protects against Zika Virus <div class="valid" valid="valid" title="valid: True, node: 442, tag: div, level: 13" node_number="442"> by <span class="valid" valid="valid" title="valid: True, node: 443, tag: span, level: 14" node_number="443"><div title="valid: False, node: 444, tag: div, level: 15" node_number="444">Lex G. Medina-Mag&#252;es</div>, </span><span class="valid" valid="valid" title="valid: True, node: 445, tag: span, level: 14" node_number="445"><div title="valid: False, node: 446, tag: div, level: 15" node_number="446">Janina Gergen</div>, </span><span class="valid" valid="valid" title="valid: True, node: 447, tag: span, level: 14" node_number="447"><div title="valid: False, node: 448, tag: div, level: 15" node_number="448">Edith Jasny</div>, </span><span class="valid" valid="valid" title="valid: True, node: 449, tag: span, level: 14" node_number="449"><div title="valid: False, node: 450, tag: div, level: 15" node_number="450">Benjamin Petsch</div>, </span><span class="valid" valid="valid" title="valid: True, node: 451, tag: span, level: 14" node_number="451"><div title="valid: False, node: 452, tag: div, level: 15" node_number="452">Jaime Lopera-Madrid</div>, </span><span class="valid" valid="valid" title="valid: True, node: 453, tag: span, level: 14" node_number="453"><div title="valid: False, node: 454, tag: div, level: 15" node_number="454">Emily S. Medina-Mag&#252;es</div>, </span><span class="valid" valid="valid" title="valid: True, node: 455, tag: span, level: 14" node_number="455"><div title="valid: False, node: 456, tag: div, level: 15" node_number="456">Cristhian Salas-Quinchucua</div> and </span><span class="valid" valid="valid" title="valid: True, node: 457, tag: span, level: 14" node_number="457"><div title="valid: False, node: 458, tag: div, level: 15" node_number="458">Jorge E. Osorio</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 459, tag: div, level: 13" node_number="459"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 460, tag: b, level: 14" node_number="460">2021</b>, 9(12), 1464; https://doi.org/10.3390/vaccines9121464 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 461, tag: div, level: 13" node_number="461"> Abstract <div class="valid" valid="valid" title="valid: True, node: 462, tag: div, level: 14" node_number="462"> Zika virus (ZIKV), a mosquito-borne flavivirus, has recently triggered global concern due to severe health complications. In 2015, a large ZIKV outbreak occurred in the Americas and established a link between ZIKV and microcephaly in newborn babies, spontaneous abortion, persistent viremia, and Guillain&#8211;Barr&#233; [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 463, tag: div, level: 14" node_number="463"> Zika virus (ZIKV), a mosquito-borne flavivirus, has recently triggered global concern due to severe health complications. In 2015, a large ZIKV outbreak occurred in the Americas and established a link between ZIKV and microcephaly in newborn babies, spontaneous abortion, persistent viremia, and Guillain&#8211;Barr&#233; syndrome. While antivirals are being developed and prevention strategies focus on vector control, a safe and effective Zika vaccine remains unavailable. Messenger RNA (mRNA) vaccine technology has arisen as a flexible, simplified, and fast vaccine production platform. Here, we report on an mRNA vaccine candidate that encodes the pre-membrane and envelope (prM&#8211;E) glycoproteins of ZIKV strain Brazil SPH2015 and is encapsulated in lipid nanoparticles (LNPs). Our ZIKV prM&#8211;E mRNA-LNP vaccine candidate induced antibody responses that protected in AG129 mice deficient in interferon (IFN) alpha/beta/gamma (IFN-&#945;/&#946;/&#947;) receptors. Notably, a single administration of ZIKV prM&#8211;E mRNA-LNP protected against a lethal dose of ZIKV, while a two-dose strategy induced strong protective immunity. E-specific double-positive IFN-&#947; and TNF-&#945; T-cells were induced in BALB/c mice after immunizations with a two-dose strategy. With the success of mRNA vaccine technology in facing the coronavirus (COVID-19) pandemic, our data support the development of prM&#8211;E RNActive<sup title="valid: False, node: 464, tag: sup, level: 15" node_number="464">&#174;</sup> as a promising mRNA vaccine against Zika to counter future epidemics. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 465, tag: div, level: 13" node_number="465"> (This article belongs to the Topic Animal Model in Biomedical Research) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 466, tag: div, level: 13" node_number="466"><div class="valid" valid="valid" title="valid: True, node: 467, tag: div, level: 14" node_number="467"><div title="valid: False, node: 468, tag: div, level: 15" node_number="468"><p title="valid: False, node: 469, tag: p, level: 16" node_number="469">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 470, tag: div, level: 10" node_number="470"> <div class="valid" valid="valid" title="valid: True, node: 471, tag: div, level: 11" node_number="471"> <div class="valid" valid="valid" title="valid: True, node: 472, tag: div, level: 12" node_number="472"> <div class="valid" valid="valid" title="valid: True, node: 473, tag: div, level: 13" node_number="473"> <a class="valid" valid="valid" title="valid: True, node: 474, tag: a, level: 14" node_number="474"> <i title="valid: False, node: 475, tag: i, level: 15" node_number="475">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 476, tag: div, level: 14" node_number="476"> Supplementary material: Supplementary File 1 (ZIP, 215 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 477, tag: div, level: 13" node_number="477"> <a class="valid" valid="valid" title="valid: True, node: 478, tag: a, level: 14" node_number="478"> <i title="valid: False, node: 479, tag: i, level: 15" node_number="479">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 480, tag: div, level: 13" node_number="480"> <a class="valid" valid="valid" title="valid: True, node: 481, tag: a, level: 14" node_number="481"> <i title="valid: False, node: 482, tag: i, level: 15" node_number="482">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 483, tag: div, level: 14" node_number="483"> View online as: Abstract Page </div> </div> <div class="valid" valid="valid" title="valid: True, node: 484, tag: div, level: 13" node_number="484">Open AccessArticle</div> Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection <div class="valid" valid="valid" title="valid: True, node: 485, tag: div, level: 13" node_number="485"> by <span class="valid" valid="valid" title="valid: True, node: 486, tag: span, level: 14" node_number="486"><div title="valid: False, node: 487, tag: div, level: 15" node_number="487">Oleguer Par&#233;s-Badell</div>, </span><span class="valid" valid="valid" title="valid: True, node: 488, tag: span, level: 14" node_number="488"><div title="valid: False, node: 489, tag: div, level: 15" node_number="489">Xavier Mart&#237;nez-G&#243;mez</div>, </span><span class="valid" valid="valid" title="valid: True, node: 490, tag: span, level: 14" node_number="490"><div title="valid: False, node: 491, tag: div, level: 15" node_number="491">Laia Pin&#243;s</div>, </span><span class="valid" valid="valid" title="valid: True, node: 492, tag: span, level: 14" node_number="492"><div title="valid: False, node: 493, tag: div, level: 15" node_number="493">Blanca Borras-Bermejo</div>, </span><span class="valid" valid="valid" title="valid: True, node: 494, tag: span, level: 14" node_number="494"><div title="valid: False, node: 495, tag: div, level: 15" node_number="495">Sonia Uriona</div>, </span><span class="valid" valid="valid" title="valid: True, node: 496, tag: span, level: 14" node_number="496"><div title="valid: False, node: 497, tag: div, level: 15" node_number="497">Susana Otero-Romero</div>, </span><span class="valid" valid="valid" title="valid: True, node: 498, tag: span, level: 14" node_number="498"><div title="valid: False, node: 499, tag: div, level: 15" node_number="499">Jos&#233; &#193;ngel Rodrigo-Pend&#225;s</div>, </span><span class="valid" valid="valid" title="valid: True, node: 500, tag: span, level: 14" node_number="500"><div title="valid: False, node: 501, tag: div, level: 15" node_number="501">Yolima Cossio-Gil</div>, </span><span class="valid" valid="valid" title="valid: True, node: 502, tag: span, level: 14" node_number="502"><div title="valid: False, node: 503, tag: div, level: 15" node_number="503">Ant&#242;nia Agust&#237;</div>, </span><span class="valid" valid="valid" title="valid: True, node: 504, tag: span, level: 14" node_number="504"><div title="valid: False, node: 505, tag: div, level: 15" node_number="505">Cristina Aguilera</div> and </span><span class="valid" valid="valid" title="valid: True, node: 506, tag: span, level: 14" node_number="506"><div title="valid: False, node: 507, tag: div, level: 15" node_number="507">Magda Campins</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 508, tag: div, level: 13" node_number="508"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 509, tag: b, level: 14" node_number="509">2021</b>, 9(12), 1463; https://doi.org/10.3390/vaccines9121463 (registering&#160;DOI) - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 510, tag: div, level: 13" node_number="510"> Abstract <div class="valid" valid="valid" title="valid: True, node: 511, tag: div, level: 14" node_number="511"> The aim of this study was to assess adverse reactions to COVID-19 vaccines, comparing the BNT162b2 or the mRNA-1273 COVID-19 vaccines and the presence and seriousness of a previous COVID-19 infection. We conducted a cross-sectional online survey of vaccinated healthcare workers at a [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 512, tag: div, level: 14" node_number="512"> The aim of this study was to assess adverse reactions to COVID-19 vaccines, comparing the BNT162b2 or the mRNA-1273 COVID-19 vaccines and the presence and seriousness of a previous COVID-19 infection. We conducted a cross-sectional online survey of vaccinated healthcare workers at a tertiary hospital in Barcelona (Spain). Thirty-eight percent of vaccine recipients responded to the questionnaire. We compared the prevalence of adverse reactions by vaccine type and history of COVID-19 infections. A total of 2373 respondents had received the BNT162b2 vaccine, and 506 the mRNA-1273 vaccine. The prevalence of at least one adverse reaction with doses 1 and 2 was 41% and 70%, respectively, in the BNT162b2 group, and 60% and 92% in the mRNA-1273 group (<i title="valid: False, node: 513, tag: i, level: 15" node_number="513">p </i>&lt; 0.001). The BNT162b2 group reported less prevalence of all adverse reactions. Need for medical leave was significantly more frequent among the mRNA-1273 group (12% versus 4.6% <i title="valid: False, node: 514, tag: i, level: 15" node_number="514">p </i>&lt; 0.001). Interestingly, respondents with a history of allergies or chronic illnesses did not report more adverse reactions. The frequency of adverse reactions with dose 2 was 96% (95% CI 88&#8211;100%) for those with a history of COVID-19 related hospitalization, and 86% (95% CI 83&#8211;89%) for those with mild or moderate symptomatic COVID-19, significantly higher than for participants with no history of COVID-19 infections (67%, 95% CI 65&#8211;69%). Our results could help inform vaccine recipients of the probability of their having adverse reactions to COVID-19 vaccines. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 515, tag: div, level: 13" node_number="515"> (This article belongs to the Special Issue Recombinant Vaccines Produced in Emerging Expression Systems for Human and Animal Health) </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 516, tag: div, level: 10" node_number="516"> <div class="valid" valid="valid" title="valid: True, node: 517, tag: div, level: 11" node_number="517"> <div class="valid" valid="valid" title="valid: True, node: 518, tag: div, level: 12" node_number="518"> <div class="valid" valid="valid" title="valid: True, node: 519, tag: div, level: 13" node_number="519"> <a class="valid" valid="valid" title="valid: True, node: 520, tag: a, level: 14" node_number="520"> <i title="valid: False, node: 521, tag: i, level: 15" node_number="521">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 522, tag: div, level: 13" node_number="522"> <a class="valid" valid="valid" title="valid: True, node: 523, tag: a, level: 14" node_number="523"> <i title="valid: False, node: 524, tag: i, level: 15" node_number="524">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 525, tag: div, level: 14" node_number="525"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 526, tag: div, level: 13" node_number="526">Open AccessArticle</div> Expected Evolution of COVID-19 Epidemic in France for Several Combinations of Vaccination Strategies and Barrier Measures <div class="valid" valid="valid" title="valid: True, node: 527, tag: div, level: 13" node_number="527"> by <span class="valid" valid="valid" title="valid: True, node: 528, tag: span, level: 14" node_number="528"><div title="valid: False, node: 529, tag: div, level: 15" node_number="529">Simon Pageaud</div>, </span><span class="valid" valid="valid" title="valid: True, node: 530, tag: span, level: 14" node_number="530"><div title="valid: False, node: 531, tag: div, level: 15" node_number="531">Catherine Pothier</div>, </span><span class="valid" valid="valid" title="valid: True, node: 532, tag: span, level: 14" node_number="532"><div title="valid: False, node: 533, tag: div, level: 15" node_number="533">Christophe Rigotti</div>, </span><span class="valid" valid="valid" title="valid: True, node: 534, tag: span, level: 14" node_number="534"><div title="valid: False, node: 535, tag: div, level: 15" node_number="535">Anne Eyraud-Loisel</div>, </span><span class="valid" valid="valid" title="valid: True, node: 536, tag: span, level: 14" node_number="536"><div title="valid: False, node: 537, tag: div, level: 15" node_number="537">Jean-Pierre Bertoglio</div>, </span><span class="valid" valid="valid" title="valid: True, node: 538, tag: span, level: 14" node_number="538"><div title="valid: False, node: 539, tag: div, level: 15" node_number="539">Alexis Bienven&#252;e</div>, </span><span class="valid" valid="valid" title="valid: True, node: 540, tag: span, level: 14" node_number="540"><div title="valid: False, node: 541, tag: div, level: 15" node_number="541">Nicolas Leboisne</div>, </span><span class="valid" valid="valid" title="valid: True, node: 542, tag: span, level: 14" node_number="542"><div title="valid: False, node: 543, tag: div, level: 15" node_number="543">Nicolas Ponthus</div>, </span><span class="valid" valid="valid" title="valid: True, node: 544, tag: span, level: 14" node_number="544"><div title="valid: False, node: 545, tag: div, level: 15" node_number="545">Romain Gauchon</div>, </span><span class="valid" valid="valid" title="valid: True, node: 546, tag: span, level: 14" node_number="546"><div title="valid: False, node: 547, tag: div, level: 15" node_number="547">Fran&#231;ois Gueyffier</div>, </span><span class="valid" valid="valid" title="valid: True, node: 548, tag: span, level: 14" node_number="548"><div title="valid: False, node: 549, tag: div, level: 15" node_number="549">Philippe Vanhems</div>, </span><span class="valid" valid="valid" title="valid: True, node: 550, tag: span, level: 14" node_number="550"><div title="valid: False, node: 551, tag: div, level: 15" node_number="551">Jean Iwaz</div>, </span><span class="valid" valid="valid" title="valid: True, node: 552, tag: span, level: 14" node_number="552"><div title="valid: False, node: 553, tag: div, level: 15" node_number="553">St&#233;phane Loisel</div>, </span><span class="valid" valid="valid" title="valid: True, node: 554, tag: span, level: 14" node_number="554"><div title="valid: False, node: 555, tag: div, level: 15" node_number="555">Pascal Roy</div> and </span>on behalf of the Group CovDyn (Covid Dynamics) </div> <div class="valid" valid="valid" title="valid: True, node: 556, tag: div, level: 13" node_number="556"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 557, tag: b, level: 14" node_number="557">2021</b>, 9(12), 1462; https://doi.org/10.3390/vaccines9121462 - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 558, tag: div, level: 13" node_number="558"> Abstract <div class="valid" valid="valid" title="valid: True, node: 559, tag: div, level: 14" node_number="559"> The outbreak of the SARS-CoV-2 virus, enhanced by rapid spreads of variants, has caused a major international health crisis, with serious public health and economic consequences. An agent-based model was designed to simulate the evolution of the epidemic in France over 2021 and [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 560, tag: div, level: 14" node_number="560"> The outbreak of the SARS-CoV-2 virus, enhanced by rapid spreads of variants, has caused a major international health crisis, with serious public health and economic consequences. An agent-based model was designed to simulate the evolution of the epidemic in France over 2021 and the first six months of 2022. The study compares the efficiencies of four theoretical vaccination campaigns (over 6, 9, 12, and 18 months), combined with various non-pharmaceutical interventions. In France, with the emergence of the Alpha variant, without vaccination and despite strict barrier measures, more than 600,000 deaths would be observed. An efficient vaccination campaign (i.e., total coverage of the French population) over six months would divide the death toll by 10. A vaccination campaign of 12, instead of 6, months would slightly increase the disease-related mortality (+6%) but require a 77% increase in ICU bed&#8211;days. A campaign over 18 months would increase the disease-related mortality by 17% and require a 244% increase in ICU bed&#8211;days. Thus, it seems mandatory to vaccinate the highest possible percentage of the population within 12, or better yet, 9 months. The race against the epidemic and virus variants is really a matter of vaccination strategy. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 561, tag: div, level: 13" node_number="561"> (This article belongs to the Section COVID-19 Vaccines and Vaccination) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 562, tag: div, level: 13" node_number="562"><div class="valid" valid="valid" title="valid: True, node: 563, tag: div, level: 14" node_number="563"><div title="valid: False, node: 564, tag: div, level: 15" node_number="564"><p title="valid: False, node: 565, tag: p, level: 16" node_number="565">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 566, tag: div, level: 10" node_number="566"> <div class="valid" valid="valid" title="valid: True, node: 567, tag: div, level: 11" node_number="567"> <div class="valid" valid="valid" title="valid: True, node: 568, tag: div, level: 12" node_number="568"> <div class="valid" valid="valid" title="valid: True, node: 569, tag: div, level: 13" node_number="569"> <a class="valid" valid="valid" title="valid: True, node: 570, tag: a, level: 14" node_number="570"> <i title="valid: False, node: 571, tag: i, level: 15" node_number="571">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 572, tag: div, level: 13" node_number="572"> <a class="valid" valid="valid" title="valid: True, node: 573, tag: a, level: 14" node_number="573"> <i title="valid: False, node: 574, tag: i, level: 15" node_number="574">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 575, tag: div, level: 14" node_number="575"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 576, tag: div, level: 13" node_number="576">Open AccessArticle</div> Public Perceptions and Acceptance of COVID-19 Booster Vaccination in China: A Cross-Sectional Study <div class="valid" valid="valid" title="valid: True, node: 577, tag: div, level: 13" node_number="577"> by <span class="valid" valid="valid" title="valid: True, node: 578, tag: span, level: 14" node_number="578"><div title="valid: False, node: 579, tag: div, level: 15" node_number="579">Xiaozhen Lai</div>, </span><span class="valid" valid="valid" title="valid: True, node: 580, tag: span, level: 14" node_number="580"><div title="valid: False, node: 581, tag: div, level: 15" node_number="581">He Zhu</div>, </span><span class="valid" valid="valid" title="valid: True, node: 582, tag: span, level: 14" node_number="582"><div title="valid: False, node: 583, tag: div, level: 15" node_number="583">Jiahao Wang</div>, </span><span class="valid" valid="valid" title="valid: True, node: 584, tag: span, level: 14" node_number="584"><div title="valid: False, node: 585, tag: div, level: 15" node_number="585">Yingzhe Huang</div>, </span><span class="valid" valid="valid" title="valid: True, node: 586, tag: span, level: 14" node_number="586"><div title="valid: False, node: 587, tag: div, level: 15" node_number="587">Rize Jing</div>, </span><span class="valid" valid="valid" title="valid: True, node: 588, tag: span, level: 14" node_number="588"><div title="valid: False, node: 589, tag: div, level: 15" node_number="589">Yun Lyu</div>, </span><span class="valid" valid="valid" title="valid: True, node: 590, tag: span, level: 14" node_number="590"><div title="valid: False, node: 591, tag: div, level: 15" node_number="591">Haijun Zhang</div>, </span><span class="valid" valid="valid" title="valid: True, node: 592, tag: span, level: 14" node_number="592"><div title="valid: False, node: 593, tag: div, level: 15" node_number="593">Huangyufei Feng</div>, </span><span class="valid" valid="valid" title="valid: True, node: 594, tag: span, level: 14" node_number="594"><div title="valid: False, node: 595, tag: div, level: 15" node_number="595">Jia Guo</div> and </span><span class="valid" valid="valid" title="valid: True, node: 596, tag: span, level: 14" node_number="596"><div title="valid: False, node: 597, tag: div, level: 15" node_number="597">Hai Fang</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 598, tag: div, level: 13" node_number="598"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 599, tag: b, level: 14" node_number="599">2021</b>, 9(12), 1461; https://doi.org/10.3390/vaccines9121461 - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 600, tag: div, level: 13" node_number="600"> Abstract <div class="valid" valid="valid" title="valid: True, node: 601, tag: div, level: 14" node_number="601"> Coronavirus disease 2019 (COVID-19) booster vaccination has been proposed in response to the new challenges of highly contagious variants, yet few studies have examined public acceptance of boosters. This study examined public acceptance of COVID-19 booster vaccination and its influencing factors by using [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 602, tag: div, level: 14" node_number="602"> Coronavirus disease 2019 (COVID-19) booster vaccination has been proposed in response to the new challenges of highly contagious variants, yet few studies have examined public acceptance of boosters. This study examined public acceptance of COVID-19 booster vaccination and its influencing factors by using the data from a self-administered online cross-sectional survey conducted in June 2021 in China. Multiple logistic analysis was used to examine the influencing factors of booster acceptance based on the health belief model (HBM). Among 1145 respondents, 84.80% reported to accept COVID-19 booster vaccination. Having COVID-19 vaccination history, perceiving high benefits and low barriers to booster vaccination, being younger (18&#8211;30 vs. 41&#8211;50), having a lower education level, being employed, and belonging to priority groups for vaccination were associated with increased odds of booster acceptance. The primary reason for refusing booster vaccination was concern about vaccine safety. The vast majority (92.8%) of respondents reported an annual willingness to pay between 0 and 300 CNY (0&#8211;46.29 USD) if the booster was not free. Our findings suggest that the acceptance rate of booster vaccination is relatively high in China, and the HBM-based analysis reveals that more efforts are needed to increase perceived benefits and reduce perceived barriers of vaccination to design effective and proper vaccination extension strategies when boosters become widely recommended. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 603, tag: div, level: 13" node_number="603"> (This article belongs to the Section COVID-19 Vaccines and Vaccination) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 604, tag: div, level: 13" node_number="604"><div class="valid" valid="valid" title="valid: True, node: 605, tag: div, level: 14" node_number="605"><div title="valid: False, node: 606, tag: div, level: 15" node_number="606"><p title="valid: False, node: 607, tag: p, level: 16" node_number="607">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 608, tag: div, level: 10" node_number="608"> <div class="valid" valid="valid" title="valid: True, node: 609, tag: div, level: 11" node_number="609"> <div class="valid" valid="valid" title="valid: True, node: 610, tag: div, level: 12" node_number="610"> <div class="valid" valid="valid" title="valid: True, node: 611, tag: div, level: 13" node_number="611"> <a class="valid" valid="valid" title="valid: True, node: 612, tag: a, level: 14" node_number="612"> <i title="valid: False, node: 613, tag: i, level: 15" node_number="613">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 614, tag: div, level: 14" node_number="614"> Supplementary material: Supplementary File 1 (ZIP, 1651 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 615, tag: div, level: 13" node_number="615"> <a class="valid" valid="valid" title="valid: True, node: 616, tag: a, level: 14" node_number="616"> <i title="valid: False, node: 617, tag: i, level: 15" node_number="617">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 618, tag: div, level: 13" node_number="618"> <a class="valid" valid="valid" title="valid: True, node: 619, tag: a, level: 14" node_number="619"> <i title="valid: False, node: 620, tag: i, level: 15" node_number="620">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 621, tag: div, level: 14" node_number="621"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 622, tag: div, level: 13" node_number="622">Open AccessArticle</div> Model-Based Planning and Delivery of Mass Vaccination Campaigns against Infectious Disease: Application to the COVID-19 Pandemic in the UK <div class="valid" valid="valid" title="valid: True, node: 623, tag: div, level: 13" node_number="623"> by <span class="valid" valid="valid" title="valid: True, node: 624, tag: span, level: 14" node_number="624"><div title="valid: False, node: 625, tag: div, level: 15" node_number="625">Dauda Ibrahim</div>, </span><span class="valid" valid="valid" title="valid: True, node: 626, tag: span, level: 14" node_number="626"><div title="valid: False, node: 627, tag: div, level: 15" node_number="627">Zolt&#225;n Kis</div>, </span><span class="valid" valid="valid" title="valid: True, node: 628, tag: span, level: 14" node_number="628"><div title="valid: False, node: 629, tag: div, level: 15" node_number="629">Kyungjae Tak</div>, </span><span class="valid" valid="valid" title="valid: True, node: 630, tag: span, level: 14" node_number="630"><div title="valid: False, node: 631, tag: div, level: 15" node_number="631">Maria M. Papathanasiou</div>, </span><span class="valid" valid="valid" title="valid: True, node: 632, tag: span, level: 14" node_number="632"><div title="valid: False, node: 633, tag: div, level: 15" node_number="633">Cleo Kontoravdi</div>, </span><span class="valid" valid="valid" title="valid: True, node: 634, tag: span, level: 14" node_number="634"><div title="valid: False, node: 635, tag: div, level: 15" node_number="635">Beno&#238;t Chachuat</div> and </span><span class="valid" valid="valid" title="valid: True, node: 636, tag: span, level: 14" node_number="636"><div title="valid: False, node: 637, tag: div, level: 15" node_number="637">Nilay Shah</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 638, tag: div, level: 13" node_number="638"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 639, tag: b, level: 14" node_number="639">2021</b>, 9(12), 1460; https://doi.org/10.3390/vaccines9121460 - 10 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 640, tag: div, level: 13" node_number="640"> Abstract <div class="valid" valid="valid" title="valid: True, node: 641, tag: div, level: 14" node_number="641"> Vaccination plays a key role in reducing morbidity and mortality caused by infectious diseases, including the recent COVID-19 pandemic. However, a comprehensive approach that allows the planning of vaccination campaigns and the estimation of the resources required to deliver and administer COVID-19 vaccines [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 642, tag: div, level: 14" node_number="642"> Vaccination plays a key role in reducing morbidity and mortality caused by infectious diseases, including the recent COVID-19 pandemic. However, a comprehensive approach that allows the planning of vaccination campaigns and the estimation of the resources required to deliver and administer COVID-19 vaccines is lacking. This work implements a new framework that supports the planning and delivery of vaccination campaigns. Firstly, the framework segments and priorities target populations, then estimates vaccination timeframe and workforce requirements, and lastly predicts logistics costs and facilitates the distribution of vaccines from manufacturing plants to vaccination centres. The outcomes from this study reveal the necessary resources required and their associated costs ahead of a vaccination campaign. Analysis of results shows that by integrating demand stratification, administration, and the supply chain, the synergy amongst these activities can be exploited to allow planning and cost-effective delivery of a vaccination campaign against COVID-19 and demonstrates how to sustain high rates of vaccination in a resource-efficient fashion. Full article </div> </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 643, tag: div, level: 13" node_number="643"><div class="valid" valid="valid" title="valid: True, node: 644, tag: div, level: 14" node_number="644"><div title="valid: False, node: 645, tag: div, level: 15" node_number="645"><p title="valid: False, node: 646, tag: p, level: 16" node_number="646">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 647, tag: div, level: 10" node_number="647"> <div class="valid" valid="valid" title="valid: True, node: 648, tag: div, level: 11" node_number="648"> <div class="valid" valid="valid" title="valid: True, node: 649, tag: div, level: 12" node_number="649"> <div class="valid" valid="valid" title="valid: True, node: 650, tag: div, level: 13" node_number="650"> <a class="valid" valid="valid" title="valid: True, node: 651, tag: a, level: 14" node_number="651"> <i title="valid: False, node: 652, tag: i, level: 15" node_number="652">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 653, tag: div, level: 14" node_number="653"> Supplementary material: Supplementary File 1 (ZIP, 1060 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 654, tag: div, level: 13" node_number="654"> <a class="valid" valid="valid" title="valid: True, node: 655, tag: a, level: 14" node_number="655"> <i title="valid: False, node: 656, tag: i, level: 15" node_number="656">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 657, tag: div, level: 13" node_number="657"> <a class="valid" valid="valid" title="valid: True, node: 658, tag: a, level: 14" node_number="658"> <i title="valid: False, node: 659, tag: i, level: 15" node_number="659">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 660, tag: div, level: 14" node_number="660"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 661, tag: div, level: 13" node_number="661">Open AccessArticle</div> Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population <div class="valid" valid="valid" title="valid: True, node: 662, tag: div, level: 13" node_number="662"> by <span class="valid" valid="valid" title="valid: True, node: 663, tag: span, level: 14" node_number="663"><div title="valid: False, node: 664, tag: div, level: 15" node_number="664">Marsia Gustiananda</div>, </span><span class="valid" valid="valid" title="valid: True, node: 665, tag: span, level: 14" node_number="665"><div title="valid: False, node: 666, tag: div, level: 15" node_number="666">Bobby Prabowo Sulistyo</div>, </span><span class="valid" valid="valid" title="valid: True, node: 667, tag: span, level: 14" node_number="667"><div title="valid: False, node: 668, tag: div, level: 15" node_number="668">David Agustriawan</div> and </span><span class="valid" valid="valid" title="valid: True, node: 669, tag: span, level: 14" node_number="669"><div title="valid: False, node: 670, tag: div, level: 15" node_number="670">Sita Andarini</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 671, tag: div, level: 13" node_number="671"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 672, tag: b, level: 14" node_number="672">2021</b>, 9(12), 1459; https://doi.org/10.3390/vaccines9121459 - 09 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 673, tag: div, level: 13" node_number="673"> Abstract <div class="valid" valid="valid" title="valid: True, node: 674, tag: div, level: 14" node_number="674"> SARS-CoV-2 and its variants caused the COVID-19 pandemic. Vaccines that target conserved regions of SARS-CoV-2 and stimulate protective T-cell responses are important for reducing symptoms and limiting the infection. Seven cytotoxic (CTL) and five helper T-cells (HTL) epitopes from ORF1ab were identified using [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 675, tag: div, level: 14" node_number="675"> SARS-CoV-2 and its variants caused the COVID-19 pandemic. Vaccines that target conserved regions of SARS-CoV-2 and stimulate protective T-cell responses are important for reducing symptoms and limiting the infection. Seven cytotoxic (CTL) and five helper T-cells (HTL) epitopes from ORF1ab were identified using NetCTLpan and NetMHCIIpan algorithms, respectively. These epitopes were generated from ORF1ab regions that are evolutionary stable as reflected by zero Shannon&#8217;s entropy and are presented by 56 human leukocyte antigen (HLA) Class I and 22 HLA Class II, ensuring good coverage for the Indonesian and world population. Having fulfilled other criteria such as immunogenicity, IFN&#947; inducing ability, and non-homology to human and microbiome peptides, the epitopes were assembled into a vaccine construct (VC) together with &#946;-defensin as adjuvant and appropriate linkers. The VC was shown to have good physicochemical characteristics and capability of inducing CTL as well as HTL responses, which stem from the engagement of the vaccine with toll-like receptor 4 (TLR4) as revealed by docking simulations. The most promiscuous peptide <sup title="valid: False, node: 676, tag: sup, level: 15" node_number="676">899</sup>WSMATYYLF<sup title="valid: False, node: 677, tag: sup, level: 15" node_number="677">907</sup> was shown via docking simulation to interact well with HLA-A*24:07, the most predominant allele in Indonesia. The data presented here will contribute to the in vitro study of T-cell epitope mapping and vaccine design in Indonesia. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 678, tag: div, level: 13" node_number="678"> (This article belongs to the Section COVID-19 Vaccines and Vaccination) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 679, tag: div, level: 13" node_number="679"><div class="valid" valid="valid" title="valid: True, node: 680, tag: div, level: 14" node_number="680"><div title="valid: False, node: 681, tag: div, level: 15" node_number="681"><p title="valid: False, node: 682, tag: p, level: 16" node_number="682">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 683, tag: div, level: 10" node_number="683"> <div class="valid" valid="valid" title="valid: True, node: 684, tag: div, level: 11" node_number="684"> <div class="valid" valid="valid" title="valid: True, node: 685, tag: div, level: 12" node_number="685"> <div class="valid" valid="valid" title="valid: True, node: 686, tag: div, level: 13" node_number="686"> <a class="valid" valid="valid" title="valid: True, node: 687, tag: a, level: 14" node_number="687"> <i title="valid: False, node: 688, tag: i, level: 15" node_number="688">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 689, tag: div, level: 14" node_number="689"> Supplementary material: Supplementary File 1 (ZIP, 591 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 690, tag: div, level: 13" node_number="690"> <a class="valid" valid="valid" title="valid: True, node: 691, tag: a, level: 14" node_number="691"> <i title="valid: False, node: 692, tag: i, level: 15" node_number="692">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 693, tag: div, level: 13" node_number="693"> <a class="valid" valid="valid" title="valid: True, node: 694, tag: a, level: 14" node_number="694"> <i title="valid: False, node: 695, tag: i, level: 15" node_number="695">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 696, tag: div, level: 14" node_number="696"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 697, tag: div, level: 13" node_number="697">Open AccessArticle</div> COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity <div class="valid" valid="valid" title="valid: True, node: 698, tag: div, level: 13" node_number="698"> by <span class="valid" valid="valid" title="valid: True, node: 699, tag: span, level: 14" node_number="699"><div title="valid: False, node: 700, tag: div, level: 15" node_number="700">Ying Liu</div>, </span><span class="valid" valid="valid" title="valid: True, node: 701, tag: span, level: 14" node_number="701"><div title="valid: False, node: 702, tag: div, level: 15" node_number="702">Junyan Han</div>, </span><span class="valid" valid="valid" title="valid: True, node: 703, tag: span, level: 14" node_number="703"><div title="valid: False, node: 704, tag: div, level: 15" node_number="704">Xin Li</div>, </span><span class="valid" valid="valid" title="valid: True, node: 705, tag: span, level: 14" node_number="705"><div title="valid: False, node: 706, tag: div, level: 15" node_number="706">Danying Chen</div>, </span><span class="valid" valid="valid" title="valid: True, node: 707, tag: span, level: 14" node_number="707"><div title="valid: False, node: 708, tag: div, level: 15" node_number="708">Xuesen Zhao</div>, </span><span class="valid" valid="valid" title="valid: True, node: 709, tag: span, level: 14" node_number="709"><div title="valid: False, node: 710, tag: div, level: 15" node_number="710">Yaruo Qiu</div>, </span><span class="valid" valid="valid" title="valid: True, node: 711, tag: span, level: 14" node_number="711"><div title="valid: False, node: 712, tag: div, level: 15" node_number="712">Leidan Zhang</div>, </span><span class="valid" valid="valid" title="valid: True, node: 713, tag: span, level: 14" node_number="713"><div title="valid: False, node: 714, tag: div, level: 15" node_number="714">Jing Xiao</div>, </span><span class="valid" valid="valid" title="valid: True, node: 715, tag: span, level: 14" node_number="715"><div title="valid: False, node: 716, tag: div, level: 15" node_number="716">Bei Li</div> and </span><span class="valid" valid="valid" title="valid: True, node: 717, tag: span, level: 14" node_number="717"><div title="valid: False, node: 718, tag: div, level: 15" node_number="718">Hongxin Zhao</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 719, tag: div, level: 13" node_number="719"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 720, tag: b, level: 14" node_number="720">2021</b>, 9(12), 1458; https://doi.org/10.3390/vaccines9121458 - 09 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 721, tag: div, level: 13" node_number="721"> Abstract <div class="valid" valid="valid" title="valid: True, node: 722, tag: div, level: 14" node_number="722"> The administration of COVID-19 vaccines is the primary strategy used to prevent further infections by COVID-19, especially in people living with HIV (PLWH), who are at increased risk for severe symptoms and mortality. However, the vaccine hesitancy, safety, and immunogenicity of COVID-19 vaccines [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 723, tag: div, level: 14" node_number="723"> The administration of COVID-19 vaccines is the primary strategy used to prevent further infections by COVID-19, especially in people living with HIV (PLWH), who are at increased risk for severe symptoms and mortality. However, the vaccine hesitancy, safety, and immunogenicity of COVID-19 vaccines among PLWH have not been fully characterized. We estimated vaccine hesitancy and status of COVID-19 vaccination in Chinese PLWH, explored the safety and impact on antiviral therapy (ART) efficacy and compared the immunogenicity of an inactivated vaccine between PLWH and healthy controls (HC). In total, 27.5% (104/378) of PLWH hesitated to take the vaccine. The barriers included concerns about safety and efficacy, and physician counselling might help patients overcome this vaccine hesitancy. A COVID-19 vaccination did not cause severe side effects and had no negative impact on CD4<sup title="valid: False, node: 724, tag: sup, level: 15" node_number="724">+</sup> T cell counts and HIV RNA viral load. Comparable spike receptor binding domain IgG titer were elicited in PLWH and HC after a second dose of the CoronaVac vaccine, but antibody responses were lower in poor immunological responders (CD4<sup title="valid: False, node: 725, tag: sup, level: 15" node_number="725">+</sup> T cell counts &lt; 350 cells/&#181;L) compared with immunological responders (CD4<sup title="valid: False, node: 726, tag: sup, level: 15" node_number="726">+</sup> T cell counts &#8805; 350 cells/&#181;L). These data showed that PLWH have comparable safety and immune response following inactivated COVID-19 vaccination compared with HC, but the poor immunological response in PLWH is associated with impaired humoral response. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 727, tag: div, level: 13" node_number="727"> (This article belongs to the Special Issue SARS-CoV-2 (COVID-19) Vaccination and Compliance/Hesitancy) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 728, tag: div, level: 13" node_number="728"><div class="valid" valid="valid" title="valid: True, node: 729, tag: div, level: 14" node_number="729"><div title="valid: False, node: 730, tag: div, level: 15" node_number="730"><p title="valid: False, node: 731, tag: p, level: 16" node_number="731">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 732, tag: div, level: 10" node_number="732"> <div class="valid" valid="valid" title="valid: True, node: 733, tag: div, level: 11" node_number="733"> <div class="valid" valid="valid" title="valid: True, node: 734, tag: div, level: 12" node_number="734"> <div class="valid" valid="valid" title="valid: True, node: 735, tag: div, level: 13" node_number="735"> <a class="valid" valid="valid" title="valid: True, node: 736, tag: a, level: 14" node_number="736"> <i title="valid: False, node: 737, tag: i, level: 15" node_number="737">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 738, tag: div, level: 14" node_number="738"> Supplementary material: Supplementary File 1 (ZIP, 789 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 739, tag: div, level: 13" node_number="739"> <a class="valid" valid="valid" title="valid: True, node: 740, tag: a, level: 14" node_number="740"> <i title="valid: False, node: 741, tag: i, level: 15" node_number="741">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 742, tag: div, level: 13" node_number="742"> <a class="valid" valid="valid" title="valid: True, node: 743, tag: a, level: 14" node_number="743"> <i title="valid: False, node: 744, tag: i, level: 15" node_number="744">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 745, tag: div, level: 14" node_number="745"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 746, tag: div, level: 13" node_number="746">Open AccessArticle</div> Comparative Evaluation of Immune Responses and Protection of Chitosan Nanoparticles and Oil-Emulsion Adjuvants in Avian Coronavirus Inactivated Vaccines in Chickens <div class="valid" valid="valid" title="valid: True, node: 747, tag: div, level: 13" node_number="747"> by <span class="valid" valid="valid" title="valid: True, node: 748, tag: span, level: 14" node_number="748"><div title="valid: False, node: 749, tag: div, level: 15" node_number="749">Priscila Diniz Lopes</div>, </span><span class="valid" valid="valid" title="valid: True, node: 750, tag: span, level: 14" node_number="750"><div title="valid: False, node: 751, tag: div, level: 15" node_number="751">Cintia Hiromi Okino</div>, </span><span class="valid" valid="valid" title="valid: True, node: 752, tag: span, level: 14" node_number="752"><div title="valid: False, node: 753, tag: div, level: 15" node_number="753">Filipe Santos Fernando</div>, </span><span class="valid" valid="valid" title="valid: True, node: 754, tag: span, level: 14" node_number="754"><div title="valid: False, node: 755, tag: div, level: 15" node_number="755">Caren Pavani</div>, </span><span class="valid" valid="valid" title="valid: True, node: 756, tag: span, level: 14" node_number="756"><div title="valid: False, node: 757, tag: div, level: 15" node_number="757">Viviane Casagrande Mariguela</div>, </span><span class="valid" valid="valid" title="valid: True, node: 758, tag: span, level: 14" node_number="758"><div title="valid: False, node: 759, tag: div, level: 15" node_number="759">Maria de F&#225;tima Silva Montassier</div> and </span><span class="valid" valid="valid" title="valid: True, node: 760, tag: span, level: 14" node_number="760"><div title="valid: False, node: 761, tag: div, level: 15" node_number="761">H&#233;lio Jos&#233; Montassier</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 762, tag: div, level: 13" node_number="762"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 763, tag: b, level: 14" node_number="763">2021</b>, 9(12), 1457; https://doi.org/10.3390/vaccines9121457 - 09 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 764, tag: div, level: 13" node_number="764"> Abstract <div class="valid" valid="valid" title="valid: True, node: 765, tag: div, level: 14" node_number="765"> Efficient vaccines are the main strategy to control the avian coronavirus (AvCoV), although several drawbacks related to traditional attenuated and inactivated vaccines have been reported. These counterpoints highlight the importance of developing new alternative vaccines against AvCoV, especially those able to induce long-lasting [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 766, tag: div, level: 14" node_number="766"> Efficient vaccines are the main strategy to control the avian coronavirus (AvCoV), although several drawbacks related to traditional attenuated and inactivated vaccines have been reported. These counterpoints highlight the importance of developing new alternative vaccines against AvCoV, especially those able to induce long-lasting immune responses. This study evaluated and compared two inactivated vaccines formulated with AvCoV BR-I variants, one composed of chitosan nanoparticles (AvCoV-CS) and the second by Montanide oily adjuvant (AvCoV-O). Both developed vaccines were administered in a single dose or associated with the traditional Mass attenuated vaccine. The AvCoV-CS vaccine administered alone or associated with the Mass vaccine was able to induce strong humoral and cell-mediated immune (CMI) responses and complete protection against IBV virulent infection, wherein single administration was characterized by high IgA antibody levels in the mucosa, whereas when associated with the Mass vaccine, the serum IgG antibody was predominantly observed. On the other hand, single administration of the oily vaccine presented poor humoral and CMI responses and consequently incomplete protection against virulent challenge, but when associated with the Mass vaccine, immune responses were developed, and complete protection against infection was observed. Both of our experimental vaccines were able to induce full protection against virulent IBV challenge. A single dose of AvCoV-CS vaccine was sufficient to achieve complete protection, while AvCoV-O required a previous priming by a Mass strain to complete the protection. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 767, tag: div, level: 13" node_number="767"> (This article belongs to the Section Veterinary Vaccines) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 768, tag: div, level: 13" node_number="768"><div class="valid" valid="valid" title="valid: True, node: 769, tag: div, level: 14" node_number="769"><div title="valid: False, node: 770, tag: div, level: 15" node_number="770"><p title="valid: False, node: 771, tag: p, level: 16" node_number="771">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 772, tag: div, level: 10" node_number="772"> <div class="valid" valid="valid" title="valid: True, node: 773, tag: div, level: 11" node_number="773"> <div class="valid" valid="valid" title="valid: True, node: 774, tag: div, level: 12" node_number="774"> <div class="valid" valid="valid" title="valid: True, node: 775, tag: div, level: 13" node_number="775"> <a class="valid" valid="valid" title="valid: True, node: 776, tag: a, level: 14" node_number="776"> <i title="valid: False, node: 777, tag: i, level: 15" node_number="777">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 778, tag: div, level: 13" node_number="778"> <a class="valid" valid="valid" title="valid: True, node: 779, tag: a, level: 14" node_number="779"> <i title="valid: False, node: 780, tag: i, level: 15" node_number="780">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 781, tag: div, level: 14" node_number="781"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 782, tag: div, level: 13" node_number="782">Open AccessArticle</div> Myelin Peptide&#8211;Mannan Conjugate Multiple Sclerosis Vaccines: Conjugation Efficacy and Stability of Vaccine Ingredient <div class="valid" valid="valid" title="valid: True, node: 783, tag: div, level: 13" node_number="783"> by <span class="valid" valid="valid" title="valid: True, node: 784, tag: span, level: 14" node_number="784"><div title="valid: False, node: 785, tag: div, level: 15" node_number="785">John Matsoukas</div>, </span><span class="valid" valid="valid" title="valid: True, node: 786, tag: span, level: 14" node_number="786"><div title="valid: False, node: 787, tag: div, level: 15" node_number="787">George Deraos</div>, </span><span class="valid" valid="valid" title="valid: True, node: 788, tag: span, level: 14" node_number="788"><div title="valid: False, node: 789, tag: div, level: 15" node_number="789">Kostas Kelaidonis</div>, </span><span class="valid" valid="valid" title="valid: True, node: 790, tag: span, level: 14" node_number="790"><div title="valid: False, node: 791, tag: div, level: 15" node_number="791">Md Kamal Hossain</div>, </span><span class="valid" valid="valid" title="valid: True, node: 792, tag: span, level: 14" node_number="792"><div title="valid: False, node: 793, tag: div, level: 15" node_number="793">Jack Feehan</div>, </span><span class="valid" valid="valid" title="valid: True, node: 794, tag: span, level: 14" node_number="794"><div title="valid: False, node: 795, tag: div, level: 15" node_number="795">Andreas G. Tzakos</div>, </span><span class="valid" valid="valid" title="valid: True, node: 796, tag: span, level: 14" node_number="796"><div title="valid: False, node: 797, tag: div, level: 15" node_number="797">Elizabeth Matsoukas</div>, </span><span class="valid" valid="valid" title="valid: True, node: 798, tag: span, level: 14" node_number="798"><div title="valid: False, node: 799, tag: div, level: 15" node_number="799">Emmanuel Topoglidis</div> and </span><span class="valid" valid="valid" title="valid: True, node: 800, tag: span, level: 14" node_number="800"><div title="valid: False, node: 801, tag: div, level: 15" node_number="801">Vasso Apostolopoulos</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 802, tag: div, level: 13" node_number="802"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 803, tag: b, level: 14" node_number="803">2021</b>, 9(12), 1456; https://doi.org/10.3390/vaccines9121456 - 08 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 804, tag: div, level: 13" node_number="804"> Abstract <div class="valid" valid="valid" title="valid: True, node: 805, tag: div, level: 14" node_number="805"> Myelin peptide&#8211;mannan conjugates have been shown to be potential vaccines in the immunotherapy of multiple sclerosis. The conjugates are comprised from the epitope peptide and the polysaccharide mannan which transfers as a carrier the antigenic peptide to dendritic cells that process and present [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 806, tag: div, level: 14" node_number="806"> Myelin peptide&#8211;mannan conjugates have been shown to be potential vaccines in the immunotherapy of multiple sclerosis. The conjugates are comprised from the epitope peptide and the polysaccharide mannan which transfers as a carrier the antigenic peptide to dendritic cells that process and present antigenic peptides at their surface in complex with MHC class I or class II resulting in T-cell stimulation. The conjugation of antigenic peptide with mannan occurs through the linker (Lys&#8211;Gly)5, which connects the peptide with the oxidized mannose units of mannan. This study describes novel methods for the quantification of the vaccine ingredient peptide within the conjugate, a prerequisite for approval of clinical trials in the pursuit of multiple sclerosis therapeutics. Myelin peptides, such as MOG<sub title="valid: False, node: 807, tag: sub, level: 15" node_number="807">35&#8211;55</sub>, MBP<sub title="valid: False, node: 808, tag: sub, level: 15" node_number="808">83&#8211;99</sub>, and PLP<sub title="valid: False, node: 809, tag: sub, level: 15" node_number="809">131&#8211;145</sub> in linear or cyclic form, as altered peptide ligands or conjugated to appropriate carriers, possess immunomodulatory properties in experimental models and are potential candidates for clinical trials. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 810, tag: div, level: 13" node_number="810"> (This article belongs to the Special Issue Multiple Sclerosis, Complications and Therapeutics 2.0) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 811, tag: div, level: 13" node_number="811"><div class="valid" valid="valid" title="valid: True, node: 812, tag: div, level: 14" node_number="812"><div title="valid: False, node: 813, tag: div, level: 15" node_number="813"><p title="valid: False, node: 814, tag: p, level: 16" node_number="814">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 815, tag: div, level: 10" node_number="815"> <div class="valid" valid="valid" title="valid: True, node: 816, tag: div, level: 11" node_number="816"> <div class="valid" valid="valid" title="valid: True, node: 817, tag: div, level: 12" node_number="817"> <div class="valid" valid="valid" title="valid: True, node: 818, tag: div, level: 13" node_number="818"> <a class="valid" valid="valid" title="valid: True, node: 819, tag: a, level: 14" node_number="819"> <i title="valid: False, node: 820, tag: i, level: 15" node_number="820">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 821, tag: div, level: 13" node_number="821"> <a class="valid" valid="valid" title="valid: True, node: 822, tag: a, level: 14" node_number="822"> <i title="valid: False, node: 823, tag: i, level: 15" node_number="823">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 824, tag: div, level: 14" node_number="824"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 825, tag: div, level: 13" node_number="825">Open AccessArticle</div> Educational Interventions on Pregnancy Vaccinations during Childbirth Classes Improves Vaccine Coverages among Pregnant Women in Palermo&#8217;s Province <div class="valid" valid="valid" title="valid: True, node: 826, tag: div, level: 13" node_number="826"> by <span class="valid" valid="valid" title="valid: True, node: 827, tag: span, level: 14" node_number="827"><div title="valid: False, node: 828, tag: div, level: 15" node_number="828">Claudio Costantino</div>, </span><span class="valid" valid="valid" title="valid: True, node: 829, tag: span, level: 14" node_number="829"><div title="valid: False, node: 830, tag: div, level: 15" node_number="830">Walter Mazzucco</div>, </span><span class="valid" valid="valid" title="valid: True, node: 831, tag: span, level: 14" node_number="831"><div title="valid: False, node: 832, tag: div, level: 15" node_number="832">Nicole Bonaccorso</div>, </span><span class="valid" valid="valid" title="valid: True, node: 833, tag: span, level: 14" node_number="833"><div title="valid: False, node: 834, tag: div, level: 15" node_number="834">Livia Cimino</div>, </span><span class="valid" valid="valid" title="valid: True, node: 835, tag: span, level: 14" node_number="835"><div title="valid: False, node: 836, tag: div, level: 15" node_number="836">Arianna Conforto</div>, </span><span class="valid" valid="valid" title="valid: True, node: 837, tag: span, level: 14" node_number="837"><div title="valid: False, node: 838, tag: div, level: 15" node_number="838">Martina Sciortino</div>, </span><span class="valid" valid="valid" title="valid: True, node: 839, tag: span, level: 14" node_number="839"><div title="valid: False, node: 840, tag: div, level: 15" node_number="840">Gabriele Catalano</div>, </span><span class="valid" valid="valid" title="valid: True, node: 841, tag: span, level: 14" node_number="841"><div title="valid: False, node: 842, tag: div, level: 15" node_number="842">Maria Rosa D&#8217;Anna</div>, </span><span class="valid" valid="valid" title="valid: True, node: 843, tag: span, level: 14" node_number="843"><div title="valid: False, node: 844, tag: div, level: 15" node_number="844">Antonio Maiorana</div>, </span><span class="valid" valid="valid" title="valid: True, node: 845, tag: span, level: 14" node_number="845"><div title="valid: False, node: 846, tag: div, level: 15" node_number="846">Renato Venezia</div>, </span><span class="valid" valid="valid" title="valid: True, node: 847, tag: span, level: 14" node_number="847"><div title="valid: False, node: 848, tag: div, level: 15" node_number="848">Giovanni Corsello</div> and </span><span class="valid" valid="valid" title="valid: True, node: 849, tag: span, level: 14" node_number="849"><div title="valid: False, node: 850, tag: div, level: 15" node_number="850">Francesco Vitale</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 851, tag: div, level: 13" node_number="851"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 852, tag: b, level: 14" node_number="852">2021</b>, 9(12), 1455; https://doi.org/10.3390/vaccines9121455 - 08 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 853, tag: div, level: 13" node_number="853"> Abstract <div class="valid" valid="valid" title="valid: True, node: 854, tag: div, level: 14" node_number="854"> Maternal immunization is considered the best intervention in order to prevent influenza infection of pregnant women and influenza and pertussis infection of newborns. Despite the existing recommendations, vaccination coverage rates in Italy remain very low. Starting from August 2018, maternal immunization against influenza [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 855, tag: div, level: 14" node_number="855"> Maternal immunization is considered the best intervention in order to prevent influenza infection of pregnant women and influenza and pertussis infection of newborns. Despite the existing recommendations, vaccination coverage rates in Italy remain very low. Starting from August 2018, maternal immunization against influenza and diphtheria-tetanus-pertussis were strongly recommended by the Italian Ministry of Health. We conducted a cross sectional study to estimate the effectiveness of an educational intervention, conducted during childbirth classes in three general hospitals in the Palermo metropolitan area, Italy, on vaccination adherence during pregnancy. To this end, a questionnaire on knowledge, attitudes, and immunization practices was structured and self-administered to a sample of pregnant women attending childbirth classes. Then, an educational intervention on maternal immunization, followed by a counseling, was conducted by a Public Health medical doctor. After 30 days following the interventions, the adherence to the recommended vaccinations (influenza and pertussis) was evaluated. At the end of the study 326 women were enrolled and 201 responded to the follow-up survey. After the intervention, among the responding pregnant women 47.8% received influenza vaccination (+44.8%), 57.7% diphtheria-tetanus-pertussis vaccination (+50.7%) and 64.2% both the recommended vaccinations (+54.8%). A significant association was found between pregnant women that received at least one vaccination during pregnancy and higher educational level (graduation degree/master&#8217;s degree), employment status (employed part/full-time) and influenza vaccination adherence during past seasons (at least one during last five years). The implementation of vaccination educational interventions, including counseling by healthcare professionals (HCPs), on maternal immunization during childbirth courses improved considerably the vaccination adherence during pregnancy. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 856, tag: div, level: 13" node_number="856"> (This article belongs to the Special Issue Measure to Improve Vaccination Coverage In at Risk Categories: Pregnant Women, Healthcare Workers and Patients with Chronic Diseases) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 857, tag: div, level: 13" node_number="857"><div class="valid" valid="valid" title="valid: True, node: 858, tag: div, level: 14" node_number="858"><div title="valid: False, node: 859, tag: div, level: 15" node_number="859"><p title="valid: False, node: 860, tag: p, level: 16" node_number="860">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 861, tag: div, level: 10" node_number="861"> <div class="valid" valid="valid" title="valid: True, node: 862, tag: div, level: 11" node_number="862"> <div class="valid" valid="valid" title="valid: True, node: 863, tag: div, level: 12" node_number="863"> <div class="valid" valid="valid" title="valid: True, node: 864, tag: div, level: 13" node_number="864"> <a class="valid" valid="valid" title="valid: True, node: 865, tag: a, level: 14" node_number="865"> <i title="valid: False, node: 866, tag: i, level: 15" node_number="866">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 867, tag: div, level: 13" node_number="867"> <a class="valid" valid="valid" title="valid: True, node: 868, tag: a, level: 14" node_number="868"> <i title="valid: False, node: 869, tag: i, level: 15" node_number="869">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 870, tag: div, level: 14" node_number="870"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 871, tag: div, level: 13" node_number="871">Open AccessArticle</div> Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Liver Transplant Recipients&#8212;Is It Related to Immunosuppression Only? <div class="valid" valid="valid" title="valid: True, node: 872, tag: div, level: 13" node_number="872"> by <span class="valid" valid="valid" title="valid: True, node: 873, tag: span, level: 14" node_number="873"><div title="valid: False, node: 874, tag: div, level: 15" node_number="874">Paulina Nazaruk</div>, </span><span class="valid" valid="valid" title="valid: True, node: 875, tag: span, level: 14" node_number="875"><div title="valid: False, node: 876, tag: div, level: 15" node_number="876">Marta Monticolo</div>, </span><span class="valid" valid="valid" title="valid: True, node: 877, tag: span, level: 14" node_number="877"><div title="valid: False, node: 878, tag: div, level: 15" node_number="878">Anna Maria J&#281;drzejczak</div>, </span><span class="valid" valid="valid" title="valid: True, node: 879, tag: span, level: 14" node_number="879"><div title="valid: False, node: 880, tag: div, level: 15" node_number="880">Natalia Krata</div>, </span><span class="valid" valid="valid" title="valid: True, node: 881, tag: span, level: 14" node_number="881"><div title="valid: False, node: 882, tag: div, level: 15" node_number="882">Barbara Moszczuk</div>, </span><span class="valid" valid="valid" title="valid: True, node: 883, tag: span, level: 14" node_number="883"><div title="valid: False, node: 884, tag: div, level: 15" node_number="884">Joanna Sa&#324;ko-Resmer</div>, </span><span class="valid" valid="valid" title="valid: True, node: 885, tag: span, level: 14" node_number="885"><div title="valid: False, node: 886, tag: div, level: 15" node_number="886">Tomasz Pilecki</div>, </span><span class="valid" valid="valid" title="valid: True, node: 887, tag: span, level: 14" node_number="887"><div title="valid: False, node: 888, tag: div, level: 15" node_number="888">Arkadiusz Urbanowicz</div>, </span><span class="valid" valid="valid" title="valid: True, node: 889, tag: span, level: 14" node_number="889"><div title="valid: False, node: 890, tag: div, level: 15" node_number="890">Micha&#322; Florczak</div>, </span><span class="valid" valid="valid" title="valid: True, node: 891, tag: span, level: 14" node_number="891"><div title="valid: False, node: 892, tag: div, level: 15" node_number="892">Leszek P&#261;czek</div>, </span><span class="valid" valid="valid" title="valid: True, node: 893, tag: span, level: 14" node_number="893"><div title="valid: False, node: 894, tag: div, level: 15" node_number="894">Bartosz Foroncewicz</div> and </span><span class="valid" valid="valid" title="valid: True, node: 895, tag: span, level: 14" node_number="895"><div title="valid: False, node: 896, tag: div, level: 15" node_number="896">Krzysztof Mucha</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 897, tag: div, level: 13" node_number="897"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 898, tag: b, level: 14" node_number="898">2021</b>, 9(12), 1454; https://doi.org/10.3390/vaccines9121454 - 08 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 899, tag: div, level: 13" node_number="899"> Abstract <div class="valid" valid="valid" title="valid: True, node: 900, tag: div, level: 14" node_number="900"> The BNT162b2 vaccine is reportedly effective in preventing severe disease in more than 90% of the general population, but its efficacy in transplant recipients remains controversial. We aimed to determine the immune response to the BNT162b2 vaccine in kidney (KTRs) and liver transplant [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 901, tag: div, level: 14" node_number="901"> The BNT162b2 vaccine is reportedly effective in preventing severe disease in more than 90% of the general population, but its efficacy in transplant recipients remains controversial. We aimed to determine the immune response to the BNT162b2 vaccine in kidney (KTRs) and liver transplant recipients (LTRs). In this retrospective cohort study, we included randomly 65 KTRs and 65 LTRs, who received two 30 &#956;g doses of BNT162b2 vaccine in 3-to6-week intervals. We analyzed the anti-SARS-CoV-2 spike protein IgG antibody (anti-S1 Ab) titer, biochemical liver and renal tests, immunosuppressive drug trough level, and clinical follow up 4&#8211;6 weeks after the first dose and 4&#8211;8 weeks after the second dose. The level of protective antibodies was 57.1% in KTRs and 88.9% in LTRs after the second dose. The anti-S1 Ab response was significantly associated with sex, age, and history of COVID-19. A tacrolimus dose at vaccination but not its trough level was significantly correlated with the increase in anti-S1 Ab titer after the second vaccine dose in LTRs. Rejection episodes did not occur after vaccination. Our results showed a higher than previously reported humoral response to the BNT162b2 vaccine in KTRs and LTRs, which was dependent upon age, type of transplanted organ, and immunosuppression. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 902, tag: div, level: 13" node_number="902"> (This article belongs to the Special Issue Assessment of Post-COVID-19 Complications and Vaccination Efficacy) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 903, tag: div, level: 13" node_number="903"><div class="valid" valid="valid" title="valid: True, node: 904, tag: div, level: 14" node_number="904"><div title="valid: False, node: 905, tag: div, level: 15" node_number="905"><p title="valid: False, node: 906, tag: p, level: 16" node_number="906">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 907, tag: div, level: 10" node_number="907"> <div class="valid" valid="valid" title="valid: True, node: 908, tag: div, level: 11" node_number="908"> <div class="valid" valid="valid" title="valid: True, node: 909, tag: div, level: 12" node_number="909"> <div class="valid" valid="valid" title="valid: True, node: 910, tag: div, level: 13" node_number="910"> <a class="valid" valid="valid" title="valid: True, node: 911, tag: a, level: 14" node_number="911"> <i title="valid: False, node: 912, tag: i, level: 15" node_number="912">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 913, tag: div, level: 13" node_number="913"> <a class="valid" valid="valid" title="valid: True, node: 914, tag: a, level: 14" node_number="914"> <i title="valid: False, node: 915, tag: i, level: 15" node_number="915">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 916, tag: div, level: 14" node_number="916"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 917, tag: div, level: 13" node_number="917">Open AccessFeature PaperArticle</div> <a class="valid" valid="valid" title="valid: True, node: 918, tag: a, level: 13" node_number="918">Mimicking Native Display of CD0873 on Liposomes Augments Its Potency as an Oral Vaccine against <i class="valid" valid="valid" title="valid: True, node: 919, tag: i, level: 14" node_number="919">Clostridioides difficile</i></a> <div class="valid" valid="valid" title="valid: True, node: 920, tag: div, level: 13" node_number="920"> by <span class="valid" valid="valid" title="valid: True, node: 921, tag: span, level: 14" node_number="921"><div title="valid: False, node: 922, tag: div, level: 15" node_number="922">Cansu Karyal</div>, </span><span class="valid" valid="valid" title="valid: True, node: 923, tag: span, level: 14" node_number="923"><div title="valid: False, node: 924, tag: div, level: 15" node_number="924">Panayiota Palazi</div>, </span><span class="valid" valid="valid" title="valid: True, node: 925, tag: span, level: 14" node_number="925"><div title="valid: False, node: 926, tag: div, level: 15" node_number="926">Jaime Hughes</div>, </span><span class="valid" valid="valid" title="valid: True, node: 927, tag: span, level: 14" node_number="927"><div title="valid: False, node: 928, tag: div, level: 15" node_number="928">Rhys C. Griffiths</div>, </span><span class="valid" valid="valid" title="valid: True, node: 929, tag: span, level: 14" node_number="929"><div title="valid: False, node: 930, tag: div, level: 15" node_number="930">Ruby R. Persaud</div>, </span><span class="valid" valid="valid" title="valid: True, node: 931, tag: span, level: 14" node_number="931"><div title="valid: False, node: 932, tag: div, level: 15" node_number="932">Patrick J. Tighe</div>, </span><span class="valid" valid="valid" title="valid: True, node: 933, tag: span, level: 14" node_number="933"><div title="valid: False, node: 934, tag: div, level: 15" node_number="934">Nicholas J. Mitchell</div> and </span><span class="valid" valid="valid" title="valid: True, node: 935, tag: span, level: 14" node_number="935"><div title="valid: False, node: 936, tag: div, level: 15" node_number="936">Ruth Griffin</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 937, tag: div, level: 13" node_number="937"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 938, tag: b, level: 14" node_number="938">2021</b>, 9(12), 1453; https://doi.org/10.3390/vaccines9121453 - 08 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 939, tag: div, level: 13" node_number="939"> Abstract <div class="valid" valid="valid" title="valid: True, node: 940, tag: div, level: 14" node_number="940"> Mucosal vaccination aims to prevent infection mainly by inducing secretory IgA (sIgA) antibody, which neutralises pathogens and enterotoxins by blocking their attachment to epithelial cells. We previously demonstrated that encapsulated protein antigen CD0873 given orally to hamsters induces neutralising antibodies locally as well [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 941, tag: div, level: 14" node_number="941"> Mucosal vaccination aims to prevent infection mainly by inducing secretory IgA (sIgA) antibody, which neutralises pathogens and enterotoxins by blocking their attachment to epithelial cells. We previously demonstrated that encapsulated protein antigen CD0873 given orally to hamsters induces neutralising antibodies locally as well as systemically, affording partial protection against <i title="valid: False, node: 942, tag: i, level: 15" node_number="942">Clostridioides difficile</i> infection. The aim of this study was to determine whether displaying CD0873 on liposomes, mimicking native presentation, would drive a stronger antibody response. The recombinant form we previously tested resembles the naturally cleaved lipoprotein commencing with a cysteine but lacking lipid modification. A synthetic lipid (DHPPA-Mal) was designed for conjugation of this protein via its N-terminal cysteine to the maleimide headgroup. DHPPA-Mal was first formulated with liposomes to produce MalLipo; then, CD0873 was conjugated to headgroups protruding from the outer envelope to generate CD0873-MalLipo. The immunogenicity of CD0873-MalLipo was compared to CD0873 in hamsters. Intestinal sIgA and CD0873-specific serum IgG were induced in all vaccinated animals; however, neutralising activity was greatest for the CD0873-MalLipo group. Our data hold great promise for development of a novel oral vaccine platform driving intestinal and systemic immune responses. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 943, tag: div, level: 13" node_number="943"> (This article belongs to the Special Issue Decoding Host and Microbial Communications in Infection and Vaccination) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 944, tag: div, level: 13" node_number="944"><div class="valid" valid="valid" title="valid: True, node: 945, tag: div, level: 14" node_number="945"><div title="valid: False, node: 946, tag: div, level: 15" node_number="946"><p title="valid: False, node: 947, tag: p, level: 16" node_number="947">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 948, tag: div, level: 10" node_number="948"> <div class="valid" valid="valid" title="valid: True, node: 949, tag: div, level: 11" node_number="949"> <div class="valid" valid="valid" title="valid: True, node: 950, tag: div, level: 12" node_number="950"> <div class="valid" valid="valid" title="valid: True, node: 951, tag: div, level: 13" node_number="951"> <a class="valid" valid="valid" title="valid: True, node: 952, tag: a, level: 14" node_number="952"> <i title="valid: False, node: 953, tag: i, level: 15" node_number="953">attachment</i> </a> <div class="valid" valid="valid" title="valid: True, node: 954, tag: div, level: 14" node_number="954"> Supplementary material: Supplementary File 1 (ZIP, 250 KiB) </div> </div> <div class="valid" valid="valid" title="valid: True, node: 955, tag: div, level: 13" node_number="955"> <a class="valid" valid="valid" title="valid: True, node: 956, tag: a, level: 14" node_number="956"> <i title="valid: False, node: 957, tag: i, level: 15" node_number="957">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 958, tag: div, level: 13" node_number="958"> <a class="valid" valid="valid" title="valid: True, node: 959, tag: a, level: 14" node_number="959"> <i title="valid: False, node: 960, tag: i, level: 15" node_number="960">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 961, tag: div, level: 14" node_number="961"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 962, tag: div, level: 13" node_number="962">Open AccessReview</div> Does Influenza Vaccination during Pregnancy Have Effects on Non-Influenza Infectious Morbidity? A Systematic Review and Meta-Analysis of Randomised Controlled Trials <div class="valid" valid="valid" title="valid: True, node: 963, tag: div, level: 13" node_number="963"> by <span class="valid" valid="valid" title="valid: True, node: 964, tag: span, level: 14" node_number="964"><div title="valid: False, node: 965, tag: div, level: 15" node_number="965">Katrine Pedersb&#230;k Hansen</div>, </span><span class="valid" valid="valid" title="valid: True, node: 966, tag: span, level: 14" node_number="966"><div title="valid: False, node: 967, tag: div, level: 15" node_number="967">Christine Stabell Benn</div>, </span><span class="valid" valid="valid" title="valid: True, node: 968, tag: span, level: 14" node_number="968"><div title="valid: False, node: 969, tag: div, level: 15" node_number="969">Thomas Aamand</div>, </span><span class="valid" valid="valid" title="valid: True, node: 970, tag: span, level: 14" node_number="970"><div title="valid: False, node: 971, tag: div, level: 15" node_number="971">Martin Buus</div>, </span><span class="valid" valid="valid" title="valid: True, node: 972, tag: span, level: 14" node_number="972"><div title="valid: False, node: 973, tag: div, level: 15" node_number="973">Isaquel da Silva</div>, </span><span class="valid" valid="valid" title="valid: True, node: 974, tag: span, level: 14" node_number="974"><div title="valid: False, node: 975, tag: div, level: 15" node_number="975">Peter Aaby</div>, </span><span class="valid" valid="valid" title="valid: True, node: 976, tag: span, level: 14" node_number="976"><div title="valid: False, node: 977, tag: div, level: 15" node_number="977">Ane B&#230;rent Fisker</div> and </span><span class="valid" valid="valid" title="valid: True, node: 978, tag: span, level: 14" node_number="978"><div title="valid: False, node: 979, tag: div, level: 15" node_number="979">Sanne Marie Thysen</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 980, tag: div, level: 13" node_number="980"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 981, tag: b, level: 14" node_number="981">2021</b>, 9(12), 1452; https://doi.org/10.3390/vaccines9121452 - 08 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 982, tag: div, level: 13" node_number="982"> Abstract <div class="valid" valid="valid" title="valid: True, node: 983, tag: div, level: 14" node_number="983"> The recommendation to provide inactivated influenza vaccine (IIV) to pregnant women is based on observed protection against influenza-related morbidity in mother and infant. Non-live vaccines may have non-specific effects (NSEs), increasing the risk of non-targeted infections in females. We reviewed the evidence from [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 984, tag: div, level: 14" node_number="984"> The recommendation to provide inactivated influenza vaccine (IIV) to pregnant women is based on observed protection against influenza-related morbidity in mother and infant. Non-live vaccines may have non-specific effects (NSEs), increasing the risk of non-targeted infections in females. We reviewed the evidence from available randomised controlled trials (RCTs) of IIV to pregnant women, to assess whether IIV may have NSEs. Four RCTs, all conducted in low- and middle-income settings, were identified. We extracted information on all-cause and infectious mortality and adverse events in women and their infants. We conducted meta-analyses providing risk ratios (RR). The meta-analysis for maternal all-cause mortality provided a RR of 1.48 (95% CI = 0.52&#8211;4.16). The estimates for miscarriage/stillbirth and infant all-cause mortality up to 6 months of age were 1.06 (0.78&#8211;1.44) and 1.11 (0.87&#8211;1.41), respectively. IIV was associated with a higher risk of non-influenza infectious adverse events, with meta-estimates of 2.01 (1.15&#8211;3.50) in women and 1.36 (1.12&#8211;1.67) in infants up to 6 months of age. Thus, following a pattern seen for other non-live vaccines, IIV was associated with a higher risk of non-influenza infectious adverse events. To ensure that scarce resources are used well, and no harm is inflicted, further RCTs are warranted. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 985, tag: div, level: 13" node_number="985"> (This article belongs to the Special Issue Non-specific Protections in Response to Vaccination and Other Stimulations of the Immune System) </div> &#9658;&#9660; Show Figures <div class="valid" valid="valid" title="valid: True, node: 986, tag: div, level: 13" node_number="986"><div class="valid" valid="valid" title="valid: True, node: 987, tag: div, level: 14" node_number="987"><div title="valid: False, node: 988, tag: div, level: 15" node_number="988"><p title="valid: False, node: 989, tag: p, level: 16" node_number="989">Figure 1</p></div></div></div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 990, tag: div, level: 10" node_number="990"> <div class="valid" valid="valid" title="valid: True, node: 991, tag: div, level: 11" node_number="991"> <div class="valid" valid="valid" title="valid: True, node: 992, tag: div, level: 12" node_number="992"> <div class="valid" valid="valid" title="valid: True, node: 993, tag: div, level: 13" node_number="993"> <a class="valid" valid="valid" title="valid: True, node: 994, tag: a, level: 14" node_number="994"> <i title="valid: False, node: 995, tag: i, level: 15" node_number="995">get_app</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 996, tag: div, level: 13" node_number="996"> <a class="valid" valid="valid" title="valid: True, node: 997, tag: a, level: 14" node_number="997"> <i title="valid: False, node: 998, tag: i, level: 15" node_number="998">subject</i> </a> <div class="valid" valid="valid" title="valid: True, node: 999, tag: div, level: 14" node_number="999"> View online as: Abstract Page Full-Text HTML </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1000, tag: div, level: 13" node_number="1000">Open AccessArticle</div> COVID-19 Vaccination Acceptance among Health Science Students in Morocco: A Cross-Sectional Study <div class="valid" valid="valid" title="valid: True, node: 1001, tag: div, level: 13" node_number="1001"> by <span class="valid" valid="valid" title="valid: True, node: 1002, tag: span, level: 14" node_number="1002"><div title="valid: False, node: 1003, tag: div, level: 15" node_number="1003">Mohamed Khalis</div>, </span><span class="valid" valid="valid" title="valid: True, node: 1004, tag: span, level: 14" node_number="1004"><div title="valid: False, node: 1005, tag: div, level: 15" node_number="1005">Mouna Boucham</div>, </span><span class="valid" valid="valid" title="valid: True, node: 1006, tag: span, level: 14" node_number="1006"><div title="valid: False, node: 1007, tag: div, level: 15" node_number="1007">Amy Luo</div>, </span><span class="valid" valid="valid" title="valid: True, node: 1008, tag: span, level: 14" node_number="1008"><div title="valid: False, node: 1009, tag: div, level: 15" node_number="1009">Abdelghafour Marfak</div>, </span><span class="valid" valid="valid" title="valid: True, node: 1010, tag: span, level: 14" node_number="1010"><div title="valid: False, node: 1011, tag: div, level: 15" node_number="1011">Soukaina Saad</div>, </span><span class="valid" valid="valid" title="valid: True, node: 1012, tag: span, level: 14" node_number="1012"><div title="valid: False, node: 1013, tag: div, level: 15" node_number="1013">Camara Mariama Aboubacar</div>, </span><span class="valid" valid="valid" title="valid: True, node: 1014, tag: span, level: 14" node_number="1014"><div title="valid: False, node: 1015, tag: div, level: 15" node_number="1015">Soukaina Ait El Haj</div>, </span><span class="valid" valid="valid" title="valid: True, node: 1016, tag: span, level: 14" node_number="1016"><div title="valid: False, node: 1017, tag: div, level: 15" node_number="1017">Manar Jallal</div>, </span><span class="valid" valid="valid" title="valid: True, node: 1018, tag: span, level: 14" node_number="1018"><div title="valid: False, node: 1019, tag: div, level: 15" node_number="1019">Fatima-Zahra Aazi</div>, </span><span class="valid" valid="valid" title="valid: True, node: 1020, tag: span, level: 14" node_number="1020"><div title="valid: False, node: 1021, tag: div, level: 15" node_number="1021">Hafida Charaka</div> and </span><span class="valid" valid="valid" title="valid: True, node: 1022, tag: span, level: 14" node_number="1022"><div title="valid: False, node: 1023, tag: div, level: 15" node_number="1023">Chakib Nejjari</div></span> </div> <div class="valid" valid="valid" title="valid: True, node: 1024, tag: div, level: 13" node_number="1024"> Vaccines <b class="valid" valid="valid" title="valid: True, node: 1025, tag: b, level: 14" node_number="1025">2021</b>, 9(12), 1451; https://doi.org/10.3390/vaccines9121451 - 08 Dec 2021 </div> <div class="valid" valid="valid" title="valid: True, node: 1026, tag: div, level: 13" node_number="1026"> Abstract <div class="valid" valid="valid" title="valid: True, node: 1027, tag: div, level: 14" node_number="1027"> While students in the health sciences occupy pivotal roles in the Moroccan COVID-19 response and vaccination campaigns, factors associated with COVID-19 vaccine acceptability among students have not been reported. This study aimed to determine the willingness and identify predictive attitudes and beliefs of [...] Read more. </div> <div class="valid" valid="valid" title="valid: True, node: 1028, tag: div, level: 14" node_number="1028"> While students in the health sciences occupy pivotal roles in the Moroccan COVID-19 response and vaccination campaigns, factors associated with COVID-19 vaccine acceptability among students have not been reported. This study aimed to determine the willingness and identify predictive attitudes and beliefs of COVID-19 vaccine acceptance among health science students in Morocco. A cross-sectional, self-administered online questionnaire was conducted among students of the Mohammed VI University of Health Sciences in Casablanca, Morocco in January 2021. In total, 1272 students participated. Univariate and multivariate logistic regression models were used to calculate odds ratios and 95% confidence intervals. Overall, 26.9% of participants reported being willing to receive the COVID-19 vaccine. Between genders, male students were more likely to accept the vaccine. Regarding individual attitudes and beliefs about COVID-19 infection, students with greater confidence in COVID-19 information, and higher perceived likelihood and perceived severity of infection were more likely to be willing to get the vaccine. Concerning a COVID-19 vaccine, students who reported lower levels of perceived harm and higher levels of perceived vaccine effectiveness were more willing to get vaccinated. Our findings help guide future efforts to tailor communication and identify strategies to increase COVID-19 vaccine uptake among students. Full article </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1029, tag: div, level: 13" node_number="1029"> (This article belongs to the Special Issue COVID-19 Vaccine Acceptance and Uptake: Insights from Behavioural and Social Sciences) </div> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1030, tag: div, level: 9" node_number="1030"> More Articles... </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1031, tag: div, level: 6" node_number="1031"> <div class="valid" valid="valid" title="valid: True, node: 1032, tag: div, level: 7" node_number="1032"> <div class="valid" valid="valid" title="valid: True, node: 1033, tag: div, level: 8" node_number="1033"> <div class="valid" valid="valid" title="valid: True, node: 1034, tag: div, level: 9" node_number="1034"> <a class="valid" valid="valid" title="valid: True, node: 1035, tag: a, level: 10" node_number="1035"> Submit to <i class="valid" valid="valid" title="valid: True, node: 1036, tag: i, level: 11" node_number="1036">Vaccines</i> </a> Review for Vaccines <div class="valid" valid="valid" title="valid: True, node: 1037, tag: div, level: 10" node_number="1037"> Share </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1038, tag: div, level: 9" node_number="1038"> <h2 class="valid" valid="valid" title="valid: True, node: 1039, tag: h2, level: 10" node_number="1039">Journal Menu</h2> &#9658; &#9660; Journal Menu <ul class="valid" valid="valid" title="valid: True, node: 1040, tag: ul, level: 10" node_number="1040"> <li class="valid" valid="valid" title="valid: True, node: 1041, tag: li, level: 11" node_number="1041"> <ul class="valid" valid="valid" title="valid: True, node: 1042, tag: ul, level: 12" node_number="1042"> <li class="valid" valid="valid" title="valid: True, node: 1043, tag: li, level: 13" node_number="1043"> Vaccines Home </li> <li class="valid" valid="valid" title="valid: True, node: 1044, tag: li, level: 13" node_number="1044"> Aims Scope </li> <li class="valid" valid="valid" title="valid: True, node: 1045, tag: li, level: 13" node_number="1045"> Editorial Board </li> <li class="valid" valid="valid" title="valid: True, node: 1046, tag: li, level: 13" node_number="1046"> Reviewer Board </li> <li class="valid" valid="valid" title="valid: True, node: 1047, tag: li, level: 13" node_number="1047"> Topical Advisory Panel </li> <li class="valid" valid="valid" title="valid: True, node: 1048, tag: li, level: 13" node_number="1048"> Instructions for Authors </li> <li class="valid" valid="valid" title="valid: True, node: 1049, tag: li, level: 13" node_number="1049"> Special Issues </li> <li class="valid" valid="valid" title="valid: True, node: 1050, tag: li, level: 13" node_number="1050"> Sections Collections </li> <li class="valid" valid="valid" title="valid: True, node: 1051, tag: li, level: 13" node_number="1051"> Article Processing Charge </li> <li class="valid" valid="valid" title="valid: True, node: 1052, tag: li, level: 13" node_number="1052"> Indexing Archiving </li> <li class="valid" valid="valid" title="valid: True, node: 1053, tag: li, level: 13" node_number="1053"> Editor's Choice Articles </li> <li class="valid" valid="valid" title="valid: True, node: 1054, tag: li, level: 13" node_number="1054"> Most Cited Viewed </li> <li class="valid" valid="valid" title="valid: True, node: 1055, tag: li, level: 13" node_number="1055"> Journal Statistics </li> <li class="valid" valid="valid" title="valid: True, node: 1056, tag: li, level: 13" node_number="1056"> Journal History </li> <li class="valid" valid="valid" title="valid: True, node: 1057, tag: li, level: 13" node_number="1057"> Journal Awards </li> <li class="valid" valid="valid" title="valid: True, node: 1058, tag: li, level: 13" node_number="1058"> Society Collaborations </li> <li class="valid" valid="valid" title="valid: True, node: 1059, tag: li, level: 13" node_number="1059"> Conferences </li> <li class="valid" valid="valid" title="valid: True, node: 1060, tag: li, level: 13" node_number="1060"> Editorial Office </li> </ul> </li> </ul> </div> <h2 class="valid" valid="valid" title="valid: True, node: 1061, tag: h2, level: 9" node_number="1061">Journal Browser</h2> &#9658; &#9660; Journal Browser <div class="valid" valid="valid" title="valid: True, node: 1062, tag: div, level: 9" node_number="1062"> <div class="valid" valid="valid" title="valid: True, node: 1063, tag: div, level: 10" node_number="1063"> <ul class="valid" valid="valid" title="valid: True, node: 1064, tag: ul, level: 11" node_number="1064"> <li class="valid" valid="valid" title="valid: True, node: 1065, tag: li, level: 12" node_number="1065"> <a class="valid" valid="valid" title="valid: True, node: 1066, tag: a, level: 13" node_number="1066"> <i class="valid" valid="valid" title="valid: True, node: 1067, tag: i, level: 14" node_number="1067"> arrow_forward_ios </i> Forthcoming issue </a> <a class="valid" valid="valid" title="valid: True, node: 1068, tag: a, level: 13" node_number="1068"> <i class="valid" valid="valid" title="valid: True, node: 1069, tag: i, level: 14" node_number="1069"> arrow_forward_ios </i> Current issue </a> </li> <div class="valid" valid="valid" title="valid: True, node: 1070, tag: div, level: 12" node_number="1070"> <div class="valid" valid="valid" title="valid: True, node: 1071, tag: div, level: 13" node_number="1071"> <div class="valid" valid="valid" title="valid: True, node: 1072, tag: div, level: 14" node_number="1072"> <li title="valid: False, node: 1073, tag: li, level: 15" node_number="1073"> Vol.&#160;9&#160;(2021) </li> <li title="valid: False, node: 1074, tag: li, level: 15" node_number="1074"> Vol.&#160;8&#160;(2020) </li> <li title="valid: False, node: 1075, tag: li, level: 15" node_number="1075"> Vol.&#160;7&#160;(2019) </li> <li title="valid: False, node: 1076, tag: li, level: 15" node_number="1076"> Vol.&#160;6&#160;(2018) </li> <li title="valid: False, node: 1077, tag: li, level: 15" node_number="1077"> Vol.&#160;5&#160;(2017) </li> <li title="valid: False, node: 1078, tag: li, level: 15" node_number="1078"> Vol.&#160;4&#160;(2016) </li> <li title="valid: False, node: 1079, tag: li, level: 15" node_number="1079"> Vol.&#160;3&#160;(2015) </li> <li title="valid: False, node: 1080, tag: li, level: 15" node_number="1080"> Vol.&#160;2&#160;(2014) </li> <li title="valid: False, node: 1081, tag: li, level: 15" node_number="1081"> Vol.&#160;1&#160;(2013) </li> </div> </div> </div> </ul> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1082, tag: div, level: 7" node_number="1082"> <div class="valid" valid="valid" title="valid: True, node: 1083, tag: div, level: 8" node_number="1083"> <h2 class="valid" valid="valid" title="valid: True, node: 1084, tag: h2, level: 9" node_number="1084">Highly Accessed Articles</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1085, tag: div, level: 8" node_number="1085"> <div class="valid" valid="valid" title="valid: True, node: 1086, tag: div, level: 9" node_number="1086"> View More... </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1087, tag: div, level: 7" node_number="1087"> <div class="valid" valid="valid" title="valid: True, node: 1088, tag: div, level: 8" node_number="1088"> <h2 class="valid" valid="valid" title="valid: True, node: 1089, tag: h2, level: 9" node_number="1089">Latest Books</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1090, tag: div, level: 8" node_number="1090"> <div class="valid" valid="valid" title="valid: True, node: 1091, tag: div, level: 9" node_number="1091"> More Open Access Books... </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1092, tag: div, level: 6" node_number="1092"> <div class="valid" valid="valid" title="valid: True, node: 1093, tag: div, level: 7" node_number="1093"> <div class="valid" valid="valid" title="valid: True, node: 1094, tag: div, level: 8" node_number="1094"> <h2 class="valid" valid="valid" title="valid: True, node: 1095, tag: h2, level: 9" node_number="1095">E-Mail Alert</h2> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1096, tag: div, level: 7" node_number="1096"> <div class="valid" valid="valid" title="valid: True, node: 1097, tag: div, level: 8" node_number="1097"> <h2 class="valid" valid="valid" title="valid: True, node: 1098, tag: h2, level: 9" node_number="1098">News</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1099, tag: div, level: 8" node_number="1099"> <div class="valid" valid="valid" title="valid: True, node: 1100, tag: div, level: 9" node_number="1100"> 3 December 2021 The 2nd International Electronic Conference on Healthcare (IECH2022)&#8212;Submissions Deadline Extension </div> <div class="valid" valid="valid" title="valid: True, node: 1101, tag: div, level: 9" node_number="1101"> 22 November 2021 720 MDPI Editorial Board Members Receiving "2021 Highly Cited Researchers" Distinction </div> <div class="valid" valid="valid" title="valid: True, node: 1102, tag: div, level: 9" node_number="1102"> 16 November 2021 Topical Advisory Panel Established to Support Editorial Board </div> <div class="valid" valid="valid" title="valid: True, node: 1103, tag: div, level: 9" node_number="1103"> More News Announcements... </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1104, tag: div, level: 7" node_number="1104"> <div class="valid" valid="valid" title="valid: True, node: 1105, tag: div, level: 8" node_number="1105"> <h2 class="valid" valid="valid" title="valid: True, node: 1106, tag: h2, level: 9" node_number="1106">Topics</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1107, tag: div, level: 8" node_number="1107"> <div class="valid" valid="valid" title="valid: True, node: 1108, tag: div, level: 9" node_number="1108"><div class="valid" valid="valid" title="valid: True, node: 1109, tag: div, level: 10" node_number="1109"> Topic in Biomedicines, Pharmaceutics, Pharmaceuticals, Cancers, Vaccines</div> Animal Model in Biomedical Research Editor-in-Chief: Marc EkkerDeadline: 31 December 2021</div> <div class="valid" valid="valid" title="valid: True, node: 1110, tag: div, level: 9" node_number="1110"><div class="valid" valid="valid" title="valid: True, node: 1111, tag: div, level: 10" node_number="1111"> Topic in Vaccines, Biology, Pathogens, Biologics, MPs</div> Global Analysis of SARS-CoV-2 Serology Editors-in-Chief: Ger Rijkers, Jean-Luc MurkDeadline: 20 April 2022</div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1112, tag: div, level: 7" node_number="1112"> <div class="valid" valid="valid" title="valid: True, node: 1113, tag: div, level: 8" node_number="1113"> <h2 class="valid" valid="valid" title="valid: True, node: 1114, tag: h2, level: 9" node_number="1114">Conferences</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1115, tag: div, level: 8" node_number="1115"> <div class="valid" valid="valid" title="valid: True, node: 1116, tag: div, level: 9" node_number="1116"> Announce Your Conference </div> <div class="valid" valid="valid" title="valid: True, node: 1117, tag: div, level: 9" node_number="1117"> 17 February&#8211;3 March 2022 2nd International Electronic Conference on Healthcare (IECH2022)</div> <div class="valid" valid="valid" title="valid: True, node: 1118, tag: div, level: 9" node_number="1118"> More Conferences... </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1119, tag: div, level: 7" node_number="1119"> <div class="valid" valid="valid" title="valid: True, node: 1120, tag: div, level: 8" node_number="1120"> <h2 class="valid" valid="valid" title="valid: True, node: 1121, tag: h2, level: 9" node_number="1121">Special Issues</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1122, tag: div, level: 8" node_number="1122"> <div class="valid" valid="valid" title="valid: True, node: 1123, tag: div, level: 9" node_number="1123"> Edit a Special Issue </div> <div class="valid" valid="valid" title="valid: True, node: 1124, tag: div, level: 9" node_number="1124"><div class="valid" valid="valid" title="valid: True, node: 1125, tag: div, level: 10" node_number="1125"> Special Issue in Vaccines</div> New Vaccine Technologies and Approaches 2.0 Guest Editors: Stephen A. Morris, Camila CoelhoDeadline: 15 December 2021</div> <div class="valid" valid="valid" title="valid: True, node: 1126, tag: div, level: 9" node_number="1126"><div class="valid" valid="valid" title="valid: True, node: 1127, tag: div, level: 10" node_number="1127"> Special Issue in Vaccines</div> Feature Papers Collection on Influenza Vaccines Guest Editors: Luis Martinez-Sobrido, Ralph A. Tripp, Aitor NogalesDeadline: 30 December 2021</div> <div class="valid" valid="valid" title="valid: True, node: 1128, tag: div, level: 9" node_number="1128"><div class="valid" valid="valid" title="valid: True, node: 1129, tag: div, level: 10" node_number="1129"> Special Issue in Vaccines</div> Frontiers in Shigella Vaccine Development Guest Editors: Duncan Steele, Calman A. MacLennanDeadline: 1 January 2022</div> <div class="valid" valid="valid" title="valid: True, node: 1130, tag: div, level: 9" node_number="1130"><div class="valid" valid="valid" title="valid: True, node: 1131, tag: div, level: 10" node_number="1131"> Special Issue in Vaccines</div> Microbial Antigen Identification and Vaccine Delivery Systems Guest Editors: Jorge H. Leit&#227;o, Paulo BettencourtDeadline: 10 January 2022</div> <div class="valid" valid="valid" title="valid: True, node: 1132, tag: div, level: 9" node_number="1132"> More Special Issues </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1133, tag: div, level: 7" node_number="1133"> <div class="valid" valid="valid" title="valid: True, node: 1134, tag: div, level: 8" node_number="1134"> <h2 class="valid" valid="valid" title="valid: True, node: 1135, tag: h2, level: 9" node_number="1135">Topical Collections</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1136, tag: div, level: 8" node_number="1136"> <div class="valid" valid="valid" title="valid: True, node: 1137, tag: div, level: 9" node_number="1137"><div class="valid" valid="valid" title="valid: True, node: 1138, tag: div, level: 10" node_number="1138"> Topical Collection in Vaccines</div> Research on Monoclonal Antibodies and Antibody Engineering Collection Editor: Tatsuya Yamazaki</div> <div class="valid" valid="valid" title="valid: True, node: 1139, tag: div, level: 9" node_number="1139"><div class="valid" valid="valid" title="valid: True, node: 1140, tag: div, level: 10" node_number="1140"> Topical Collection in Vaccines</div> COVID-19 Vaccines and Vaccination Collection Editors: Ralph Tripp, Steven B. Bradfute, Scott Anthony</div> <div class="valid" valid="valid" title="valid: True, node: 1141, tag: div, level: 9" node_number="1141"><div class="valid" valid="valid" title="valid: True, node: 1142, tag: div, level: 10" node_number="1142"> Topical Collection in Vaccines</div> Vaccines against Infectious Diseases Collection Editor: E.Diane Williamson</div> <div class="valid" valid="valid" title="valid: True, node: 1143, tag: div, level: 9" node_number="1143"><div class="valid" valid="valid" title="valid: True, node: 1144, tag: div, level: 10" node_number="1144"> Topical Collection in Vaccines</div> Vaccines against Chronic and Persistent Bacterial Infections </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1145, tag: div, level: 7" node_number="1145"> <div class="valid" valid="valid" title="valid: True, node: 1146, tag: div, level: 8" node_number="1146"> <h2 class="valid" valid="valid" title="valid: True, node: 1147, tag: h2, level: 9" node_number="1147">Jobs in Research</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1148, tag: div, level: 8" node_number="1148"> <div class="valid" valid="valid" title="valid: True, node: 1149, tag: div, level: 9" node_number="1149"> Post New Job Opening </div> </div> </div> </div> </div> </div> </section> <div class="valid" valid="valid" title="valid: True, node: 1150, tag: div, level: 3" node_number="1150"> <div class="valid" valid="valid" title="valid: True, node: 1151, tag: div, level: 4" node_number="1151"> Vaccines, EISSN 2076-393X, Published by MDPI <span class="valid" valid="valid" title="valid: True, node: 1152, tag: span, level: 5" node_number="1152"> Disclaimer <div class="valid" valid="valid" title="valid: True, node: 1153, tag: div, level: 6" node_number="1153"> The statements, opinions and data contained in the journal Vaccines are solely those of the individual authors and contributors and not of the publisher and the editor(s). MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. </div> </span> <div class="valid" valid="valid" title="valid: True, node: 1154, tag: div, level: 5" node_number="1154"> RSS Content Alert </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1155, tag: div, level: 4" node_number="1155"> <div class="valid" valid="valid" title="valid: True, node: 1156, tag: div, level: 5" node_number="1156"> <h3 class="valid" valid="valid" title="valid: True, node: 1157, tag: h3, level: 6" node_number="1157"> Further Information </h3> Article Processing Charges Pay an Invoice <a class="valid" valid="valid" title="valid: True, node: 1158, tag: a, level: 6" node_number="1158"> Open Access Policy </a> <a class="valid" valid="valid" title="valid: True, node: 1159, tag: a, level: 6" node_number="1159"> Contact MDPI </a> <a class="valid" valid="valid" title="valid: True, node: 1160, tag: a, level: 6" node_number="1160"> Jobs at MDPI </a> </div> <div class="valid" valid="valid" title="valid: True, node: 1161, tag: div, level: 5" node_number="1161"> <h3 class="valid" valid="valid" title="valid: True, node: 1162, tag: h3, level: 6" node_number="1162"> Guidelines </h3> <a class="valid" valid="valid" title="valid: True, node: 1163, tag: a, level: 6" node_number="1163"> For Authors </a> <a class="valid" valid="valid" title="valid: True, node: 1164, tag: a, level: 6" node_number="1164"> For Reviewers </a> <a class="valid" valid="valid" title="valid: True, node: 1165, tag: a, level: 6" node_number="1165"> For Editors </a> <a class="valid" valid="valid" title="valid: True, node: 1166, tag: a, level: 6" node_number="1166"> For Librarians </a> <a class="valid" valid="valid" title="valid: True, node: 1167, tag: a, level: 6" node_number="1167"> For Publishers </a> <a class="valid" valid="valid" title="valid: True, node: 1168, tag: a, level: 6" node_number="1168"> For Societies </a> </div> <div class="valid" valid="valid" title="valid: True, node: 1169, tag: div, level: 5" node_number="1169"> <h3 class="valid" valid="valid" title="valid: True, node: 1170, tag: h3, level: 6" node_number="1170"> MDPI Initiatives </h3> <a class="valid" valid="valid" title="valid: True, node: 1171, tag: a, level: 6" node_number="1171"> Sciforum </a> <a class="valid" valid="valid" title="valid: True, node: 1172, tag: a, level: 6" node_number="1172"> MDPI Books </a> <a class="valid" valid="valid" title="valid: True, node: 1173, tag: a, level: 6" node_number="1173"> Preprints </a> <a class="valid" valid="valid" title="valid: True, node: 1174, tag: a, level: 6" node_number="1174"> Scilit </a> <a class="valid" valid="valid" title="valid: True, node: 1175, tag: a, level: 6" node_number="1175"> SciProfiles </a> <a class="valid" valid="valid" title="valid: True, node: 1176, tag: a, level: 6" node_number="1176"> Encyclopedia </a> <a class="valid" valid="valid" title="valid: True, node: 1177, tag: a, level: 6" node_number="1177"> JAMS </a> <a class="valid" valid="valid" title="valid: True, node: 1178, tag: a, level: 6" node_number="1178"> Proceedings Series </a> </div> <div class="valid" valid="valid" title="valid: True, node: 1179, tag: div, level: 5" node_number="1179"> <h3 class="valid" valid="valid" title="valid: True, node: 1180, tag: h3, level: 6" node_number="1180"> Follow MDPI </h3> <a class="valid" valid="valid" title="valid: True, node: 1181, tag: a, level: 6" node_number="1181"> LinkedIn </a> <a class="valid" valid="valid" title="valid: True, node: 1182, tag: a, level: 6" node_number="1182"> Facebook </a> <a class="valid" valid="valid" title="valid: True, node: 1183, tag: a, level: 6" node_number="1183"> Twitter </a> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1184, tag: div, level: 4" node_number="1184"> <div class="valid" valid="valid" title="valid: True, node: 1185, tag: div, level: 5" node_number="1185"> <div class="valid" valid="valid" title="valid: True, node: 1186, tag: div, level: 6" node_number="1186"> &#169; 1996-2021 MDPI (Basel, Switzerland) unless otherwise stated </div> <div class="valid" valid="valid" title="valid: True, node: 1187, tag: div, level: 6" node_number="1187"> <a class="valid" valid="valid" title="valid: True, node: 1188, tag: a, level: 7" node_number="1188"> Disclaimer </a> <div class="valid" valid="valid" title="valid: True, node: 1189, tag: div, level: 7" node_number="1189"> The statements, opinions and data contained in the journals are solely those of the individual authors and contributors and not of the publisher and the editor(s). MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. </div> <a class="valid" valid="valid" title="valid: True, node: 1190, tag: a, level: 7" node_number="1190"> Terms and Conditions </a> <a class="valid" valid="valid" title="valid: True, node: 1191, tag: a, level: 7" node_number="1191"> Privacy Policy </a> </div> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1192, tag: div, level: 3" node_number="1192"> <div class="valid" valid="valid" title="valid: True, node: 1193, tag: div, level: 4" node_number="1193"> We use cookies on our website to ensure you get the best experience. Read more about our cookies <a class="valid" valid="valid" title="valid: True, node: 1194, tag: a, level: 5" node_number="1194">here</a>. </div> <div class="valid" valid="valid" title="valid: True, node: 1195, tag: div, level: 4" node_number="1195"> <a class="valid" valid="valid" title="valid: True, node: 1196, tag: a, level: 5" node_number="1196">Accept</a> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1197, tag: div, level: 3" node_number="1197"> <div class="valid" valid="valid" title="valid: True, node: 1198, tag: div, level: 4" node_number="1198"> We have just recently launched a new version of our website. Help us to further improve by taking part in this short 5 minute survey here. here. </div> <div class="valid" valid="valid" title="valid: True, node: 1199, tag: div, level: 4" node_number="1199"> <a class="valid" valid="valid" title="valid: True, node: 1200, tag: a, level: 5" node_number="1200">Never show this again</a> </div> </div> </div> <div class="valid" valid="valid" title="valid: True, node: 1201, tag: div, level: 2" node_number="1201"> <div class="valid" valid="valid" title="valid: True, node: 1202, tag: div, level: 3" node_number="1202"> <div class="valid" valid="valid" title="valid: True, node: 1203, tag: div, level: 4" node_number="1203"> <h2 class="valid" valid="valid" title="valid: True, node: 1204, tag: h2, level: 5" node_number="1204">Share Link</h2> </div> <div class="valid" valid="valid" title="valid: True, node: 1205, tag: div, level: 4" node_number="1205"> <a class="valid" valid="valid" title="valid: True, node: 1206, tag: a, level: 5" node_number="1206">Copy</a> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 1207, tag: a, level: 3" node_number="1207"> <i class="valid" valid="valid" title="valid: True, node: 1208, tag: i, level: 4" node_number="1208">clear</i> </a> </div> <div class="valid" valid="valid" title="valid: True, node: 1209, tag: div, level: 2" node_number="1209"> <div class="valid" valid="valid" title="valid: True, node: 1210, tag: div, level: 3" node_number="1210"> <div class="valid" valid="valid" title="valid: True, node: 1211, tag: div, level: 4" node_number="1211"> <h2 class="valid" valid="valid" title="valid: True, node: 1212, tag: h2, level: 5" node_number="1212">Share</h2> </div> </div> <a class="valid" valid="valid" title="valid: True, node: 1213, tag: a, level: 3" node_number="1213"> <i class="valid" valid="valid" title="valid: True, node: 1214, tag: i, level: 4" node_number="1214">clear</i> </a> </div> <a class="valid" valid="valid" title="valid: True, node: 1215, tag: a, level: 2" node_number="1215">Back to TopTop</a> </body>
        <style tyle='text/css'>
body{
    position: relative;
    padding-left: 30px;
    top: 60px;
}
* {
    border: 1px solid #eee;
    padding: 5px 12px;
    margin: 3px 0;
    box-sizing: content-box;
    background-color: #fff;
    cursor: no-drop;
}
main:hover > *, section:hover > *, header:hover > *, nav:hover > *, a:hover > *, div:hover > *, p:hover > *, ul:hover > *, h1:hover > *, h2:hover > *, h3:hover > *, li:hover > *, span:hover > *{
    border: 2px solid green;
    background-color: #fffeee;
    padding: 5px 23px !important;
    margin: 1px 0;
    color: green;
}
main:hover, section:hover, header:hover, nav:hover, a:hover, div:hover, p:hover, ul:hover, h1:hover, h2:hover, h3:hover, li:hover, span:hover{
    border: 1px solid #fff;
    background-color: #eee;
}
a, span {
    display: block;
}
.selected {
    border: 2px solid orchid !important;
    opacity: 0.8;
    color: orchid !important;
}
.selected * {
    padding: 2px !important;
    color: orchid !important;
}
.valid {
  cursor: pointer;
}
.btn{
  cursor: pointer;
  font-weight: bolder;
  padding: 8px;
}
</style> 
        <script>function OpenOriginalLink($event){
    $event.stopPropagation();
    console.log(url);
}

function removeItem($event){
    $event.stopPropagation();
    console.log('Remove item: ', url)
    localStorage.removeItem(url)
}

function exportData($event){
    $event.stopPropagation();

    result = []
    for(let i=0; i<localStorage.length; i++) {
        let key = localStorage.key(i);
        result.push(localStorage.getItem(key))
    }
    const _url = URL.createObjectURL(new Blob([result.join("\n")], {type: 'text/plain'}))
    $event.target.href = _url;
    localStorage.clear()
}

var removeItemBtn = document.createElement("BUTTON");   // Create a <button> element
removeItemBtn.innerHTML = "Remove Item";
removeItemBtn.classList.add('btn');
removeItemBtn.style.position = "fixed";
removeItemBtn.style.left = '5px';
removeItemBtn.style.top = 0;
removeItemBtn.style.border = "1px solid";
removeItemBtn.style.boxShadow = "3px 3px #888";
removeItemBtn.onclick = removeItem;
document.body.appendChild(removeItemBtn);

var goToOriginLink = document.createElement("A");   // Create a <button> element
goToOriginLink.innerHTML = "GoToOrigin";
goToOriginLink.classList.add('btn');
goToOriginLink.style.position = "fixed"
goToOriginLink.style.left = '115px'
goToOriginLink.style.top = 0;
goToOriginLink.onclick = OpenOriginalLink;
goToOriginLink.setAttribute('href', decodeURIComponent(url));
goToOriginLink.target = '_blank';
document.body.appendChild(goToOriginLink);

var current = new Date
var exportDataLink = document.createElement("A");   // Create a <button> element
exportDataLink.innerHTML = "Export data";
exportDataLink.classList.add('btn');
exportDataLink.download = current.toISOString() + '.exported.txt';
exportDataLink.style.position = "fixed";
exportDataLink.style.right = '5px';
exportDataLink.style.top = 0;
exportDataLink.style.border = "1px solid #888";
exportDataLink.style.boxShadow = "3px 3px #888";
exportDataLink.onclick = exportData;
document.body.appendChild(exportDataLink);

data = {
    'title': null ,
    'article': null
}

var body = document.getElementsByTagName("body")[0];

body.onclick = function($e){
    var num = $e.target.getAttribute('node_number')
    var valid = $e.target.getAttribute('valid')

    if(!valid){
        console.log("Element is invalid")
        return
    }

    if(data.length > 2){
        data = data.splice(0, 2)
    }

    console.log("node:", $e.target)

    if(!data.title && !data.article){
        data.title = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else if (data.title && !data.article){
        data.article = num;
        console.log("data:", data)
        $e.target.classList.add('selected')
    }else{
        selected = Array.from(document.getElementsByClassName("selected"))
        selected.forEach(function(el){
            el.classList.remove('selected')
        })

        data.title = num;
        data.article = null;
        $e.target.classList.add('selected')

    }

    if(data.title && data.article){
        var obj = {
            url: url,
            text: body_html,
            title: data.title,
            article: data.article,
        }

        var datasetItem = JSON.stringify(obj)
        localStorage.setItem(url, datasetItem)
    }
}
</script> 
      </html>